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Chapter 1
General introduction, aim 
and outline of the thesis
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General introduction
Moraxella catarrhalis is part of the normal bacterial flora in the nasopharynx of children, 
although over the past two decades, it has emerged as a significant bacterial pathogen 
and not simply a commensal colonizer. The bacterium rapidly colonizes the nasopharynx 
soon after birth and many factors affect nasopharyngeal carriage of this human-specific 
pathogen, including for example, the presence of siblings, day-care attendance and re-
spiratory illness. Otitis media (OM) is a particularly important respiratory illness during 
early childhood and the primary reason for children to visit a physician. The most com-
mon bacterial species cultured from the nasopharynx of children during OM episodes 
are Streptococcus pneumoniae, Haemophilus influenzae and M. catarrhalis, either as 
single pathogens or as co-cultures, with the patterns of nasopharyngeal colonization 
by microorganisms being important determinants for OM disease. There is increasing 
information regarding the biological mechanisms facilitating M. catarrhalis-mediated 
colonization and disease development, with most publications stressing the importance 
of bacterial adherence as an essential step in this process.
Treatment of OM is not always appropriate, and the long-term overuse of antibiotics 
in OM reduces the effectiveness of treatment and places children at an increased risk of 
antibiotic-resistant infections. Because there is currently no ideal treatment for OM, an 
alternative to the use of antibiotics is vaccination. To date, several M. catarrhalis vaccine 
candidates have been described, which may be effective in reducing the burden of 
OM disease. The challenge in identifying potential vaccine candidates for M. catarrhalis 
lies in identifying antigens that are able to generate an appropriate immune response 
to prevent colonization and infection. However, there is no licensed vaccine available 
against M. catarrhalis, and none of the putative vaccine candidates so far described 
have progressed to clinical trials.
Aim and outl ine of the thesis
The aim of this thesis is to help understand the epidemiology and pathogenesis of M. 
catarrhalis colonization and infection, with special emphasis on isolate variation, the 
humoral immune response and novel immunologically relevant vaccine candidates of 
M. catarrhalis.
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In this respect, Chapter 2 provides a detailed description of our current knowledge 
regarding M. catarrhalis as a human pathogen and the treatment and management of 
this organism. The subsequent seven chapters are then divided into two main themes, 
relating to the dynamics of M. catarrhalis colonization and infection (Chapters 3 – 7) 
and the humoral immune response (Chapter 8 – 9).
In Chapter 3, determinants of M. catarrhalis colonization in healthy Dutch children 
during the first months of life were defined, whereas in Chapter 4, pulsed-field gel 
electrophoresis, PCR and PCR-RFLP are used to determine the genotypic relationship be-
tween colonizing M. catarrhalis strains of healthy children, and to study virulence gene 
diversity. Further, co-colonization with H. influenzae was also investigated. In Chapter 
5, the age-related genotypic and phenotypic differences in M. catarrhalis isolates from 
children and adults presenting with respiratory disease were investigated. Chapter 6 
gives an overview of a prospective study that looked into the differences in the presence 
of bacteria and viruses in the middle ear and nasopharynx of children diagnosed with 
recurrent acute otitis media (rAOM) and chronic otitis media with effusion (COME). The 
role of the major bacterial pathogens S. pneumoniae, H. influenzae and M. catarrhalis, 
in the absence or presence of 15 respiratory viruses, was studied in detail. In fact, 
previous research has shown that bacterial co-colonization does lead to increased colo-
nization and infection, with S. pneumoniae, H. influenzae and M. catarrhalis being the 
predominant co-colonizing bacterial organisms associated with OM. However, group A 
Streptococcus (GAS) may also be included as one of the most frequent causative agents 
of OM, especially with reference to the increasing importance of GAS in OM disease in 
Eastern Europe. Therefore, in Chapter 7, studies were performed to investigate the 
effect of M. catarrhalis co-culture on GAS gene expression, particularly with respect to 
the expression of GAS virulence genes.
Relatively little is known about the development of the humoral immune response 
to M. catarrhalis surface antigen vaccine candidates within the first few years of life in 
healthy and sick children. In this respect, the studies presented in Chapter 8 and 9 
were established in order to study the humoral immune response generated against 
the currently identified surface antigens of M. catarrhalis (Chapter 8 and 9) and S. 
pneumoniae (Chapter 9). The relationship between colonization and immune response 
was also investigated.
Finally, Chapter 10 gives a summary of the research presented within this thesis 
and discusses the findings with respect to M. catarrhalis vaccine development.
Chapter 2
Moraxella catarrhalis: a human pathogen
Adapted from:
Suzanne J.C. Verhaegh and John P. Hays. Chapter 80 Moraxella. In: Liu, D. (ed), Mo-
lecular Detection of Human Bacterial Pathogens. 2011. Taylor & Francis CRC Press, Boca 
Raton, FL, USA. In press.
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The genus Moraxella
The genus Moraxella belongs to the family Moraxellaceae, which includes the closely 
related genera Acinetobacter and Psychrobacter. The Moraxella genus itself currently 
contains 15 different species, including M. lacunata, M. atlantae, M. boevrei, M. bovis, 
M. canis, M. caprae, M. catarrhalis, M. caviae, M. cuniculi, M. equi, M. lincolnii, M. 
nonliquefaciens, M. osloensis, M. ovis and M. saccharolytica [1]. Recently, M. plurani-
malium has been described as a new species of the genus Moraxella after its isolation 
from sheep and pigs [2]. Although all of these 16 species have been classified within 
the genus Moraxella, the classification of the Moraxellaceae family is still not definitive 
but continuously evolving. For example, molecular systematic studies (of which 16S 
ribosomal RNA (rRNA) gene sequencing has long been the ‘gold standard’) has led 
to the re-classification of Riemerella anatipestifer, Psychrobacter phenylpyruvicus and 
Oligella urethralis, which were formally known as Moraxella anatipestifer, Moraxella 
phenylpyruvica and Moraxella urethralis, respectively [1, 3].
Of the 16 Moraxella species, M. caprae, M. caviae, M. cuniculi, M. equi, M. lincol-
nii, M. ovis, M. saccharolytica, M. boevrei, M. bovis and M. pluranimalium are only 
associated are only associated with diseases in animals. Occasionally however, some 
Moraxella species are associated with human disease. Specifically, M. lacunata has 
been associated with chronic conjunctivitis, arthritis and endocarditis in humans, [4-8] 
whilst M. nonliquefaciens has been known to cause bacterial infection (botryomycosis) 
and inflammation (endophthalmitis) [9-11]. M. atlantae is an unusual and only rarely 
isolated species that has been associated with bacteremia in humans, [12-13] whilst 
M. osloensis rarely causes infections but has been associated with bacteremia and en-
dophthalmitis [14-16]. Interestingly, M. canis is an upper airway commensal bacterium 
in cats and dogs, and has been considered non-pathogenic for humans even although 
it has been isolated from humans in a few cases [17-18]. The single most important 
exception to this ‘Moraxella-animal disease’ relationship is M. catarrhalis, an organism 
which is a strictly human pathogen and causes a range of human diseases.
Classif ication, biology and epidemiology of 
Moraxella catarrhalis
M. catarrhalis (formally known as Branhamella catarrhalis) has undergone several 
name changes in the past 100 years [19-20]. It was first described at the end of the 
nineteenth century when it was named Micrococcus catarrhalis, and it was later changed 
to Neisseria catarrhalis because of its similarity in phenotype and ecological niche to 
16  Chapter 2
species of Neisseria [21]. In 1970, the bacterium was transferred to a new genus, Bran-
hamella, based on differences between N. catarrhalis and the type species of the genus 
Neisseria and six other species of this genus [19]. In 1984, Branhamella catarrhalis 
was reassigned to the genus Moraxella as Moraxella (Branhamella) catarrhalis [22]. 
M. catarrhalis is now the most widely accepted and currently preferred name for this 
bacterial species.
M. catarrhalis is an oxidase-positive, Gram-negative diplococcus, which grows well 
on both blood and chocolate agars, as well as several selective agar media. Optimal 
growth is achieved at a temperature of 35°C and may be enhanced in an atmosphere 
of 5% carbon dioxide. Colonies are generally non-hemolytic, gray to white, opaque and 
smooth, and can be pushed along the agar surface without losing colonial integrity, the 
so-called ‘hockey puck sign’ [23-24].
M. catarrhalis is an important colonizer of the respiratory tract. Until recently, M. 
catarrhalis was thought to be a harmless commensal. However, it is now recognized as 
one of the more important bacterial pathogens associated with both upper and lower 
respiratory tract infections in humans. These upper and lower respiratory tract infec-
tions include acute, chronic and chronic suppurative otitis media and exacerbations of 
chronic obstructive pulmonary disease (COPD).
Acute otitis media (AOM) involves inflammation of the middle ear, including the 
eardrum, the inner ear, and the Eustachian tube. AOM is generally considered a bacterial 
infection, and bacteria may be isolated from the middle ear fluid (MEF) in approximately 
80% of children with AOM. Streptococcus pneumoniae is reported to be the predominant 
bacterial species cultured in AOM disease, followed by Haemophilus influenzae and M. 
catarrhalis. However, this ranking is subject to some debate as there are still questions 
regarding which bacterial species plays the most important role in middle ear infection 
and therefore AOM [25]. Bacteria have been cultured from 30 to 50% of patients with 
chronic otitis media with effusion (COME), where H. influenzae predominates, and to 
a lesser extent, S. pneumoniae and M. catarrhalis [25-26]. Chronic suppurative otitis 
media (CSOM) is one of the most common chronic diseases of childhood in many un-
derdeveloped countries (especially among the poor), and in certain populations of the 
developed nations. In contrast to AOM and COME, Pseudomonas aeruginosa is the most 
predominant species isolated, with a minor role for M. catarrhalis [27-28].
In contrast to the upper respiratory tract infections (URTI) associated with M. ca-
tarrhalis in children, M. catarrhalis in adults is mostly associated with lower respiratory 
tract infections (LRTI). COPD is a major LRTI and a considerable public health problem. 
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It is predicted to become the fifth leading cause of death worldwide in 2020 and the 
prevalence of, and mortality due to this disease are currently increasing [29]. Several 
lines of evidence developed in the last decade have established that M. catarrhalis is 
associated with exacerbations of COPD. For example, non-typeable H. influenzae, M. 
catarrhalis, and S. pneumoniae are the three predominant bacterial species isolated 
from sputum in 40 to 60% of acute exacerbations of COPD, with M. catarrhalis being 
isolated in 4-21% of sputa [30]. The high prevalence of bacterial colonization of the 
airways observed in COPD is generally related to the degree of airflow obstruction and 
cigarette smoking [31]. However, more research is needed to test the hypothesis that 
bacterial colonization accelerates the progressive decline in lung function seen in COPD 
(the vicious circle hypothesis), although neutrophilic airway inflammation and systemic 
inflammation are more intense in the presence of bacteria [30, 32].
Colonization and the immune response
Colonization with M. catarrhalis begins very early in life with a high percentage of infants 
being colonized, but a much lower percentage of adults being colonized (1-5%) [24]. 
In fact, a M. catarrhalis colonization peak is observed at 2 years of age, with both 
infants and children tending to acquire and eliminate a number of different strains [33-
34]. Factors that have been particularly associated with an increased likelihood of M. 
catarrhalis colonization include the presence of siblings and day-care attendance [35]. 
Further, studies have shown that frequent colonization with M. catarrhalis increases the 
risk of otitis media (OM) and that patterns of colonization are important determinants of 
OM-related disease [24, 36-37].
In young infants, high antibody levels exist due to immunization by passively ac-
quired maternal immunoglobulin G (IgG) antibodies, which are transferred to the fetus 
through the placenta. This passive immunity lasts until about six months after birth. 
In this period, the actively acquired humoral immune response is being established in 
which children are susceptible for M. catarrhalis colonization and infection. A significant 
fall in antibody concentration during the first 3 months of life from healthy children is 
observed and the IgG antibodies to M. catarrhalis remain at a low level in children below 
1 year of age. However, from the age of 1 year, the immune response of the children 
increases slowly to reach maternal levels at the age of 10 years [38].
The development of mature IgG antibodies to M. catarrhalis is reflected in the age-
related development of IgG subclass responses to M. catarrhalis. Usually, subclass 1 
is the first antibody subclass to develop, and it is found after the first year of life, 
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where subclass 3 develops during the second and third years of life and is known to 
be elicited by bacterial outer membrane proteins (OMPs) [39-40]. The peak level of M. 
catarrhalis colonization (age of 2 years) and where children have a high susceptibility to 
M. catarrhalis infections coincides with the age range where the levels of M. catarrhalis 
IgG antibodies are low. This may indicate that the eradication of M. catarrhalis may be 
related to rising titers of M. catarrhalis-specific serum IgG1 and IgG3 after 2 years of 
age.
Pathogenesis
The recent recognition of M. catarrhalis as an important pathogen in both the upper 
and lower respiratory tract has resulted in an increased interest in both the bacterium’s 
interaction with the human host and its antigenic composition.
Two distinct genetic lineages related to 3 different 16S rRNA types have been identi-
fied for M. catarrhalis, which differ phenotypically in their ability to resist the killing ef-
fect of human serum (sero-resistant versus sero-sensitive), and in their ability to adhere 
to human epithelial cells [41-42]. Further, the sero-resistant lineage of M. catarrhalis 
(16S rRNA type 1 lineage) has been reported to be more virulent than 16S rRNA types 
2 and 3 (lineage 2 isolates) [42].
There is increasing information regarding the mechanisms facilitating M. catarrhalis 
colonization and infection of the respiratory tract. In particular, bacterial adherence to 
the respiratory mucosa is an essential step towards colonization of the human respira-
tory tract epithelium and the development of disease. Important adhesins responsible 
for the attachment of M. catarrhalis to host cells include the family of ubiquitous surface 
protein A (UspA) proteins UspA1 and UspA2, which have been extensively studied in 
M. catarrhalis and were initially described approximately 17 years ago [43]. The closely 
related UspA2H protein appears to be a hybrid protein that most closely resembles 
UspA1 at its N-terminal and UspA2 at its C-terminal region [44]. UspA1 and UspA2 
acquire their adherence characteristics through multifunctional binding sites, which 
include domains that have the ability to attach to epithelial cells via cell-associated 
fibronectin, laminin and vitronectin [45]. Further, UspA1 includes a critical binding 
site for carcinoembryonic antigen-related cell adhesion molecules (CEACAMs), which 
are expressed in various human tissues including respiratory epithelial cells [46]. The 
CEACAM-1 receptor-binding domain is located in the stalk region of UspA1 and consists 
of an extended, rod-like left-handed trimeric coiled-coil. The stalk region is capable of 
changing conformation after CEACAM-1 binding to allow a closer approach between 
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M. catarrhalis and the host cell membrane [47]. The stalk region of UspA1 and UspA2 
share multiple amino acid repeats and distinct sequence ‘motifs’, a finding that suggests 
that the make-up of the UspA proteins might be interchangeable, possibly under the 
influence of immune pressure. This extensive sharing of sequences between UspA1 and 
UspA2 does not include the N- and C-terminal regions of these proteins [48-49]. The 
UspA stalk region contains one or two copies of the NINNY motif (which contains the 
epitope for the protective monoclonal antibody (MAb) 17C7), and the CEACAM binding 
motif (which contains the epitope for a separate anti-UspA1 antibody that also inhibits 
CEACAM binding) [49-50]. The exchange of repeats and motifs in UspA proteins may 
allow M. catarrhalis populations to exhibit various combinations of binding properties, 
which could help define the virulence of individual strains [49].
Another OMP that is important for bacterial attachment is the Moraxella im-
munoglobulin D-binding protein (MID), also referred to as Hag (human erythrocyte 
agglutinin), due to the ability of M. catarrhalis to agglutinate human erythrocytes and 
the unique immunoglobulin-binding properties [51-52]. The adhesive domain of MID 
is located in the 149 amino acid fragment MID764-913 of M. catarrhalis strain Bc5 and 
promotes the attachment of bacteria to epithelial cells, whereas the IgD-binding domain 
is located within the 238 amino acid fragment MID962-1200 of the same protein [51, 53]. 
Further, antibodies directed against MID764-913 effectively inhibit attachment of the high 
MID-expressing isolates to alveolar epithelial cells, and animals immunized with MID764-
913 clear M. catarrhalis much more efficiently when compared to mice immunized with 
bovine serum albumin (BSA) [54].
M. catarrhalis has developed several mechanisms to evade the effect of human 
complement, allowing it to evade the host innate immune response. Three biochemi-
cal pathways activate the complement system: the classical pathway, the alternative 
pathway, and the mannose-binding lectin (MBL) pathway. The classical pathway of the 
complement system is initiated by the binding of the complement component (C)-1 
complex to antibodies bound to an antigen on the surface of a bacterial cell, whereas the 
alternative pathway is initiated by the covalent binding of a small amount of C3b to the 
surface of a microbe and is activated by cleavage of C3 in plasma. Activation of these 
systems leads to a cascade of protein deposition on the bacterial surface, resulting in 
formation of the membrane attack complex (MAC) and opsonization of the pathogen, 
followed by phagocytosis [55-56].
M. catarrhalis has evolved mechanisms to interfere with the activation of the 
complement pathway, including the binding of complement inhibitor C4-binding protein 
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(C4BP; classical pathway) and by noncovalently binding C3 (alternative pathway). The 
M. catarrhalis OMPs UspA1 and UspA2 bind C4BP and C3, and UspA2 interferes with the 
proper formation of the MAC porin complex that inserts into bacterial outer membranes, 
due to the stable binding of vitronectin [57-60].
Another example of the ability of M. catarrhalis to evade the host immune system 
is phase variation and antigenic variation [61]. Phase variation in general refers to a 
reversible switch between an on-off expressing phase, resulting in variation in the level 
of expression of one or more OMPs between individual bacteria of a clonal population. 
Antigenic variation refers to the expression of functionally conserved OMPs within a 
clonal population of bacteria that are antigenically distinct [62]. As OMPs are found 
on the bacterial cell surface and may be exposed to the immune system, antigenic 
variation influences the efficacy of antibody-mediated defense mechanisms against the 
respective OMPs and hence against the bacterium per se. Currently, M. catarrhalis OMPs 
UspA1, UspA2 and Hag/MID are known to undergo phase variation, with antigenic varia-
tion reported in the target region of MAb 17C7 (a conserved UspA1 and UspA2 binding 
site), although this variation involves only minor amino acid changes [63-67]. Whether 
antigenic variation is actually a virulence mechanism for M. catarrhalis, is a subject 
of debate, as Meier et al. (2005) demonstrated that reduced or absent expression of 
UspA1, rather than antigenic variation, was responsible for non-reactivity with the MAb 
17C7 [65].
Interestingly, M. catarrhalis releases outer membrane vesicles (OMVs), or ‘blebs’ 
from the surface of the cell during growth in various environments, including liquid 
culture, solid culture, and during biofilm formation. Blebs are thought to contain some of 
the underlying periplasm, together with OMPs and lipopolysaccharides (LPS) of the outer 
membrane layer [68]. The OMVs that are secreted by M. catarrhalis carry UspA1 and 
UspA2, and have been shown to interfere with successful complement activation against 
H. influenzae in mixed infections. Thus, OMVs from M. catarrhalis may contribute to the 
pathogenicity of pure and mixed M. catarrhalis populations by binding and depleting C3 
in their immediate environment [69].
Another important component of the innate immune system are the transmem-
brane toll-like receptors (TLRs). TLRs are pathogen recognition receptors (PRRs) that 
recognize pathogen-associated molecular patterns (PAMPs), small conserved molecular 
motifs found in microbes, for example bacterial LPS. The specific inflammatory re-
sponses induced by M. catarrhalis may be mediated by activation of these PRRs, with 
the inflammatory immune response to M. catarrhalis in respiratory epithelial cells being 
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mainly dependent on TLR2 [70]. This TLR2 inflammatory immune response is mediated 
by the cytokine interleukin (IL)-8, which has a critical role in regulating neutrophil and 
monocyte chemotaxis toward sites of infection. Further, the activation of protein kinase 
C (PKC) through nuclear factor (NF)-κB signaling pathways, which induces IL-8 release, 
has been found to be dependent on expression of UspA2 [71]. Additionally, IL-8 release 
is inhibited by UspA1-dependent interactions with CEACAM-1 [72].
A single highly homologous 32-amino acid sequence of M. catarrhalis UspA1 and 
UspA2 is also responsible for binding and neutralizing α1-antichymotrypsin. This serine 
protease inhibitor is not active anymore as an inhibitor when bound to M. catarrhalis 
UspA1 and UspA2. As a result, proteases disrupt the host tissue structure and provide 
bacteria with soluble substrates and extracellular matrix proteins for adhesion, which 
may be beneficial for bacterial colonization. M. catarrhalis α1-antichymotrypsin neutral-
ization is therefore a novel microbial virulence mechanism [73].
Research has shown that co-colonization leads to increased colonization and infection, 
for example Verhaegh et al. (2010) showed that co-colonization of M. catarrhalis and H. 
influenzae was significantly more likely than single species colonization with either M. 
catarrhalis or H. influenzae [74-76]. Additionally, Armbruster et al. (2010) showed that 
quorum sensing during M. catarrhalis and H. influenzae co-culture positively influenced 
indirect pathogenicity in polymicrobial OM infections [77]. In fact, many pathogenic bac-
terial species use quorum sensing systems to coordinate their gene expression, in order 
to, for example, coordinate the formation of biofilm (as a response to the local bacterial 
population density). It is known that M. catarrhalis exists in biofilms and that it is able to 
prolong its survival through biofilm formation on mucosal surfaces in the nasopharynx. 
Biofilms are usually defined as microbial communities, surrounded by an extracellular 
polymeric substance (EPS) matrix that adhere to biological or non-biological surfaces 
[78]. Biofilm formation has been demonstrated for numerous pathogens and is clearly 
an important microbial survival strategy [79]. Several other pathogens associated with 
infections, including H. influenzae and S. pneumoniae in chronic OM, are also linked to 
biofilm formation. These bacteria benefit from this microbial community thanks to, for 
instance, the phenomenon of indirect pathogenicity, where S. pneumoniae is protected 
from the action of certain β-lactam antibiotics in the presence of BRO β-lactamase 
positive M. catarrhalis, and where M. catarrhalis protects H. influenzae due to binding 
and depleting C3 by release of OMVs [69, 80-81].
Studies have shown that several M. catarrhalis genes are associated with biofilm 
formation, for example uspA1, uspA2, uspA2H and hag/mid, although the exact role 
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of each of the resultant proteins in biofilm formation is still open to question. Further, 
Wang et al. (2007) showed that growth of M. catarrhalis in a biofilm results in increased 
expression of genes encoding a nitrate reductase, a nitrite reductase, and a nitric oxide 
reductase, which can function not only in energy generation but also in resisting the 
innate immune response [82].
Diagnosis
Recognition of the pathogenic status of M. catarrhalis means that the detection of M. 
catarrhalis in clinical specimens is now an important topic in disease management 
and diagnosis. In the routine clinical laboratory, the detection of M. catarrhalis tends 
to be based on conventional methods only, although a variety of molecular detection 
techniques are being used within research laboratories to investigate M. catarrhalis 
specific genes and virulence. These techniques include PCR and DNA hybridization-
based bacterial detection methods, which are usually reliant on the specific detection 
and amplification of genes encoding for M. catarrhalis OMPs. For both research and 
diagnostic purposes, further details concerning the relatedness of M. catarrhalis iso-
lates may be obtained by using one of several M. catarrhalis typing techniques. These 
epidemiological investigation techniques include pulsed-field gel electrophoresis (PFGE) 
and multilocus sequence typing (MLST) as the most popular, as well as electrophoretic 
profiling of OMPs, iso-electric focusing of BRO β-lactamase enzymes and serological 
typing of LPS [83-85]. More recent developments include a M. catarrhalis micro-array 
assay that has been developed to study gene expression of M. catarrhalis under varying 
environmental conditions [82].
Despite being somewhat old-fashioned, time-consuming and unable to detect un-
culturable isolates, the conventional approaches for identifying M. catarrhalis (including 
selective culture media, Gram stain morphology and biochemical testing, for example 
the tributyrin disc test) are still extremely useful. The use of PCR tests directed against 
M. catarrhalis genes in the routine clinical microbiology laboratories is hindered by the 
lack of sensitivity, specificity and reproducibility data, as well as the lack of an accepted 
library of quality control M. catarrhalis isolates to test. Issues related to cost per unit 
specimen, as well as the fact that bacterial culture tends to be a ‘catch-all’ technique 
(rather than the more specific molecular techniques), also play a role in current deci-
sions related to the implementation of molecular tests for M. catarrhalis in the routine 
clinical microbiology laboratory.
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Treatment and management
M. catarrhalis is known to produce a BRO β-lactamase, an enzyme responsible for 
the resistance of M. catarrhalis to certain β-lactam antibiotics. Moreover, in the last 
30 years, major changes have occurred in the incidence of β-lactamase production 
in M. catarrhalis isolates. BRO β-lactamase was derived from an, as yet unknown, 
Gram-positive bacterium, with its lipid modification being a remainder of its origin, and 
spread through the population mainly by horizontal transfer [86]. The first β-lactamase-
producing isolate was detected in clinical specimens reported by Malmvall et al. in 1977, 
with a prevalence rate of 3.8% [87]. However, by 1980, 75% of M. catarrhalis isolates 
from the United States produced β-lactamase [88]. Recent studies have shown that 
thirty years after the first discovery of β-lactamase producing strains, over 95% of the 
clinical isolates worldwide produce a BRO β-lactamase [89].
All strains of M. catarrhalis are resistant to amoxicillin due to the production of BRO 
β-lactamase, but the discovery of the β-lactamase inhibitor clavulanic acid in the year 
1972 and its co-administration with amoxicillin as amoxicillin/clavulanate still allows 
the continued use of β-lactam antibiotics to treat infections caused by M. catarrhalis. 
The efficacy of this combination has been demonstrated in a range of clinical trials, and 
since 1981, amoxicillin/clavulanate has been registered for the treatment of URTIs and 
other diseases [90]. Although amoxicillin is recommended as the initial antibacterial 
agent of choice for most children, it is shown that recurrent OM occurs more often in 
children originally treated with amoxicillin [91]. Further, the frequent use of antibiotics 
as therapy for AOM tends to result in a rise in antibiotic resistance, and increasing 
evidence is becoming available regarding the limited clinical efficacy of antibiotics in the 
successful treatment of AOM [92].
The American Academy of Pediatrics published a guideline in 2004 that addressed 
the diagnosis and treatment of AOM. This guideline recommended the use of watchful 
waiting as a potential strategy for the treatment of AOM, although rates of antibiotic 
prescription for AOM still vary to a great extent internationally [92-93].
An alternative to the use of antibiotics is vaccination. However, there is currently 
no licensed vaccine against M. catarrhalis, and to date, none of the putative vaccine 
candidates so far described have progressed to clinical trials. The challenge in identify-
ing potential vaccine candidates for M. catarrhalis lies in identifying antigens that i) are 
able to generate an appropriate immune response to prevent colonization and infection 
and ii) are conserved among global strains. A further major obstacle in vaccine develop-
ment has been the absence of a satisfactory animal model for M. catarrhalis-mediated 
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diseases, and consequently, problems associated with the identification and verification 
of the ‘correlates of protection’ against M. catarrhalis [24].
On a further note, effective vaccines against viruses and bacteria involved in AOM 
could have a dramatic impact on the overall incidence of this disease. However, the po-
tential use of vaccines against for example non-typeable H. influenzae or S. pneumoniae 
(e.g. Prevnar™, Wyeth) may lead to a reduction in the incidence of these two pathogens 
in the etiology of AOM, possibly allowing M. catarrhalis to capitalize on the available 
niche and become the main bacterial AOM pathogen of the future.
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Abstract
Moraxella catarrhalis is an established bacterial pathogen, previously thought to be an 
innocent commensal of the respiratory tract of children and adults. The objective of this 
study was to identify significant risk factors associated with M. catarrhalis colonization 
in the first year of life in healthy Dutch children. This study investigated a target cohort 
group of 1,079 children forming part of the Generation R Study, a population-based 
prospective cohort study following children from fetal life until young adulthood, con-
ducted in Rotterdam, The Netherlands. Nasopharyngeal swabs for M. catarrhalis culture 
were obtained at 1.5, 6 and 14 months of age, with all three swabs being available for 
analyses from 443 children. Data on risk factors possibly associated with M. catarrhalis 
colonization were obtained by questionnaire at 2, 6 and 12 months. M. catarrhalis 
colonization increased from 11.8% at age 1.5 months to 29.9% and 29.7% at 6 and 14 
months, respectively. Two significantly important colonization risk factors were found: 
the presence of siblings and day-care attendance, which both increased the risk of being 
positive for M. catarrhalis colonization on two or more occasions within the first year of 
life. Colonization with M. catarrhalis was not associated with gender, educational level of 
the mother, maternal smoking, breast-feeding, or antibiotic use. Apparently, crowding 
is an important risk factor for early and frequent colonization with M. catarrhalis in the 
first year of life.
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Introduction
Moraxella catarrhalis is an acknowledged respiratory tract pathogen [1]. The bacterium 
has the capacity to colonize the nasopharynx, and may be isolated in pure culture or 
together with other bacterial pathogens, e.g. Staphylococcus aureus, Streptococcus 
pneumoniae and/or Haemophilus influenzae [2]. Although colonization does not always 
result in disease, it may be the first step towards invasive disease, and a source of hori-
zontal spread of M. catarrhalis in the community [3]. Children are frequently colonized 
with M. catarrhalis, and frequent colonization with M. catarrhalis has been reported to 
increase the risk of otitis media (OM) [4]. Risk factors associated with M. catarrhalis 
colonization have been previously studied in several countries and age groups, and 
the findings have indicated that crowding and contact with children are risk factors for 
colonization, not only for M. catarrhalis, but also for S. pneumoniae and H. influenzae 
[5]. Other reported risk factors are genetics [6-7], smoking [8], socio-economic status 
[9], synergy and interference with other micro-organisms [10-11], frequency and loca-
tion of sampling [12], season [12], gender [13], and vaccination [14]. However, medical 
and living conditions in The Netherlands may be quite different from those in other 
countries. For example, there is a restrictive prescription policy for antibiotic usage. 
These differences could lead to differences in M. catarrhalis epidemiology and coloniza-
tion rate in The Netherlands, as compared with other countries.
The objective of this study was to assess risk factors for M. catarrhalis colonization in 
the first year of life in healthy Dutch infants within a geographically restricted environ-
ment (Generation R Focus cohort, living in Rotterdam, The Netherlands).
Materials and methods
This study was embedded in the Generation R Study, a population-based prospec-
tive cohort study following children from fetal life until young adulthood, conducted 
in Rotterdam, The Netherlands [15-16]. As part of the Generation R Study, detailed 
assessments of fetal and post-natal growth and development were conducted in 1,232 
Dutch pregnant women and their children (Generation R Focus cohort), who were born 
between February 2003 and August 2005. The Medical Ethics Committee of the Erasmus 
MC, Rotterdam, The Netherlands, has approved the study. Written informed consent 
was obtained from the parents of the children who were included. The mothers gave 
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birth to 1,244 infants, 138 of whom were excluded from the study analysis because 
consent was withdrawn after birth. Twins (n=27) were also excluded from the analysis 
because of genetic relatedness, leaving a final total of 1,079 infants. Infants visited the 
Generation R Focus cohort research center at 1.5 months (n=884), 6 months (n=882) 
and 14 months (n=863) after birth, resulting in 627 swabs being successfully taken at 
1.5 months, 832 swabs at 6 months, and 757 swabs at 14 months. Seven hundred and 
fifty-eight infants attended all visits, and 443 provided three swabs for use in longitudi-
nal analysis. Nasopharyngeal samples were taken using a sterile transport swab suitable 
for aerobes and anaerobes by a trained research nurse, using Amies transport medium. 
Infants treated with antibiotic in the preceding 48 hours were excluded from naso-
pharyngeal sampling [15-16]. Swabs were processed within the medical microbiology 
laboratory of the Erasmus MC, Rotterdam, The Netherlands, within 6 hours of sampling, 
using blood agar plates containing 5% sheep blood at an incubation temperature of 
35°C in 5% CO2 for 48 hours. Plates were examined daily for growth of M. catarrhalis.
Information related to determinants of colonization (birth weight, gestational period, 
gender, educational level of the mother, breast-feeding, maternal smoking (prenatal and 
postnatal), day-care attendance, presence of siblings, and antibiotic usage) was ob-
tained from midwives, from hospital registries and by questionnaire at infant ages of 2, 
6 and 12 months. Binary logistic regression analysis was used to determine significant 
associations between the parameters described above and M. catarrhalis colonization. 
Additionally, multivariate analysis was performed to adjust for confounding factors. 
All variables from the univariate analysis were included in the multivariate model. For 
all determinants the missing values were modelled as a separate category and thus 
adjusted for in all analyses. Statistical analyses were performed using the Statistical 
Package of Social Sciences version 15.0 (SPSS Inc., Chicago, IL, USA).
Results
Characteristics of the study participants are shown in Table 1. The prevalence of M. 
catarrhalis increased from 11.8% at the age of 1.5 months to 29.9% at the age of 6 
months and 29.7% at the age of 14 months. The corresponding cumulative colonization 
rates were 12% (74/627), 22% (323/1459), and 25% (548/2216). The presence of 
siblings at the age of 1.5 months (adjusted OR (aOR) 2.36, 95% CI 1.37 – 4.06) and 14 
months (aOR 1.73, 95% CI 1.02 – 2.91) and day-care attendance at the age of 6 months 
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Table 1. Characteristics of infants enrolled in the study (n=1,079)
Parameter
Birth weight (kg) 3.509 (0.538)
Gestational period (weeks) 40.3 (37.1 - 42.1)
Gender, n (%)
- Female
- Male
521 (48.3%)
558 (51.7%)
Mother’s educational level, n (%)
- Lower/intermediate
- Higher
382 (35.9%)
683 (64.1%)
Prenatal smoking mother, n (%)
- No
- Yes
885 (87.5%)
127 (12.5%)
Postnatal smoking mother, n (%)
- No
- Yes
606 (87.1%)
90 (12.9%)
Siblings, n (%)
- No
- Yes
583 (61.1%)
371 (38.9%)
Day-care attendance, n (%)
- No
- Yes
164 (20.0%)
654 (80.0%)
Breast-feeding at 2 months, n (%)
- No
- Yes
332 (33.5%)
659 (66.5%)
Breast-feeding at 6 months, n (%)
- No
- Yes
714 (70.6%)
297 (29.4%)
Moraxella catarrhalis at 1.5 months, n (%)
- No
- Yes
553 (88.2%)
74 (11.8%)
Moraxella catarrhalis at 6 months, n (%)
- No
- Yes
Moraxella catarrhalis at 14 months, n (%)
- No
- Yes
583 (70.1%)
249 (29.9%)
532 (70.3%)
225 (29.7%)
Birth weights are presented as mean and standard deviation. Gestational period, with a skewed distribution, 
is presented with a median with a 95% range. All other values are presented as percentages. Incomplete data 
parameters included: educational level of the mother (n=14), prenatal smoking mother (n=67), postnatal 
smoking mother (n=383), siblings (n=125), day-care attendance (n=261), breast-feeding at 2 months (n=88) 
and 6 months (n=68), 1.5 month swab (n=452), 6 months swab (n=247), 14 months swab (n=322).
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(aOR 2.57, 95% CI 1.35 – 4.89) and 14 months (aOR 5.39, 95% CI 2.30 – 12.64) were 
found to be significant risk factors for colonization with M. catarrhalis. However, gender, 
educational level of the mother, maternal smoking and breast-feeding were found to 
be non-significant (Table 2). Additionally, children who were colonized twice or more 
with M. catarrhalis were significantly more likely to have siblings (aOR 2.22, 95% CI 
1.20 – 4.13) and attend day-care centers (aOR 5.84, 95% CI 1.67 – 20.41) (Table 3).
In this study, no antibiotics were given 48 hours before the swabs were taken. Of 
the 1,079 children enrolled in the study (all of whom were swabbed at least once), 93 
Table 3. Determinants of frequent (≥2) M. catarrhalis colonization events in the first year of life
Parameter OR aOR
Birth weight (kg) 1.58 (0.87 – 2.87) 1.27 (0.60 – 1.41)
Gestational period (weeks) 1.14 (0.93 – 1.41) 1.08 (0.83 – 1.41)
Gender
- Male
- Female
1.00
1.17 (0.67 – 2.06)
1.00
1.13 (0.62 – 2.04)
Breast-feeding at 6 months
- Yes
- No
1.00
1.81 (0.91 – 3.58)
1.00
1.72 (0.82 – 3.60)
Educational level mother
- Higher education
- Lower/intermediate education
1.00
0.86 (0.47 – 1.56)
1.00
1.17 (0.59 – 2.31)
Prenatal smoking mother
- No
- Yes
1.00
0.93 (0.34 – 2.53)
1.00
1.22 (0.35 – 4.17)
Postnatal smoking mother
- No
- Yes
1.00
0.74 (0.25 – 2.21)
1.00
0.82 (0.22 – 3.03)
Siblings
- No
- Yes
1.00
2.31 (1.29 – 4.14)
1.00
2.22 (1.20 – 4.13)
Day-care attendance
- No
- Yes
1.00
6.55 (1.98 – 21.69)
1.00
5.84 (1.67 – 20.41)
Values represent crude odds ratios (OR) and adjusted odds ratios (aOR) including 95% confidence intervals.
Incomplete data parameters included: breastfeeding (n=10), educational level of the mother (n=3), prenatal 
smoking mother (n=14), postnatal smoking mother (n=60), siblings (n=18) and day-care attendance (n=54). 
Significant ORs are shown in bold.
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children received antibiotics in the first 6 months after birth. Two hundred twenty-seven 
children received antibiotics between 6 and 12 months of age and 109 children received 
antibiotics in the first 12 months after birth. Two hundred and seventy-six children did 
not receive any antibiotics in their first year of life. There was no significant association 
between antibiotic use in the first 6 months after birth and M. catarrhalis colonization at 
6 months, or antibiotic use in the first year of life and M. catarrhalis colonization at 14 
months (data not shown).
Discussion
In this study of a large number of Dutch children, born in Rotterdam between Febru-
ary 2003 and August 2005, an increase in M. catarrhalis colonization prevalence was 
observed, from 11.8% at 1.5 months of age up to almost 30% at the ages of 6 and 14 
months, where a ‘plateau’ phase of colonization was seen. The corresponding cumula-
tive acquisition rates were 12%, 22%, and 25%, respectively.
The figure of 12% at 1.5 months is almost identical to that of an American study 
dating from 1997, although in this latter study, the cumulative colonization rates at the 
ages of 6 and 12 months were approximately 55% and 70%, respectively [4]. A reason 
for the difference in the cumulative colonization rate between The Netherlands and 
the USA is not available, although geographical and/or chronological differences in the 
genetic background of both bacteria and the human hosts cannot be ruled out. Interest-
ingly, both studies indicated a peak in cumulative colonization rates at approximately 6 
months of age (although this peak was much lower in the Rotterdam study). It appears, 
therefore, that geographically and/or chronologically distinct child populations remain 
susceptible to M. catarrhalis colonization up to approximately 6 months of age, but that 
after this time the cumulative acquisition and elimination rates of M. catarrhalis remain 
constant. This phenomenon may be due to the development of a more effective immune 
response against M. catarrhalis colonization, possibly as a consequence of children ac-
quiring and eliminating genotypically distinct strains [17-18].
Of the environmental factors investigated in this study, only the presence of siblings 
within the family and day-care attendance were found to be significantly associated with 
the risk of acquiring M. catarrhalis. Moreover, both risk factors were also significantly 
associated with an increased frequency of colonization. Previous studies in France and 
Sweden have also identified both of these environmental factors as contributing signifi-
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cantly to M. catarrhalis colonization [19-20]. From these findings, it appears likely that 
crowding is a global risk factor in facilitating M. catarrhalis colonization. Furthermore, 
this phenomenon is not only confined to the home environment but has also been 
found to be related to the hospital environment, as a recent publication indicated that 
multi-bed wards constituted a significant risk factor for patient-to-patient M. catarrhalis 
transmission in adults [21].
No significant association between the use of antibiotics and colonization with M. 
catarrhalis at 6 and 14 months of age was observed in this study. This means that 
there was no significant increase, or decrease, in colonization rates in children receiv-
ing antibiotics as compared with children who had received no antibiotics. In contrast, 
Varon et al. (2000) studied 629 children with respiratory tract infections in France, and 
cultured nasopharyngeal swabs before and after antibiotic treatment [19]. In this study, 
a significant decrease in the nasopharyngeal carriage of M. catarrhalis was observed af-
ter antibiotic treatment. However, the antibiotics used included amoxicillin-clavulanate, 
cefixime, erythromycin-sulfisoxazole, and cefpodoxime, antibiotics that are particularly 
effective against M. catarrhalis. In another study, Molstad et al. (1992) showed that 
increasing use of antibiotics was associated with an increase in β-lactam resistance in M. 
catarrhalis [22]. This effect may be reduced by enforcing strict national antibiotic pre-
scription policies, as demonstrated by data obtained from Denmark [23]. Unfortunately, 
our study did not have access to individual antibiotic prescription patterns. Further, The 
Netherlands has a strict policy on (limiting) antibiotic usage and the number and type 
of antibiotics that may be prescribed, although the use of amoxicillin-clavulanic acid is 
increasing in children [24]. In any case, antibiotic resistance rates in bacteria obtained 
from the nasopharynx of children who have not previously been treated with antibiot-
ics may be relatively high. For example, Faden et al. (1994) reported M. catarrhalis 
resistance rates of 90% for amoxicillin and 19% for trimethoprim-sulfamethoxazole in 
children who had not previously been treated with such antibiotics [25].
Prenatal and postnatal smoking was not found to be a significant risk factor for M. 
catarrhalis colonization, which is in contrast with the study of Brook and Gober (2008), 
who found that the nasopharynx of healthy children of smokers harbors a high number 
of pathogens that are similar to the bacterial flora found in their parents when compared 
with healthy children and non-smoking parents (P<0.005) [8]. In a previous study 
by Principi et al. (1999), it was shown that passive smoking was not a significant risk 
factor for M. catarrhalis colonization, which agrees with our findings if we consider that 
children whose parents smoke are likely to be passively exposed to cigarette smoke.
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Breast-feeding was not a significant risk factor. Breast-feeding has been found to be 
beneficial in reducing the risk of respiratory infections, but appears not to be significant 
with respect to bacterial nasopharyngeal colonization rates [26-28].
In conclusion, the presence of siblings and day-care attendance are important 
independent risk factors for M. catarrhalis colonization in infants in The Netherlands. 
Consequently, crowding is an important risk factor for early (and frequent) colonization. 
The M. catarrhalis cumulative colonization rate increases until a peak is reached at 6 
months of age, whereupon a colonization plateau is observed. This plateau could be a 
consequence of clearing of maternal antibodies or the development of a more effective 
immune response against the many different M. catarrhalis genotypes circulating in the 
first year of life, although this hypothesis requires further investigation.
Finally, this study was set up purely to investigate the genetic and environmental 
factors associated with nasopharyngeal carriage of respiratory bacterial pathogens in 
infancy. Although information about (presumed) OM episodes is available for this study, 
the diagnosis of OM was based on parental reports (postal questionnaires at the infant 
ages of 6, 12 and 24 months). Mothers were asked whether their children suffered from 
fever in the preceding period, whether this period of fever was accompanied by earache, 
and whether they had visited a general practitioner. The diagnosis of (presumed) OM 
required the presence of at least one period of fever accompanied by earache for which 
a doctor was visited. However, no association was found between the frequency of 
M. catarrhalis colonization and OM using these criteria (J.A.M. Labout, personal com-
munication). Studies have shown that the use of parental reports for the definition of 
a clinical symptom may influence the outcome of epidemiological research [29-30]. In 
order to collect more definite data, OM should be diagnosed by a medical practitioner in 
future studies [4]. Additional studies will be necessary in order to investigate the effect 
of (multiple) colonization events on the prevalence of upper respiratory tract disease in 
infants.
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Abstract
The colonization dynamics of Moraxella catarrhalis were studied in a population com-
prising 1,079 healthy children living in Rotterdam, The Netherlands (the Generation 
R Focus cohort). A total of 2,751 nasopharyngeal swabs were obtained during four 
clinic visits timed to take place at 1.5, 6, 14 and 24 months of age, yielding a total of 
709 Moraxella catarrhalis and 621 Haemophilus influenzae isolates. Between January 
2004 and December 2006, approximate but regular 6-monthly cycles of colonization 
were observed, with peak colonization incidences occurring in the autumn/winter for M. 
catarrhalis, and winter/spring for H. influenzae. Co-colonization was significantly more 
likely than single-species colonization with either M. catarrhalis or H. influenzae, with 
genotypic analysis revealing no clonality for co-colonizing or single colonizers of either 
bacterial species. This finding is especially relevant considering the recent discovery of 
the importance of H. influenzae - M. catarrhalis quorum sensing in biofilm formation 
and host clearance. Bacterial genotype heterogeneity was maintained over the 3-year 
period of the study, even within this relatively localized geographical region, and there 
was no association of genotypes with either season or year of isolation. Furthermore, 
chronological and genotypic diversity in three immunologically important M. catarrhalis 
virulence genes (uspA1, uspA2 and hag/mid) was also observed. This study indicates 
that genotypic variation is a key factor contributing to the success of M. catarrhalis 
colonization of healthy children in the first years of life. Furthermore, variation in im-
munologically relevant virulence genes within colonizing populations, and even within 
genotypically identical M. catarrhalis isolates, may be a result of immune evasion by this 
pathogen. Finally, the factors facilitating M. catarrhalis and H. influenzae co-colonization 
need to be further investigated.
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Introduction
Moraxella catarrhalis is part of the normal bacterial flora in the nasopharynx of children, 
although over the past two decades, it has emerged as a significant bacterial pathogen 
and not simply a commensal colonizer [1]. Studies have shown that the bacterium 
rapidly colonizes the nasopharynx soon after birth and that the carriage rate of M. 
catarrhalis in healthy children varies between 7 and 36% [2]. However, in children 
with upper respiratory tract infections (URTI), including acute otitis media (AOM), the 
carriage rate increases to approximately 50% [3-5]. Otitis media itself is a particularly 
important URTI during early childhood and the primary reason for children to visit a 
physician [6-7]. Furthermore, in many countries, AOM is the most common reason for 
prescribing antibiotics [7-10] or to undergo surgery (for the placement of grommets) 
[11]. The most common bacterial species cultured from the nasopharynx of children 
during otitis media episodes are Streptococcus pneumoniae, Haemophilus influenzae, 
M. catarrhalis and Staphylococcus aureus, either as single pathogens or as co-cultures 
[3, 5], with the patterns of nasopharyngeal colonization by micro-organisms being 
important determinants for otitis media disease [12-14].
With respect to M. catarrhalis, it has been shown that many factors affect nasopha-
ryngeal carriage of this human-specific pathogen, including, for example, the presence 
of siblings, day-care attendance and respiratory illness [2, 12, 15-17]. Furthermore, 
there is increasing information regarding the biological mechanisms facilitating M. 
catarrhalis-mediated colonization and disease development, with most publications 
stressing the importance of bacterial adherence as an essential first step in this pro-
cess. To date, several important M. catarrhalis adhesins have been described, including 
the ubiquitous surface proteins UspA1 and UspA2, and the hemagglutinin/Moraxella 
IgD-binding protein Hag/MID [18-19]. UspA1 and UspA2 acquire their adherence char-
acteristics through multifunctional binding sites, which include domains that have the 
ability to attach to epithelial cells via cell-associated fibronectin, laminin and vitronectin 
[20]. Furthermore, UspA1 includes a critical binding site for carcinoembryonic antigen-
related cell adhesion molecules, which are expressed in various human tissues including 
respiratory epithelia [21-22]. The Moraxella IgD-binding protein, also referred to as Hag 
(human erythrocyte agglutinin), is also important for host attachment. MID is an outer 
membrane protein (OMP) with specific affinity for soluble and cell-bound human IgD and 
is the only IgD-binding protein in Moraxella [23].
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Several other virulence-associated genes have been identified that may be associ-
ated with colonization and infection of M. catarrhalis, including the OMPs copB, OMPCD, 
McaP, MhaB, MhaC, Msp22, Msp75, Msp78 and lipooligosaccharide (LOS) [24-31]. 
Furthermore, several of these virulence genes have also been associated with the induc-
tion of the humoral immune response, making them potential vaccine candidate genes. 
However, relatively little is known about the frequency and the extent of genotypic 
variation within these virulence genes, and in particular how this variation may be 
associated with colonization over time.
The aim of this study was to investigate the seasonal and yearly prevalence patterns 
of longitudinal colonization, genotypic variation and variation in virulence-associated 
genes of M. catarrhalis isolates colonizing children within a single and distinct geographi-
cal region. Using these data, we hoped to discover whether distinct isolate genotypes, 
and/or identical putative vaccine candidate gene types circulated during specific time 
periods in healthy colonized children. We also investigated the longitudinal prevalence of 
M. catarrhalis and H. influenzae within our cohort of children, looking for co-colonization 
trends within this age group. These results will further help our understanding of M. 
catarrhalis population dynamics and provide insights into the chronological diversity and 
functionality of virulence-associated genes for this bacterial pathogen.
Methods
Study population
This study was embedded within the Generation R Focus cohort, part of a population-
based prospective cohort study from fetal life until young adulthood based in Rotterdam, 
The Netherlands (the Generation R Study) [32-33]. Within the Generation R Focus 
cohort, detailed assessments of fetal and postnatal growth and development were 
performed on 1,232 pregnant Dutch women. The mothers gave birth to 1,244 infants 
between February 2003 and August 2005, in Rotterdam, The Netherlands, of whom 
138 were excluded from the study analysis because consent was withdrawn after birth. 
Twins were also excluded from the analysis because of genetic relatedness, leaving a 
total of 1,079 infants. The Medical Ethics Committee of the Erasmus MC approved the 
study. Written informed consent was obtained from the parents of all the participants.
Infants visited the Generation R Focus cohort research centre at 1.5, 6, 14 and 24 
months after birth, resulting in 630 swabs being taken at 1.5 month, 787 swabs at 6 
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months, 717 swabs at 14 months and 617 swabs at 24 months between November 2003 
and September 2007. From 623 children, at least 3 swabs were available for bacterial 
culturing.
Bacterial isolates
Bacterial isolates were cultured from nasopharyngeal swabs taken from infants at 1.5, 
6, 14 and 24 months of age by a trained research nurse, using a sterile transport swab 
immersed in Amies transport medium. Swabs were cultured within 6 hours of sampling, 
using blood agar plates containing 5% sheep blood, chocolate agar and Haemophilus-
selective agar at an incubation temperature of 35°C in 5% CO2 for 48 hours. Plates were 
examined daily for the growth of M. catarrhalis and/or H. influenzae.
Genotyping
Genotyping of M. catarrhalis isolates was performed using PFGE and multilocus sequence 
typing (MLST). PFGE was also performed on H. influenzae isolates.
PFGE for M. catarrhalis was performed as detailed by Verduin et al. [34]. Briefly, M. 
catarrhalis plug digestions were performed using SpeI at 20 U per reaction and an elec-
trophoresis protocol comprising a first block with a constant voltage of 6 V cm-1, a pulse 
time from 3.5 to 25 seconds during the first 12 hours, followed by a second block of 8 
hours where the pulse time increased linearly from 1 to 5 seconds. The PFGE protocol 
for H. influenzae was adapted from Moor et al. [35]. Digestions were performed using 
SmaI at 30 U per reaction and an electrophoresis protocol comprising a first block with 
a constant voltage of 6 V cm-1, a pulse time from 6 to 8 seconds during the first 7 hours, 
followed by a second block of 17 hours where the pulse time increased linearly from 1 
to 38 seconds. All PFGE patterns were analyzed using BioNumerics (Applied Maths), with 
gel lanes normalized against a lambda DNA ladder (Bio-Rad) and band tolerance set at 
1.5%. PFGE products between 48.5 and 339.5 kb for M. catarrhalis and 48.5 and 485 
kb for H. influenzae were included in the band matching analysis.
MLST genotyping was performed to determine whether M. catarrhalis genotypes cir-
culating in the Rotterdam area were similar to M. catarrhalis genotypes worldwide and 
to establish genetic relationships with other internationally recognized clones available 
in the M. catarrhalis MLST database. MLST was performed on 12 M. catarrhalis isolates 
that had been cultured serially on three separate occasions from four children. Briefly, 
PCR was performed to detect and sequence the abcZ, adk, efp, fumC, glyRS, mutY, ppa 
and trpE genes as described in the guidelines available at the MLST website (http://
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mlst.ucc.ie/). A touchdown thermocycling program was used for glyRS and adk. The 
touchdown protocol used an initial annealing temperature of 70°C, which was reduced 
by 1°C per cycle over 15 PCR cycles. The following 20 cycles of amplification used an 
annealing temperature of 55°C. For ppa, efp, abcZ and trpE, a standard PCR protocol 
comprising an annealing temperature of 52°C and an elongation time of 2 minutes at 
72°C for 25 cycles was used, whilst for fumC and mutY an annealing temperature of 
55°C was used. PCR primer pairs were used for amplicon sequencing, except for the 
genes glyRS, fumC and mutY, which required separate sequencing primers (primers 
are available at http://mlst.ucc.ie/). Allelic profiles were defined and compared with the 
MLST types of isolates from different geographic regions available at http://mlst.ucc.ie/.
PCR screening of virulence genes
M. catarrhalis isolates were grown from the glycerol stock overnight at 37°C on blood 
agar plates. DNA was extracted using the MagNA Pure LC System (Roche Applied Sci-
ence). PCR was performed to detect the uspA1, uspA2, uspA2H, hag/mid and ompJ 
genes and 16S rRNA and LOS types as described previously [36]. A touchdown thermo-
cycling program was used for all PCRs except for hag/mid and LOS PCRs. The touchdown 
protocol used an initial annealing temperature of 70°C, which was reduced by 1°C per 
cycle over 15 cycles of PCR. The following 20 cycles of amplification used an annealing 
temperature of 55°C. All isolates negative for both uspA2 and uspA2H genes were 
tested using primers uspA2end.f and uspA2end [36], which amplify a conserved region 
found at the 3’-end of both uspA2 and uspA2H genes.
For the hag/mid gene PCR, a standard PCR protocol comprising an annealing tem-
perature of 55°C and an extension time of 8 minutes at 68°C for 25 cycles was used. 
The LOS-typing PCR protocol was performed as described by Edwards et al. [37].
After amplification, 16S rRNA PCR products were digested using the enzymes FspBI 
(10 U) and HhaI (10 U) to identify the 16S rRNA types [36].
Virulence gene variation
Virulence gene variation was assessed using PCR-RFLP typing on three major M. ca-
tarrhalis virulence genes. These genes comprised the ubiquitous surface protein genes 
A1 and A2 (uspA1 and uspA2), and the hemagglutinin/IgD-binding protein gene hag/
mid. PCR products of these genes were digested using the restriction enzyme HaeIII 
(BsuRI), using 10 U per reaction mix, and incubated overnight at 37°C. The HaeIII 
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restriction enzyme was chosen because its recognition site(s) is found within immuno-
logical important regions of the uspA1, uspA2 and hag/mid genes.
PCR-RFLP patterns were analyzed using BioNumerics (Applied Maths), with gel lanes 
normalized against a 1 kb (uspA2 and hag/mid) and 100 bp (uspA1) ladder and band 
tolerance set at 1.5%.
Data analysis
To evaluate potential predictors of colonization, logistic regression analysis was per-
formed with general estimating equations using the logit link function as implemented in 
the GENMOD procedure in SAS version 9.1.3 (SAS Institute, 2002, SAS version 9.1.3.). 
Separate analyses were conducted for the binary dependent variables of presence or 
absence of either M. catarrhalis or H. influenzae in a repeated measures design. The 
repeated variable was children, each of which had 1-4 swabs in the study period. Predic-
tor variables were the presence/absence of the non-target species, year and season. 
Seasons were defined as winter (December – February), spring (March – May), summer 
(June – August) and autumn (September – November). An independent correlation 
matrix structure among predictor variables was used but there were no differences in 
assessment of significances using exchangeable or unstructured correlation matrices. 
Two- and three-way interaction terms were not included in the final model because (i) 
all covariances between model variables in all analysis were low (r<0.04), (ii) explor-
atory analyses that excluded the repeated design showed interaction terms that did not 
contribute to the efficiency of the models and (iii) all, except one, of the 64 potential 
interaction terms for each target species were not significant.
Results
Bacterial isolates
A total of 709 M. catarrhalis isolates and 621 H. influenzae isolates were cultured from a 
total of 2,751 nasopharyngeal swabs obtained during the 3-year study period. The ages 
of the subjects when the cultures were taken are given in Table 1.
Population dynamics
Approximate, but regular 6-monthly cycles of peak colonization prevalence were ob-
served over the 3-year study period for M. catarrhalis, with a less regular pattern ob-
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served for H. influenzae. Peak seasonal prevalence differed between M. catarrhalis and 
H. influenzae, with M. catarrhalis prevalence highest in autumn and winter (odds ratio 
[OR] = 1.3 – 2.0 compared to spring or summer with P<0.03 for each comparison) and 
H. influenzae prevalence highest in winter and spring (OR = 1.5 – 1.9; P<0.01). Each 
species seasonal peak represented a significantly higher risk of carriage compared to 
non-peak seasons and the odds of a child being colonized by one of the two pathogens 
were significantly increased if the other species was present (OR = 1.5; P<0.0001). The 
peak in joint occurrences occurred in autumn. If the product of the individual species 
occurrence proportions is considered an indicator of the expected proportion of joint 
occurrences, chi-squared analyses showed significant excesses over expectations of 
joint occurrences for spring (P<0.01), summer (P<0.01), and autumn (P=0.04). Both 
pathogens were at or near their peak prevalence in 2006 and so the joint prevalence 
was highest that year at 10.8%. Conversely, the combined absence of both species in 
children was at its lowest in 2006 at 49.3%. For M. catarrhalis, there were significantly 
higher risks in 2006 and 2007 compared to 2004 and 2005 (OR = 1.5 – 2.1; P<0.01). 
In contrast, the risk for H. influenzae was highest in 2006 compared to other years (OR 
= 1.3 – 1.7; P<0.03) (Figure 1).
Genetic diversity of M. catarrhalis and H. 
influenzae isolates
A selection of 112 isolates were arbitrarily chosen for PFGE genotyping from the 709 
M. catarrhalis isolates cultured in this study, including isolates from children colonized 
only once during the study period and serial isolates cultured from the same child. A 
high degree of genotypic heterogeneity was maintained over the entire study period. 
While 16S rRNA types 2 and 3 (lineage 2) comprised a distinct clade, heterogeneity of 
all markers was independent of year, season and serial colonization status (Figure 2).
Table 1. Number of M. catarrhalis and H. influenzae cultures used in this study
Age at collection (months)
M. catarrhalis
n=709
H. influenzae
n=621
1.5 73 44
6 240 194
14 212 227
24 184 156
Total number in study population = 2,751
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MLST genotyping of 12 M. catarrhalis isolates was performed in order to determine 
the global context of colonizing isolates obtained from Rotterdam, The Netherlands. 
These 12 isolates originated from four different children that were colonized with M. 
catarrhalis on three separate occasions, and represented different PFGE genotypic clus-
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Figure 1. Colonization prevalence of M. catarrhalis and H. influenzae during 2004-2006. A. 
Proportion of M. catarrhalis (black line) and H. influenzae (dashed line) compared with the total 
number of swabs per month. The proportion of the joint occurrence of the two pathogens in each 
month compared with the total number of swabs taken per month is also shown (grey line). Note 
the approximate 6-monthly colonization cycle (from peak to peak), especially for M. catarrhalis. 
B. Cumulative percentage of M. catarrhalis-positive (black line) and H. influenzae-positive 
(dashed line) swabs recorded during the 3-year study period. Co-culture-positive swabs are also 
shown (grey line). The cumulative colonization burden in the study population increases at a 
constant rate for both pathogens and co-colonization over the 3-year study period.
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ters. The Rotterdam isolates tested were found to be non-clonal in nature with many 
(8 out of 12) singleton MLST types, further indicating the genetic heterogeneity of M. 
catarrhalis isolates, even within a relatively restricted geographical region (Figure 3).
Figure 3. MLST genotyping of 12 M. catarrhalis isolates. The sequence types assigned to the 
isolates are indicated with black arrows, showing the non-clonal nature of the isolates. Each dot 
represents a distinct MLST type, and MLST types connected with a black line possess similar 
allelic profiles, possibly derived from a common ancestor.
Due to the significant association between M. catarrhalis and H. influenzae colonization, 
36 H. influenzae isolates (including both co-colonizing and single-species isolations) 
Figure 2. Dendogram based on PFGE genotypic variation of 112 colonizing M. catarrhalis isolates 
obtained from 74 children aged 1.5-24 months during November 2003 and September 2007 
in Rotterdam. Time period after birth when nasopharyngeal swabs were taken: 1, 6 weeks; 2, 
6 months; 3, 14 months; 4, 24 months. Colonization events: 1, children colonized in a single 
sampling period only during the course of the study; 3, children colonized three times during 
the study period. 16S rRNA type: 1, lineage 1; 2/3, lineage 2. The month and year of isolate 
culture from the nasopharynx of children is also shown (year of peak prevalence underlined). 
Co-colonization with H. influenzae is indicated with asterisks (*). No clustering of serial isolates 
cultured from the same child, or co-colonizing (with H. influenzae) isolates, was observed.
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were chosen for PFGE genotyping to study their genetic diversity. No single H. influenzae 
genotype or clonal cluster was associated with co-colonization events (Figure 4).
PCR screening of virulence genes
PCR screening of the same 112 M. catarrhalis isolates for which PFGE was performed 
revealed an incidence of 97% (109/112) for uspA1, 80% (90/112) for hag/mid, 83% 
(85/102) for uspA2, 17% (17/102) for uspA2H and 100% (112/112) for ompJ. Ten 
isolates were found to be PCR-negative using previously published uspA2- and uspA2H-
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Figure 4. Dendogram of PFGE genotypic variation for 36 H. influenzae isolates obtained from 
12 children in Rotterdam. Time period after birth when nasopharyngeal swabs were taken: 1, 6 
weeks; 2, 6 months; 3, 14 months; 4, 24 months. The month and year of isolate culture from 
the nasopharynx of children is also shown (year of peak prevalence underlined). Co-colonization 
with M. catarrhalis is indicated with asterisks (*). Note the non-clonal nature of co-colonizing H. 
influenzae genotypes.
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specific primers, but positive using primers designed to amplify a conserved region of 
both uspA2 and uspA2H. These 10 isolates were not included in subsequent uspA2 and 
uspA2H prevalence calculations, though their inclusion as either uspA2 or uspA2H would 
not have affected the significance of the results (Table 2).
Table 2. Prevalence of virulence genes for 112 M. catarrhalis isolates for which PFGE genotyping 
was performed
Virulence gene Positive (%) Negative (%)
uspA1  97  3
hag/mid  80 20
uspA2  83 17
uspA2H  17 83
ompJ 100  0
16S rRNA gene type analysis revealed an incidence of 80% for 16S rRNA type 1 (lineage 
1), and a combined 20% for types 2 and 3 (lineage 2). All isolates that belonged to 
lineage 1 were associated with the presence of the hag/mid gene and OMPJ type 2.
Virulence gene diversity
PCR-RFLP was performed on amplified PCR products of the hag/mid, uspA2 and uspA1 
virulence genes of 86 M. catarrhalis isolates to assess virulence gene diversity of coloniz-
ing M. catarrhalis. Figure 5 shows the diverse nature of the PCR-RFLP patterns obtained 
for hag/mid, uspA2 and uspA1 circulating between 2004 and 2006 in healthy children 
in Rotterdam, The Netherlands. No distinct clustering of PCR-RFLP patterns was ob-
served during particular months or years, suggesting that many different virulence gene 
variants circulate within colonizing M. catarrhalis populations at any given time. This 
indicates that individual gene variation is as extensive as whole genome polymorphism.
Discussion
The colonization dynamics of M. catarrhalis and H. influenzae were studied in a popula-
tion of 1,079 healthy children living in Rotterdam, The Netherlands. Over the 3-year 
study period, a trend towards a regular 6-monthly M. catarrhalis colonization cycle 
(peak to peak) was observed for M. catarrhalis (which was less evident for H. influen-
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zae), without a pronounced seasonal peak for either. This observation tends to contrast 
with other studies reporting a seasonal influence on M. catarrhalis colonization, although 
these studies also reported that higher detection rates of M. catarrhalis during the 
colder months could be a side effect of nasal hyper-secretion induced by viral illness 
or cold weather [15]. Marchisio et al. (2001) concluded that the seasonal influence 
(comparison between spring and autumn) on nasopharyngeal carriage of respiratory 
tract pathogens in healthy children was negligible [38]. However, their study was lim-
ited in describing seasonal variations due to lack of observations in other years, which 
would have allowed a better understanding of the dynamics of the individual pathogens. 
Our results suggest that colonization with M. catarrhalis (and to a lesser extent H. 
influenzae) occurs via regular cycles of colonization and clearance, with the apparent 
increase in M. catarrhalis and H. influenzae detection during the winter months probably 
being a consequence of increased viral respiratory infections, e.g. influenza, resulting in 
increased opportunity for secondary bacterial infection by bacterial pathogens. The link 
between seasonal virus infections and resultant secondary bacterial infections has been 
indicated by several publications [5, 39-40]. However, reports by Meijer et al. (2007) 
and Arkema et al. (2008), who collected clinical and virological data via the European 
Influenza Surveillance Scheme (EISS), concluded that the 2005-2006 and 2006-2007 
influenza seasons in Europe were characterized by moderate clinical activity [41-42], 
and as a consequence may have resulted in less viral predisposition of the middle ear 
epithelium to bacterial infection.
At least two studies have suggested that the presence of a particular bacterial spe-
cies during URTIs may create a more hospitable niche for co-colonization by a second 
distinct bacterial species [5, 43]. Armbruster et al. (2010) showed that H. influenzae 
promotes M. catarrhalis persistence within polymicrobial biofilms via inter-species 
quorum signaling, and that co-infection with both species promotes the increased resis-
tance of biofilms to antibiotics and host clearance [43]. In fact, the process of biofilm 
formation has been demonstrated for numerous pathogens and is clearly an important 
microbial survival strategy.
Figure 5. Diversity of PCR-RFLP patterns obtained from the hag/mid, uspA2 and uspA1 virulence 
genes of 86 colonizing M. catarrhalis isolates cultured during the years 2004-2006 from healthy 
children in Rotterdam, The Netherlands. Note the diversity of restriction patterns, even within 
the same year, and that there is no linkage between genotype pattern combinations for the three 
immunologically relevant virulence genes tested.
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In our present study, co-colonization between M. catarrhalis and H. influenzae 
was significantly more likely than colonization with either bacterial species alone. This 
is an interesting result, as (for example) competition for cellular binding sites may 
be expected to occur in the presence of two distinct bacterial species, although this 
hypothesis needs further study. In detail, both species can bind to carcinoembryonic 
antigen-related cell adhesion molecules (CEACAM)-1, which is a receptor for the OMPs 
UspA1 and P5 of M. catarrhalis and H. influenzae, respectively [44]. CEACAM-1 is a 
specific innate immune receptor and although the CEACAM-binding ligands of respira-
tory pathogens are structurally diverse, they target a common site on the receptor 
[45-46]. However, competition for binding sites could be outweighed by non-receptor-
mediated factors associated with co-colonization events. For example, M. catarrhalis 
releases outer membrane vesicles (OMVs) or ‘blebs’ from its surface during growth in 
several environments, e.g. liquid culture, solid culture and biofilms. The OMVs that are 
secreted by M. catarrhalis carry UspA1 and UspA2, which are known to interfere with 
the activation of the complement cascade. Tan et al. (2007) showed that blebs carrying 
UspA1/A2 protected H. influenzae from complement-mediated killing, suggesting that 
M. catarrhalis may promote the survival of H. influenzae during co-colonization [47]. 
Deich & Hoyer (1982) demonstrated the generation and release of DNA-binding vesicles 
by H. influenzae [48], although this study did not mention the effect of H. influenzae 
blebs on the complement cascade. At this time, no other studies have reported the 
presence of H. influenzae blebs and their possible beneficial effect on other bacterial 
species in co-culture.
Whatever the exact cause of co-colonization dominance, neither co-colonizing M. 
catarrhalis or H. influenzae belonged to specific genotypic clones, suggesting that a 
ubiquitous system is facilitating the significant difference in co-colonization (versus 
single-species colonization) observed in this study. As recently described by Armbruster 
et al. (2010), the most likely (non-clonal genotype-related) ubiquitous system driv-
ing co-colonization events of these two bacterial pathogens appears to be the quorum 
sensing system [43]. However, complement-evading systems, e.g. via OMV-mediated 
protection, may also play a significant role.
Genotypic analysis revealed a high degree of diversity in colonizing M. catarrhalis 
isolates, an observation which is in agreement with previous studies showing that geno-
typic heterogeneity is typical of worldwide M. catarrhalis isolates colonizing both children 
and adults [36, 49-50]. Also, no significant association between genotype (cluster) and 
season, or year of isolation was observed, which is in contrast to a previous publication 
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by Levy et al. (2009) who reported that winter and spring season was a significant risk 
factor for clustering. However, Levy et al. (2009) studied transmission between patients 
within a relatively confined hospital setting [51], whereas the focus of our study was 
related to community transmission.
The prevalence of the virulence genes uspA1, uspA2 and hag/mid within our Rot-
terdam isolates was very similar to that previously reported for global M. catarrhalis 
isolates [36]. These virulence genes encode OMPs that play an important role in bacte-
rial adherence to human epithelia and complement resistance, as well as being immuno-
genic [19, 52-53]. This finding suggests that equilibrium has been reached with respect 
to virulence gene distribution in global M. catarrhalis isolates, as local geographical 
factors do not appear to generate significant differences in virulence gene prevalence.
Finally, a high degree of gene sequence diversity was identified in uspA1, uspA2 
and hag/mid virulence genes during the 3-year study period, with no apparent link-
age between uspA1, uspA2 and hag/mid banding patterns. Moreover, the PCR-RFLP 
method used was chosen to target restriction sites associated with immunologically 
important regions of the corresponding UspA1, UspA2 and Hag/MID proteins. The lack 
of intra-gene band pattern clustering and lack of inter-gene band pattern linkage in-
dicate that these three immunologically relevant virulence genes may be experiencing 
immune pressure, each separately adapting to evade the human immune response. 
The consequence would be immune evasion and an increased ability to colonize human 
populations over time.
Conclusion
Regular 6-monthly cycles of M. catarrhalis and H. influenzae colonization peaks were 
observed during 2004-2006 in healthy children residing in Rotterdam, The Netherlands. 
Colonization was characterized by a high degree of M. catarrhalis genotypic diversity 
that was maintained over the 3-year study period, and was independent of year and 
season of isolation. Genetic diversity was observed in three immunologically important 
virulence genes, with no clustering of band pattern types during particular months or 
years. This high degree of whole-cell genotypic variation, coupled to independent (un-
linked) virulence gene variation, is likely to be one of the factors ensuring the success of 
M. catarrhalis colonization events in the early years of life, facilitating immune evasion 
and further cycles of colonization.
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The fact that the co-colonization prevalence was significantly greater than single-
species prevalence alone for these two microbial pathogens, adds weight to the recently 
published findings indicating the importance of quorum sensing-mediated inter-species 
cooperation in biofilm maturation and increased resistance to host clearance. Our study 
provides the first evidence to indicate the importance of this quorum sensing interaction 
within the community setting.
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Abstract
Moraxella catarrhalis is generally associated with upper respiratory tract infections in 
children and lower respiratory tract infections in adults. However, little is known regard-
ing the population biology of isolates infecting these two age groups. To address this, a 
population screening strategy was employed to investigate 195 worldwide M. catarrhalis 
isolates cultured from children (<5 years of age) and adults (>20 years of age) present-
ing with respiratory disease in the years 2001-2002. Parameters compared included: 
genotype analysis; autoagglutination/biofilm forming ability; serum resistance; uspA1, 
uspA2, uspA2H, hag and mcaP incidence; copB/LOS/ompCD/16S rRNA types; and 
UspA1/Hag expression. A significant difference in biofilm formation (P=0.002), but not 
autoagglutination or serum resistance was observed, as well as significant differences 
in the incidence of uspA2- and uspA2H-positive isolates, and the distribution of LOS 
types (P<0.0001 and P=0.01, respectively). Further, a significant decrease in the inci-
dence of Hag expression (for isolates possessing the hag gene) was observed in adult 
isolates (P=0.001). Both uspA2H and LOS type B were associated with 16S rRNA type 
1 isolates only, and 2 surrogate markers (copB and ompCD PCR-RFLP types) for the 2 
major M. catarrhalis 16S rRNA genetic lineages were identified. In conclusion, there are 
significant differences in phenotype and gene incidence between M. catarrhalis isolates 
from children and adults presenting with respiratory disease, possibly as a result of 
immune evasion in the adult age group. Our results should also be useful in the choice 
of effective vaccine candidates against M. catarrhalis.
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Introduction
Moraxella catarrhalis has been associated with a number of respiratory-associated 
infections affecting both children and adults, including laryngitis [1], bronchitis [2] and 
pneumonia [3, 4]. However, the bacterium is mostly associated with upper respiratory 
tract infections in children e.g. otitis media [5], and lower respiratory tract infection in 
adults e.g. exacerbations of chronic obstructive pulmonary disease (COPD) [6].
M. catarrhalis populations may be sub-divided into two distinct genetic lineages, 
phenotypically characterized by (1) their ability to resist the destructive effect of human 
serum (i.e. complement resistant versus complement sensitive), and (2) differences in 
their ability to adhere to human epithelial cells [7, 8]. Recent research indicates that a 
population expansion (including the acquisition of virulence genes) probably occurred 
within the sero-resistant lineage of M. catarrhalis around the time of hominid expansion 
some 5 million years ago [8]. Further, the existence of these two subpopulations has 
implications for vaccine design, economics and vaccine development.
Several virulence-associated genes (and potential vaccine candidates), have been 
identified in M. catarrhalis, including the outer membrane proteins UspA1 [9], UspA2 
[10], Hag [11], OMPCD [12], CopB [13] and lipooligosaccharide (LOS) [14]. All of these 
vaccine candidates have been associated with the production of antibody [15-20], al-
though little is known about the frequency and expression of the corresponding genes 
in global isolates recovered from children and adults.
In this study, PFGE analysis, PCR screening methodologies, ELISA protein expression 
and phenotypic characterization studies were performed on a collection of worldwide M. 
catarrhalis isolates obtained from both children and adults presenting with respiratory 
disease. The study was set up to determine whether different M. catarrhalis populations 
infect these two age groups, and to provide preliminary incidence data that may be 
useful in the appraisal of current putative vaccine candidates against this pathogen.
Materials and methods
Bacterial isolates
Bacterial isolates comprised 195 M. catarrhalis isolates cultured between 2001 and 2002 
from children and adults presenting with respiratory disease (GR Micro, London, UK). 
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Approximately 40 random isolates from 5 world regions (11 countries) were included in 
the study (Tables 1 and 2). All isolates were cultured on Columbia blood agar at 37°C.
Autoagglutination assay
M. catarrhalis autoagglutination was measured according to Pearson et al. [21]. Briefly, 
isolates were grown overnight on brain heart infusion (BHI) agar, washed and resus-
pended in 4 ml of PBS to an OD405 of 1.0±0.1 (Pharmacia Biotech Novaspec II). The 
suspension was then allowed to stand undisturbed at room temperature. After 1 hour, 1 
Table 1. Geographical region of M. catarrhalis isolates
World region Country Number of isolates
North America USA 20
Canada 20
Western Europe Belgium  4
Germany 16
Spain 20
Latin America Brazil 14
Ecuador 10
Peru  5
Venezuela 10
Far East Japan 36
South Africa South Africa 40
Table 2. Clinical source of M. catarrhalis isolates
Source
Number of isolates
Children Adults
Ear fluid 14  1
Nasopharyngeal aspirate 27 13
Sinus 11  6
Blood  3  0
Throat  6  3
Unspecified  0  1
Sputum 33 61
Bronchoalveolar lavage  4 12
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ml aliquots were taken from the surface, the OD405 measured, and the difference in the 
OD405 between the two time periods calculated.
Biofi lm assay
Biofilm formation was assessed according to Pearson et al. [11]. M. catarrhalis isolates 
were grown in BHI broth overnight at 37°C, resuspended in BHI broth to approximately 
2-4×108 cells ml-1 (OD600 approximately 0.2 using a Pharmacia Biotech Novaspec II 
spectrophotometer) and 2 ml volumes were pipetted into 24-well cell culture plates 
(Corning, COSTAR) in duplicate. Plates were incubated for 19 hours at 37°C, then the 
BHI broth was replaced with 2 ml 199 medium/Earle’s balanced salt solution/crystal 
violet followed by incubation at room temperature for 15 minutes. After washing three 
times with deionized water, 2 ml of 95% ethanol was added and the plate gently rocked 
for 15 minutes. The absorbance of the ethanol solution was measured at 570 nm. 
Isolates whose duplicate absorbance’s differed by >25% were re-tested and an average 
from four OD570 readings was taken.
Serum resistance assay
Serum resistance was determined using the culture-and-spot test [22]. A suspension of 
M. catarrhalis was made in PBS to an OD600 of 1.0±0.1 and 100 μl evenly spread over 
a Columbia blood agar plate. After drying, 50 μl of pooled human serum (obtained from 
10 healthy adult volunteers) and 50 μl heat-inactivated serum (30 min at 56°C), were 
spotted onto the plate and the plate was incubated overnight at 37°C. Isolates were 
considered serum resistant (no effect on growth), intermediate (effect on growth visible 
but >50 colonies growing in active serum zone), or sensitive (<50 colonies growing in 
active serum zone). No effect on growth should be observed for the heat-inactivated 
(control) serum.
PFGE typing
Pulsed-field gel electrophoresis (PFGE) was performed as detailed by Verduin et al. 
[23]. Digestions were performed using SpeI at 20 U per reaction and the following 
electrophoresis protocol: the first block consisted of a constant voltage of 6 V cm-1, 
with the pulse time increased from 3.5 to 25 seconds during the first 12 hours; it was 
followed by a second block of 8 hours where the pulse time increased linearly from 1 
to 5 seconds. PFGE patterns were analyzed using GelCompar software (Applied Maths) 
74  Chapter 5
with gel lanes normalized against a lambda DNA ladder (Bio-Rad) and band tolerance 
set at 1.5%. PFGE products between 48.5 and 339.5 kb were included in the analysis.
PCR screening of genes
Isolates were grown overnight at 37°C on blood agar plates and DNA extracted us-
ing the MagNA Pure LC system (Roche). PCR was performed to detect uspA1, uspA2, 
uspA2H, hag, ompCD, copB, mcaP, 16S rRNA type and LOS type (see Table 3 for primer 
sequences). A touchdown thermocycling program was used for all PCRs except for hag 
and LOS PCRs. The touchdown protocol used an initial annealing temperature of 70°C, 
which was reduced by 1°C per cycle over 15 cycles of PCR. The following 20 cycles of 
amplification used an annealing temperature of 55°C. All isolates negative for both 
uspA2 and uspA2H genes were tested using primers uspA2end.f and uspA2end, which 
amplify a conserved region at the 3’-end of both uspA2 and uspA2H genes.
Table 3. Primer sequences used in this study
Primer Sequence (5’-3’) Gene
uspA2start cgctgtaaccagtgccatga uspA2
uspA2end acgatagccagcaccgatag uspA2/UspA2H
uspA2end.f gacagcagacgccattacca uspA2/UspA2H
MeierRTB2-10 ttgagccatagccaccaagtgc UspA2H
MeierRTF1-9 ctgaatttgccaaaggtcat UspA2H
MeierRTF1-8 cgttatgcactaaaagagcaggtc UspA1
MeierRTB1-8 gcatctgaccagcttagaccaatc UspA1
UspA1tl tgtgagcaaatgactggc UspA1
Pr406LOS caaaagaagacaaacaagcagc LOS
Pr408LOS catcaaaaacccccctacc LOS
Pr649LOS atcctgctccaactgactttc LOS
McCOPB2F ggcgtgcgtgttgaccgttttg copB
McCOPB2R gtttggcaggcgataggcgacat copB
Mcat.ompCD.f acgcactggcaagaagctaga ompCD
Mcat.ompCD.r gacctgcaccaaccaagacat ompCD
McatHag-2 gtcagcatgtatcattttttaagg hag
McatHagR4 tgagcggtaaatggtttaagtg hag
EUB-R agagtttgatcctggttcag 16S rRNA
EUB-L ctttacgcccatttaatccg 16S rRNA
mcaP-f cgcaataaagatcaccatgcttg mcaP
mcaP-r cgggatcccgctgacacattgcattgataaa mcaP
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For the hag gene PCR, a standard PCR protocol comprising an annealing temperature 
of 55°C and an extension time of 8 minutes at 68°C for 25 cycles was used. The LOS-
typing PCR protocol was performed as previously described by Edwards et al. [24].
After amplification, 16S rRNA PCR products were digested with FspBI (10 U) and 
HhaI (10 U) according to the manufacturer’s instructions. Gel electrophoresis revealed 
the following 16S rRNA types: type 1, FspBI 439/124 bp and HhaI 563 bp; type 2, FspBI 
332/124/107 bp and HhaI 563 bp; type 3, FspBI 332/124/106 bp and HhaI 370/192 
bp. The digestion method was based on the 16S rRNA type sequence results published 
by Bootsma et al. [7].
copB and ompCD PCR-RFLP
copB and ompCD PCR products were digested with RsaI and BseJI (BsaBI). Five U of 
RsaI (copB) or 5 U of BseJI (ompCD) were used per reaction mix, incubated at 37°C or 
65°C, respectively. The copB PCR-RFLP typing method was based upon sequence data 
published by Liu et al. (2006) but cannot distinguish between CopB types I and III [25]. 
Expected visible product sizes were: 374 and 157 bp for CopB type 0; 342 and 157 bp 
for CopB types I/III; 332 and 187 bp for CopB type II, and 519 bp for CopB type IV.
The restriction digestion site for ompCD PCR product (BseJI) was situated within the 
first A549 cell-binding domain (amino acids 16-236) of OMPCD [26].
UspA1 and Hag ELISA
The presence or absence of UspA1 and Hag expression was assessed in uspA1 and 
hag PCR-positive isolates using a standard ELISA methodology and specific anti-UspA1 
MAb 24B5 and anti-Hag 5D2 antibodies (kindly supplied by Prof. E. Hansen, UT South-
Western Medical Center at Dallas, Texas, USA). Briefly, M. catarrhalis isolates were 
grown overnight on Columbia blood agar at 37°C and resuspended in PBS to an OD600 of 
0.5 (equivalent to approximately 5×108 cells ml-1). One hundred microlitres of each sus-
pension was then loaded into 96-well MaxiSorp ELISA plates (NUNC), and allowed to dry 
by overnight incubation at 37°C. The following morning, plates were washed four times 
with PBS, blocked in 150 μl PBS with 2% (w/v) BSA and 5% (w/v) sucrose for 2 hours at 
37°C, and then re-washed four times in PBS with 0.05 % (v/v) Tween 20. One hundred 
microlitres of primary antibody was then added (at a 1:10 dilution of stock in PBS/BSA/
sucrose for both 24B5 and 5D2) and incubated for 1 hour at 37°C, before being washed 
four times in PBS/Tween 20. One hundred microlitres of secondary antibody (1:5,000 
dilution of stock of polyclonal goat anti-mouse for 24B5 or 1:10,000 dilution for 5D2 
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in PBS/BSA/sucrose) was added and incubated for 1 hour at 37°C before washing four 
times in PBS/Tween 20. Finally, 50 μl tetramethylbenzidine substrate was added to each 
well and color allowed to develop at room temperature; two PCR-negative isolates were 
included in triplicate in each ELISA plate. The geometric mean absorbance plus 4 times 
the standard deviation for the six negative control wells was calculated per plate and 
used as a negative cut-off value. Results were recorded as either positive or negative, 
dependent on this cut-off value.
Results
Autoagglutination and biofi lm assays
No significant difference in autoagglutination ability was observed between M. catarrhalis 
isolates cultured from children and adults, from lower versus upper respiratory tract in-
fection, or world region (unpaired t-test P=0.5 and P=0.88, Kruskal-Wallis test P=0.31). 
Also, autoagglutination ability was not significantly affected by the presence/absence of 
hag, uspA1, uspA2 or uspA2H genes, copB type, 16S rRNA type, ompCD PCR-RFLP type, 
LOS type or ability to form a biofilm. However, only two isolates were found to be uspA1 
PCR-negative, which makes comparison rather difficult for this gene. Results from the 
biofilm assay revealed no significant difference between upper versus lower respiratory 
tract infection, or world region (unpaired t-test P=0.94 and Kruskal-Wallis test P=0.18). 
Further, biofilm-forming ability was not significantly affected by the presence/absence 
of the hag or uspA1 genes, copB type, 16S rRNA type, ompCD PCR-RFLP type or LOS 
type. However, a significant difference in biofilm formation was observed between M. 
catarrhalis isolates cultured from children and adults (P=0.002) and between isolates 
carrying the mutually exclusive uspA2 and uspA2H genes (P<0.0001) (Figure 1).
Serum resistance assay
In total, 120 isolates were found to be serum-resistant, 64 of intermediate resistant 
and 11 sensitive. The distribution between the age groups was 65 (66%) resistant, 28 
(29%) intermediate and 5 (5%) sensitive for the <5 years age group, and 55 (57%) 
resistant, 36 (37%) intermediate and 6 (6%) sensitive for the >20 years age group 
(chi-squared test P=1).
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PFGE and 16S RNA types
Analysis of PFGE patterns showed two major lineages (at 34% similarity) within the 195 
isolates (data not shown), with 15/15 isolates in the first lineage comprising 16S rRNA 
types 2 and 3 only and 176/180 isolates in the second lineage being 16S rRNA type 1. 
No difference was observed between age groups and genotype lineage, or age group 
and 16S rRNA types. However, a significant difference was observed between 16S rRNA 
types versus upper or lower respiratory tract infection (Fisher’s exact test P<0.0001). 
In particular, 62% (109/176) of type 1 isolates were cultured from lower respiratory 
tract samples (i.e. sputa and bronchial alveolar lavages), whilst 95% (18/19) of types 2 
and 3 isolates were cultured from upper respiratory tract samples (i.e. nasopharyngeal 
aspirates, sinus fluids, ear fluids and throat swabs). Three type 1 isolates were also 
cultured from blood samples and one type 1 isolate was cultured from a sample of 
unknown origin. These isolates were not included in the analysis.
PCR screening of genes
PCR screening of the 195 M. catarrhalis isolates revealed an incidence of 99% (193/195) 
for uspA1, 90% (176/195) for hag, 78% (141/180) for uspA2, 22% (39/180) for us-
pA2H and 99% (194/195) for mcaP. The copB and ompCD genes were present in all the 
isolates screened. When divided into age groups, uspA1 was found to be present in 99% 
(97/98) of child isolates and 99% (96/97) of adult isolates, and hag in 90% (88/98) 
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Figure 1. Difference in biofilm-forming ability (OD570) with respect to age group (A) and presence 
of the mutually exclusive uspA2 and uspA2H genes (B). Significant differences in biofilm-forming 
ability may be seen (P values = unpaired t-test). <5, isolates obtained from children less than 
5 years of age; >20, isolates obtained from adults older than 20 years of age. uspA2 / uspA2H, 
uspA2 and uspA2H PCR-positive isolates.
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and 91% (88/97), respectively. Interestingly, uspA2 was present in 95% (88/93) of 
child-associated but only 61% (53/87) of adult-associated isolates, whilst the mutually 
exclusive uspA2H was present in only 5% (5/93) of child-associated and 39% (34/87) 
of adult-associated isolates (Fisher’s exact test P<0.0001). Fifteen isolates (8%) were 
found to be PCR-negative for uspA2- and uspA2H-specific PCRs, but positive using prim-
ers uspA2end.f and uspA2end. Although these isolates were not included in the above 
uspA2 and uspA2H calculations, their inclusion as either uspA2 or uspA2H would not 
have affected the significance of the results. All uspA2H PCR-positive isolates belonged 
to the 16S rRNA type 1, irrespective of age group and specimen source.
The majority of isolates belonged to LOS type A, representing 81% (79/98) and 63% 
(61/97) of child and adult isolates, respectively. The incidence of the LOS types is shown 
in Table 4. Within the age groups, 4% (4/98) and 7% (7/97) of isolates were untypeable 
(generated no PCR products). All negative PCRs were tested twice by PCR and were 
shown to contain DNA using a 16S rDNA PCR.
copB and ompCD PCR-RFLP
The distribution of CopB types was not significant between age groups, although there 
appeared to be a trend towards an increase in CopB types I/III (54/99) and a decrease 
in CopB type II (31/75) in adult-associated M. catarrhalis isolates. Further, CopB types 
I/III and II were almost exclusively associated with 16S rRNA type 1 (173/176 isolates), 
and CopB types 0 and IV were mainly associated with 16S rRNA types 2 and 3 (18/19 
isolates).
Two PCR-RFLP patterns were observed for ompCD, comprising bands of approxi-
mately 200/100 bp (pattern 1), and 180/80 bp (pattern 2). All 18 ompCD PCR-RFLP 
pattern 2 isolates belonged to 16S rRNA types 2 and 3, with 176/177 of PCR-RFLP 
pattern 1 isolates belonging to 16S rRNA type 1.
Table 4. Incidence of LOS types
LOS type
A B C
<5 79 13 2
>20 61 27 2
16S type* 127/6/7 40/0/0 2/2/0
* = incidence 16S rRNA types 1/2/3 with respect to individual LOS types. A significant difference is observed 
between LOS types A and B and age group (Fisher’s exact test P=0.01). All LOS B isolates and the great 
majority of LOS A isolates belonged to 16S rRNA type 1. <5, isolates from children; >20, isolates from adults
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UspA1 and Hag ELISA
The incidence of UspA1 and Hag expression in uspA1 and hag PCR-positive isolates is 
shown in Table 5. A significant difference in Hag expression (but not UspA1 expression) 
between the child and adult age groups was observed (Fisher’s exact test P=0.001).
Table 5. Incidence of hag and uspA1 gene expression
Hag UspA1
positive negative positive negative
<5 81 (92%) 7 (8%) 95 (98%) 2 (2%)
>20 64 (73%) 24 (27%) 93 (97%) 3 (3%)
Incidence of Hag and UspA1 expression (measured using ELISA) related to age group for global M. catarrhalis 
isolates PCR-positive for the hag and uspA1 genes. A significant difference in the incidence of Hag, but 
not UspA1, expression may be seen between child and adult groups (Fisher’s exact test P=0.001 and P=1, 
respectively). <5, isolates from children; >20, isolates from adults
Discussion
The ability to autoagglutinate has been linked to virulence in several Gram-negative 
bacterial species, including Moraxella bovis [27-29]. Further, the ability to autoagglu-
tinate has been shown to be independent of the strain isolation site (i.e. lower versus 
upper respiratory tract), which was also indicated by our own results [30]. The loss of 
autoagglutination ability has previously been linked to the insertional inactivation of the 
hemagglutinin (hag) gene, but not the uspA1 or uspA2 genes, in M. catarrhalis isolate 
O35E [21, 31]. From our own population-based study, it appears that the hag gene 
may not be equally important in influencing autoagglutination ability in all isolates of 
M. catarrhalis.
Bacterial biofilms on the middle-ear mucosa are associated with chronic otitis media 
[32, 33]. Further, M. catarrhalis is an important etiological agent of otitis media in 
children that has been shown to be capable of forming such biofilms [11]. Published 
evidence suggests a role for both UspA1 and UspA2H in biofilm formation [11, 34]. 
From our results, only two isolates were found to be uspA1-negative by PCR, which 
makes comparisons between uspA1-positive and -negative populations in our study 
difficult. Further, we found that isolates positive for uspA2 (a gene always found to be 
mutually exclusive of uspA2H) were better biofilm formers than isolates carrying the 
uspA2H gene, suggesting that uspA2 could also have a role in biofilm formation. In 
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fact, several recently described genes have also been associated with biofilm formation, 
including mcmA, mcaP [35, 36] and pil genes for type-IV pili (TFP) [37, 38]. In this 
study, the gene mcaP was equally distributed within child and adult age groups; mcmA, 
however, was not tested, as only one sequence is available (GenBank accession no. 
EF017300), meaning that conserved primers could not be designed. Luke et al. (2007) 
recently showed that TFP play an important role in nasopharyngeal colonization of M. 
catarrhalis and that biofilm formation is enhanced by TFP expression; and that TFP 
genes are ubiquitous within M. catarrhalis [38]. So it seems likely that a combination 
of several genes is important in biofilm formation in M. catarrhalis. Whatever the true 
situation, our results indicate that M. catarrhalis isolates from children are better biofilm 
formers than isolates from adults, possibly related to differences in hag gene expression 
levels. The fact that no significant difference in biofilm formation was observed between 
isolates cultured from the upper and lower respiratory tract indicates that biofilm forma-
tion is probably not reliant on a particular cell type, unless that particular cell type or a 
particular receptor is present in both upper and lower respiratory tract tissues.
The distribution of serum-resistant and serum-sensitive isolates was similar to that 
previously reported by Schmitz et al. (2002), who reported a serum-sensitive incidence 
of 19% in 419 M. catarrhalis isolates collected during the 1997-1999 European SENTRY 
surveillance study [39]. It appears from our data that the incidence of serum resistance 
in clinical M. catarrhalis isolates has remained relatively constant during the period 
1997-2002.
In this study, 99% of isolates possessed the uspA1, 78% uspA2 and 22% uspA2H 
genes, an incidence similar to that previously reported by Meier et al. (99% uspA1, 79% 
uspA2 and 21% uspA2H) [40]. However, significant differences in the incidence of uspA2 
(increased) and uspA2H (decreased) were observed between the child and adult groups. 
One possible scenario arising from our results is that children are initially immuno-naïve 
towards the various M. catarrhalis outer membrane proteins (and especially uspA2), 
but gain a repertoire of neutralizing antibodies over time. Non-naïve adults on the other 
hand would generally possess neutralizing antibodies (and in this scenario, especially 
anti-UspA2 antibodies), resulting in selection pressure for non-uspA2-expressing iso-
lates. The reduced incidence of uspA2 in adults could therefore be a consequence of 
immune evasion in M. catarrhalis. However, it should be noted that the actual presence 
of the uspA2 or uspA2H gene does not necessarily indicate UspA2 or UspA2H expres-
sion [41]. At present there is unfortunately no antibody available that can specifically 
distinguish between the UspA2 and UspA2H proteins.
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Three different LOS serotypes (A, B and C) have been described in M. catarrhalis, 
with a study by Vaneechoutte et al. (1990) indicating a worldwide incidence of 61.3% 
for type A, 28.8% for type B and 5.3% for type C, using an assortment of isolates 
obtained from children and adults. In that study, 4.6% of isolates remained unidentified 
[42]. A similar distribution of LOS types was found in our isolates, with the majority of 
isolates producing LOS type A in both children and adults, and 5.6% of isolates remain-
ing untypeable. Interestingly, LOS type B was twice as prevalent in isolates from adults 
compared to children and was exclusively associated with 16S rRNA type 1 isolates. 
This result could also possibly be a consequence of immune evasion by adult-infecting 
M. catarrhalis isolates, and has, in any case, negative consequences with respect to the 
development of single-type LOS vaccines.
One of the major findings of this study was a statistically significant decrease in 
the incidence of M. catarrhalis hag gene expression (in isolates proven to possess the 
hag gene) in adult-associated versus child-associated isolates. In contrast, a significant 
difference in the incidence of the hag gene between child- and adult-associated M. ca-
tarrhalis isolates was not found. Hag expression appears therefore to be downregulated 
in M. catarrhalis isolates infecting adults, a phenomenon that could again possibly occur 
as part of an immune-evasion response. Hag (and indeed UspA1) have been previously 
shown to be immunogenic in children and adults [6, 17, 19, 20]. It is, however, possible 
that UspA1 and Hag expression in vivo may differ from that observed in vitro, meaning 
that further research is necessary to verify the clinical significance of our observations.
In this study, an attempt has been made to map genotypic and phenotypic differences 
occurring in M. catarrhalis isolates infecting children and adults. It was observed that 
the isolates from these two age groups are genetically diverse and are not associated 
with the two major genetic lineages of M. catarrhalis previously determined. However, 
our results do indicate that disease-causing isolates infecting children possess a greater 
biofilm-forming capacity, and that differences in the incidence and expression of outer 
membrane-associated virulence genes exist between child- and adult-associated M. ca-
tarrhalis isolates within a global context, possibly as a consequence of immune evasion. 
We also discovered two surrogate genetic markers that distinguish between isolates 
of 16S rRNA type 1, and types 2 and 3 (rRNA types associated with the two major M. 
catarrhalis lineages, as well as between upper and lower respiratory tract infections). 
Finally, from our data, it appears that vaccines directed against single immunogenic 
outer membrane proteins (e.g. UspA2, UspA2H, UspA1 and Hag) and/or LOS types 
alone may be unsuitable in preventing both child- and adult-associated M. catarrhalis 
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infections. A multivalent vaccine comprising a combination of immunogenic epitopes 
may provide better protection against M. catarrhalis-mediated disease.
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Abstract
Otitis media (OM) is one of the most frequent diseases in childhood. Although often self-
limiting, in some cases recurrent acute otitis media (rAOM) or chronic otitis media with 
effusion (COME) occurs. In previous studies, the presence of bacteria and viruses was 
shown to be primarily associated with cases of (r)AOM, whereas COME is considered to 
be a mostly sterile condition. In this respect, we investigated whether microbiological 
infection patterns could be used to differentiate between rAOM and COME disease in 
children.
Children <6 years of age, suffering from rAOM (n=46) or COME (n=131), and sched-
uled for tympanostomy tube insertion were enrolled in a prospective study. Middle ear 
fluids (n=127) and nasopharyngeal samples (n=177) were collected during surgery for 
bacterial culture, PCR analysis for Streptococcus pneumoniae, Haemophilus influenzae 
and Moraxella catarrhalis, as well as multiplex PCR to detect 15 respiratory viruses. 
Serotyping and genotyping analyses was also performed to further characterize the 
bacterial pathogens isolated.
The pattern of bacterial and viral pathogens in middle ear fluids did not significantly 
differ between patients suffering from rAOM or COME, with a single bacterial pathogen 
being primarily cultured. Seventy-seven per cent (H. influenzae) to 100% (S. pneu-
moniae and M. catarrhalis) of cultured bacteria were genetically identical between middle 
ear fluid and nasopharynx. However, in rAOM patients, nasopharyngeal carriage was 
dominated by colonization with a single bacterial pathogen, whereas in COME patients, 
colonization with 2 or 3 pathogens was significantly more often seen. In both patient 
groups, H. influenzae and rhinovirus were the predominant pathogens in the middle ear 
(20% and 44%, respectively) and nasopharynx (68% and 50%, respectively).
From our results, the common perception that rAOM is associated with recurrent 
episodes of microbiologically-mediated AOM, whereas COME is generally a sterile in-
flammation, should be reconsidered.
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Introduction
Otitis media (OM) is one of the most frequent diseases during childhood and the most 
common reason for young children to visit a physician. In many countries, it is the most 
common reason for children to receive antibiotics or to undergo surgery [1-3]. In fact, 
the costs associated with OM disease are extremely high, not only due to the direct 
burden on healthcare systems per se, but also due to indirect effects associated with 
lost working days as parents stay at home in order to attend their sick children [4-6].
OM is the common denominator for a variety of middle ear diseases and can be 
divided into various categories, including acute otitis media (AOM) and otitis media with 
effusion (OME) [7-8]. AOM can be defined as the presence of middle ear effusion accom-
panied by signs of acute inflammation of the middle ear, such as otalgia, otorrhea, fever, 
and malaise or irritability of the child [3]. OME on the other hand, can either develop as 
a sequel to AOM, or develop de novo. The primary symptom of OME is hearing loss, due 
to the presence of middle ear fluid in the middle ear cavity, but in the absence of signs 
of acute inflammation [9]. Albeit often self-limiting, in 10-20% of the cases, OM results 
in chronic OME (COME) or recurrent AOM (rAOM) disease [10-11].
Although there is currently no universal standard for OM management, it may imply 
watchful waiting, antibiotic treatment, adenotomy, insertion of tympanostomy tubes 
or vaccination. AOM management involves, after initial observation and adequate an-
algesics, antibiotic treatment or, in case of recurrent infections, antibiotic prophylaxis 
or tympanostomy tube insertion. For OME, medical intervention is appropriate only if 
persistent clinical benefits can be achieved in the absence of spontaneous resolution. 
Therefore, healthy children with OME should be observed for at least 3 months before 
medical intervention is considered, in which case, surgical treatment involving the inser-
tion of tympanostomy tubes, or adenoidectomy, is feasible [3].
Vaccination against OM diseases is currently very limited. For example, the heptava-
lent pneumococcal conjugate vaccine (implemented in the Dutch National Immunization 
Program in 2006), is primarily directed against pneumococcal invasive disease, offering 
only a limited protective effect against OM [12-15]. Therefore, the development of new 
OM medical interventions, such as antimicrobial drug design and vaccine development, 
are required in order to improve current OM treatment options [16-17]. In order to 
effectively target new therapies, a detailed understanding of the role of bacteria and 
viruses in facilitating OM disease is warranted [18].
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A key element in the pathogenesis of OM is the nasopharynx, as this niche is the 
reservoir for bacterial pathogens related to middle ear infections [8]. Colonization of the 
nasopharynx with Streptococcus pneumoniae, Haemophilus influenzae and Moraxella 
catarrhalis (the 3 most important bacterial pathogens associated with OM disease) at 
an early stage, has been shown to predispose children to develop rAOM [19]. In ad-
dition, OM prone children have increased carriage rates of these bacterial pathogens 
compared to healthy controls [20-21]. In AOM, S. pneumoniae is the most frequently 
detected pathogen in middle ear fluid, followed by non-typeable H. influenzae and M. 
catarrhalis [22-23]. However, previous studies have indicated that this balance shifts 
towards H. influenzae and M. catarrhalis when AOM and COME are compared, although 
S. pneumoniae can still be present in the middle ear in a minority of these patients [24]. 
In general, fewer bacteria have been found in the middle ear of children suffering from 
COME compared to AOM.
Viral upper respiratory tract infections (URI) also predispose children to OM, as 
infection may cause Eustachian tube dysfunction, facilitates an increase in adherence of 
bacteria to epithelial cells, resulting in a rise in bacterial colonization of the nasopharynx 
and in a modulation of the host’s immune function [25-27].
In this study, we investigated differences in the patterns of bacterial and viral coloni-
zation and infection in the middle ear and nasopharynx of children diagnosed with rAOM 
or COME. In particular, the contribution of the major bacterial pathogens S. pneumoniae, 
H. influenzae and M. catarrhalis in the absence or presence of 15 respiratory viruses 
was studied in relation to rAOM and COME disease. We demonstrate that clear-cut 
differences in the clinical presentation between rAOM and COME cannot be explained 
by differences in the microbial flora in the middle ear. We therefore conclude that the 
common perception that rAOM is caused by recurrent episodes of AOM associated with 
bacteria and/or viral infections, whereas COME is generally a sterile inflammation, 
should be reconsidered.
Materials and methods
Study design
This prospective clinical study comprised a cohort of children <6 years of age who suf-
fered from rAOM or COME. The cohort was enrolled at a secondary and a tertiary hospital 
in Nijmegen, The Netherlands, from April 1st 2008 to July 1st 2009, and included children 
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suffering from rAOM or COME, as well as children who underwent surgery for the inser-
tion of tympanostomy tubes, in addition to adenotomy, at the same surgical setting. 
Recurrent AOM was defined as 3 or more episodes of AOM in the last 6 months or 4 epi-
sodes in the last 12 months [28]. The COME patient population consisted of children who 
had experienced a period of persistent OM with effusion lasting longer than 3 months. 
Signs, symptoms, and results of audiometry and tympanometry, were documented prior 
to surgery by an ear nose and throat (ENT) specialist. Patients with a prior history of 
malignancy, organ transplantation or immune deficiency were excluded from participa-
tion, as well as patients with recent elective ear surgery or systemic infectious diseases. 
Patient characteristics and risk factors were identified using a questionnaire. Ethical 
permission was obtained from the Committee on Research Involving Human Subjects 
in January 2008 (CMO 2007/239, international trial register number: NCT00847756).
Cl inical materials
Middle ear fluid was collected during surgery using a middle ear fluid aspiration system 
(Kuijpers Instruments) [29], whilst nasopharyngeal samples were obtained using a cot-
ton wool swab (192C, Copan). Middle ear fluid was suspended in 2 ml saline and divided 
into aliquots for bacterial culture, bacterial PCR and viral PCR. The nasopharyngeal 
samples were used for bacterial culture and thereafter stored at -80°C in 1 ml of 80% 
glycerol for subsequent viral PCR analysis.
Microbiology
Middle ear fluid and the nasopharyngeal samples were cultured to determine the 
presence of S. pneumoniae, H. influenzae and M. catarrhalis. Bacteria were cultured 
according to standard laboratory procedures [19] and stored at -80°C in the appropri-
ate culture media containing an additional 15% or 50% glycerol (S. pneumoniae, H. 
influenzae and M. catarrhalis, respectively). The less frequently described otopathogens 
Staphylococcus aureus, Streptococcus pyogenes, Haemophilus parainfluenzae, Pseudo-
monas aeruginosa and Alloicoccus otitidis were also included in the analysis if found to 
be present during bacterial culture.
To further characterize the bacterial isolates, all S. pneumoniae and H. influenzae 
isolates were cultured overnight on blood agar and chocolate agar plates at 37°C 
supplemented with 5% CO2, respectively. Pneumococcal isolates were serotyped using 
the Quellung reaction (Statens Serum Institute) and multiplex PCR was performed as 
previously described [30]. H. influenzae isolates were serotyped using slide aggluti-
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nation according to the instructions of the manufacturer (Difco laboratories, Becton 
Dickinson) [31].
S. pneumoniae, H. influenzae or M. catarrhalis obtained from middle ear fluid, as 
well as the equivalent pathogen detected in the nasopharynx, were further analyzed 
using multilocus sequence typing (MLST). Genomic DNA was isolated using a Qiagen 
Genomic-tip 20/G Kit according to the manufacturer’s instructions. To assign the strains 
to a sequence type (ST), 7 house-keeping genes were subjected to PCR amplifica-
tion and DNA nucleotide sequencing. The primer sets were obtained from the MLST 
website (www.mlst.net). Fifty microliter reaction mixtures were prepared with 1.25 U 
Taq polymerase (Applied Biosystems), 1× Taq polymerase buffer (10 mmol/L Tris HCl 
[pH 8.3], 50 mmol/L KCl), 1.5 mmol/L MgCl2, 0.2 mmol/L of each deoxynucleoside 
triphosphate, and 0.2 mmol/L of each primer. One microliter of genomic DNA was added 
to each reaction. The following parameters were used for amplification: denaturation at 
95°C for 5 minutes, 30 subsequent cycles of amplification, each consisting of 1 minute 
at 95°C, 1 minute at 50°C, and 30 seconds at 72°C, with a final extension at 72°C for 7 
minutes. PCR products were analyzed by gel electrophoresis on a 1% agarose gel, and 
the amplicon size was evaluated by comparing it with a 1 kb ladder (Invitrogen). PCR 
products were purified by using the QIAquick PCR purification kit (Qiagen). Sequencing, 
with forward and reverse primers, was performed on the ABI 377 DNA sequencer with 
Big Dye chemistry (Applied Biosystems), according to the manufacturer’s instructions.
PCR for quantitative DNA analysis of S. pneumoniae, H. influenzae and M. catarrhalis 
was performed. The respective genes chosen for bacterial detection were the S. pneu-
moniae ply gene [32], H. influenzae 16S rRNA gene [33] and the M. catarrhalis ompJ 
gene [34].
Virology
Samples were analyzed by multiplex PCR as previously described [35]. Briefly, upon 
thawing, nucleic acids were extracted from each sample, using the MagNA Pure LC 
System and the MagNA Pure LC Total Nucleic Acid Isolation Kit (Roche Applied Science) 
according to manufacturer’s instructions. A multiplex real-time PCR assay containing 15 
different viral pathogens was used. This assay was designed for the detection of specific 
viral genomes belonging to influenzavirus (IV) type A and B, coronavirus (CoV) 229E 
and OC43, human bocavirus (hBoV), enterovirus (EV), adenovirus (AdV), parechovirus 
(PeV), parainfluenzavirus (PIV) types 1-4, human metapneumovirus (hMPV), rhinovirus 
(RV) and respiratory syncytial virus (RSV). An internal control consisting of phocine 
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herpesvirus (PhPV, IC DNA control) and equine arthritis virus (EAV, IC RNA control) was 
included in the assay. RNA was reverse transcribed to cDNA using the TaqMan Reverse 
Transcription Reagents kit (Applied Biosystems) in a 50 μl reaction mix containing 20 
μl of nucleic acid isolate and random hexamers as primers, according to the manu-
facturer’s instructions. PCRs were performed on the LightCycler 480 instrument using 
LightCycler 480 Probes Master Mix (Roche Diagnostics). Validated primer/probe-mixes 
were purchased from Diagenode and used according to the manufacturer’s instruc-
tions. Cycling conditions were 95°C for 5 minutes, followed by 50 cycles of 95°C for 15 
seconds and 55°C for 15 seconds and 72°C for 20 seconds. The amount of virus was 
recorded semi-quantitatively based on the Ct value (cycle threshold value).
Statistical analysis
Statistical analysis was performed using the Statistical Package of Social Sciences ver-
sion 17.0 (SPSS Inc., Chicago, IL, USA). The chi-square test or Mann-Whitney U-test 
was used when appropriate to calculate the statistical differences between patient 
baseline characteristics. The chi-square test was used in the analysis of categorical data 
obtained from bacterial and viral culture and PCR.
Results
Bacterial patterns in the middle ear do not 
discriminate between rAOM and COME
From April 2008 to July 2009, 177 children were enrolled in this study. Selected de-
mographic and clinical characteristics of the cohort are shown in Table 1. Recurrent 
AOM was mostly diagnosed at a younger age, while the prevalence of COME increased 
by age (rAOM 75% during the first year of life vs. 17% at 5 years of age; COME 25% 
during the first year of life vs. 83% at 5 years of age). A middle ear fluid specimen was 
collected from 72% of the children (n=127), and there was a significant difference in 
the presence of middle ear fluid and OM diagnosis (rAOM n=27 (59%) vs. COME n=99 
(76%), P=0.03). Children suffering rAOM presented with less ENT-related surgery in 
their medical history when compared to children suffering from COME, but received 
significantly more antibiotics <1 year prior to surgery.
In rAOM, no pneumococci were cultured from middle ear fluid, whereas H. influen-
zae and M. catarrhalis were detected in 23% and 4% of rAOM, respectively (Table 2). 
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S. pneumoniae was observed in 5% of the COME specimens, H. influenzae in 19% and 
M. catarrhalis in 9%. Based on bacterial culture, the presence of multiple bacteria in 
middle ear fluid was found sporadically and only in patients diagnosed with COME. Co-
infection by S. pneumoniae and H. influenzae was found in only a single patient (<1%), 
as was co-infection by H. influenzae and M. catarrhalis (<1%). The less frequently 
described otopathogens S. aureus, S. pyogenes, H. parainfluenzae, P. aeruginosa and 
A. otitidis were only cultured sporadically and therefore excluded from further analysis.
PCR detection of the bacterial species present in rAOM middle ear fluids gener-
ated 12%, 46% and 27% positive results for S. pneumoniae, H. influenzae and M. 
catarrhalis bacteria, respectively, compared to 6%, 31% and 25% in the middle ear 
fluids of children suffering from COME. With respect to co-culture, rAOM PCR analysis 
indicated co-infection with S. pneumoniae and M. catarrhalis in a single child (4%), 
co-infection of H. influenzae and M. catarrhalis in 2 children (8%), and PCR positivity 
for all 3 pathogens in a single child (4%). In children suffering from COME, bacterial 
Table 1. Characteristics of children suffering from rAOM and COME
rAOM
n=46
COME
n=131
P-value
Male sex, n (%) 31/46 (67) 70/131 (53) 0.10
Mean age (years [SD]) 3.065 [1.686] 3.974 [1.406] 0.01
Presence of middle ear fluid, n (%) 27/46 (59) 99/131 (76) 0.03
≥4 URTI in the preceding year, n (%)1 17/43 (40) 31/119 (26) 0.09
Antibiotics prescribed in the preceding year, n (%) 12/44 (27) 15/127 (12) 0.02
History of ENT surgery, n (%) 9/32 (28) 50/94 (53) 0.01
Asthma/wheezing, n (%) 3/44 (7) 8/121 (7) 0.96
Allergic rhinitis, n (%) 5/43 (12) 5/120 (4) 0.08
Eczema, n (%) 7/44 (16) 20/120 (17) 0.90
Birth weight, mean (g) 3374 3370 0.93
Breast-feeding <3 months, n (%) 29/42 (69) 69/120 (58) 0.19
Prevnar immunization, n (%)2 18/38 (47) 35/110 (32) 0.08
Tobacco smoke exposure, n (%) 16/42 (38) 34/118 (29) 0.26
Older siblings, n (%) 24/33 (73) 66/104 (63) 0.68
Day-care attendance, n (%) 22/43 (51) 57/118 (48) 0.75
Significant differences are shown in bold
1Upper respiratory tract infections
2The Prevnar vaccine was introduced in the Dutch National Immunization Program for children born after 
01-04-2006
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co-infections with S. pneumoniae and M. catarrhalis were found in 3 children (3%), M. 
catarrhalis and H. influenzae in 5 children (5%), and S. pneumoniae and H. influenzae 
in 2 children (2%).
A comparative analysis relating the detection of S. pneumoniae, H. influenzae and M. 
catarrhalis by culture and PCR was performed on 121 middle ear samples. As expected, 
PCR detected bacterial DNA in a significant percentage of culture negative middle ear 
effusions: S. pneumoniae in 4.1% (NS), H. influenzae in 16.5% (P<0.001) and M. 
catarrhalis in 19% (P<0.001).
Finally, the presence of each specific pathogen, measured using conventional culture 
techniques or qualitative PCR, was not significantly different between the rAOM and 
COME groups. Additionally, quantitative PCR detected no significant difference in bacte-
rial load between the two groups (data not shown).
Nasopharyngeal carriage with a single pathogen 
dominates in rAOM patients
H. influenzae was the most frequently detected bacterial pathogen isolated from the 
nasopharynx and equally present in both rAOM and COME groups (65% versus 68%, 
respectively). M. catarrhalis was detected in 37% and 44% of the rAOM and COME 
patients, respectively. Eleven percent of the children were non-carriers, a result that 
was again similar between both patient cohorts. Importantly however, a significant dif-
ference in S. pneumoniae colonization was observed between the groups, comprising 
35% positivity in rAOM patients compared to 60% positivity in COME patients (P=0.003) 
(Table 2).
Table 2. Frequency of S. pneumoniae, H. influenzae and M. catarrhalis in middle ear fluid and the 
nasopharynx of children suffering from rAOM and COME
Bacterial culture middle 
ear fluid
Bacterial PCR middle 
ear fluid
Bacterial culture 
nasopharynx
rAOM
n=26
COME
n=97
rAOM
n=26
COME
n=100
rAOM
n=46
COME
n=130
No bacteria 19 (73) 67 (69) 9 (35) 48 (48) 5 (11) 14 (11)
S. pneumoniae 0 (0) 5 (5) 3 (12) 6 (6) 16 (35) 78 (60)*
H. influenzae 6 (23) 18 (19) 12 (46) 31 (31) 30 (65) 89 (68)
M. catarrhalis 1 (4) 9 (9) 7 (27) 25 (25) 17 (37) 57 (44)
* P=0.003
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A single pathogen was more frequently detected in the nasopharynx of children 
suffering from rAOM, compared to those suffering from COME (48 vs. 29%; P=0.02) 
(Table 3), with co-colonization by more than 2 pathogens being significantly higher in 
children suffering from COME (42 vs. 60%, P=0.02). Moreover, co-colonization of two 
or more pathogens was significantly associated with the presence of bacteria in middle 
ear fluid of patients suffering from COME (P=0.04).
Bacteria in the nasopharynx and middle ear are 
often genetically identical
The presence of S. pneumoniae or H. influenzae in middle ear fluid was positively cor-
related with the presence of either S. pneumoniae or H. influenzae in the nasopharynx 
(S. pneumoniae P=0.049, H. influenzae P=0.034). M. catarrhalis was found in the 
nasopharynx of 42% of the children, with simultaneous occurrence of M. catarrhalis in 
the middle ear in 8% of the children. This association was not significant.
Serotype analysis of the 5 S. pneumoniae isolates cultured from middle ear fluid 
revealed the following serotypes: 23A, 23F, 6B, 19A, 7F. In all cases, the corresponding 
serotype was also found in the nasopharynx. Statistically significant differences were 
not observed between 1) pneumococcal vaccine types (i.e. those present in Pneumococ-
cal Conjugate Vaccine 7) and non-vaccine types (NVT: rAOM 71%; COME 66%), or 2) 
between typeable and non-typeable (NT) pneumococcal strains, when children suffering 
rAOM and COME were compared (NT: rAOM 14%; COME 3%).
Ninety-six percent of the H. influenzae isolates (n=23) cultured from the middle 
ear were non-typeable, compared to 95% non-typeable isolates cultured from the 
nasopharynx (n=113). Serotype E was detected in 4% of the middle ear fluid and 
4% of the nasopharynx specimens. Serotype B was detected in 1 nasopharyngeal 
specimen (1%).
Table 3. Presence of S. pneumoniae, H. influenzae and M. catarrhalis, as either single or multiple 
species, in the nasopharynx of children suffering rAOM or COME
Nasopharynx, bacterial culture
rAOM
n=46, (%)
COME
n=130, (%)
P-value
no pathogens 5 (11) 14 (11) 0.99
1 pathogen 22 (48) 38 (29) 0.02
≥2 pathogens 19 (42) 78 (60) 0.02
Significant differences are shown in bold
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MLST analysis revealed that the majority of nasopharyngeal and middle ear fluid 
isolates obtained from the same child were genetically identical (S. pneumoniae 100%; 
H. influenzae 77%; M. catarrhalis 100%). Further, no clonal relationships were observed 
for any of the 3 bacterial pathogens, i.e. there was no evidence to suggest that isolates 
originated from a single ‘founder’ isolate spreading throughout the community. This 
diversity of S. pneumoniae, H. influenzae and M. catarrhalis genotypes probably reflects 
a genetically heterogeneous population structure for these bacterial pathogens within 
this region of The Netherlands.
Rhinovirus dominates in both rAOM and COME 
patients and contributes to bacterial colonization
Rhinovirus was the most frequently detected virus present in middle ear fluids in both 
patient groups (rAOM 44%; COME 45%), followed by enteroviruses (7% and 8%, 
respectively), coronavirus (7% and 2%, respectively), and parainfluenzaviruses (4% 
and 1% respectively) (Table 4). The presence of enteroviruses in middle ear fluid was 
associated with the presence of rhinovirus, as 8 out of the 9 enterovirus-infected middle 
ears were also infected with rhinovirus (88%, P=0.01). Nevertheless, in the vast major-
ity of the samples only a single virus was detected.
Rhinoviruses were also the most frequently detected viruses in the nasopharynx, (rAOM 
51%; COME 50%), followed by parainfluenza viruses 1-4 (both 11%), adenoviruses (11% 
and 5%, respectively) and RSV (0% and 6%, respectively) (Table 4). The frequency of the 
different virus infections was not significantly different between the two groups.
Table 4. Presence of viruses in middle ear fluid and the nasopharynx of children suffering rAOM 
or COME
Middle ear fluid Nasopharynx
rAOM COME rAOM COME
n=27 (23%) n=91 (76%) n=37 (25%) n=109 (75%)
No viruses 11 (41) 42 (47) 9 (24) 38 (35)
Rhinovirus 12 (44) 41 (45) 19 (51) 54 (50)
Enterovirus 2 (7) 7 (8) 6 (16) 9 (8)
Parainfluenza virus 1-4 1 (4) 1 (1) 4 (11) 12 (11)
Others* 2 (7) 9 (10) 6 (16) 23 (21)
*AdV, CoV, IV type A and B, hMPV, PeV, hBoV, RSV
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The presence of rhinovirus in the nasopharynx was significantly correlated with 
co-occurrence of this virus in the middle ear (P=0.02), though this was not true for 
enteroviruses or parainfluenzaviruses.
Interestingly, a significant association was observed for bacterial-viral co-occurrence 
in the nasopharynx, the presence of S. pneumoniae or H. influenzae being significantly 
associated with the presence of rhinoviruses (P=0.047 and P=0.02 respectively), and 
the presence of M. catarrhalis being significantly associated with the presence of en-
teroviruses (P=0.02). No significant difference in bacterial-viral co-colonization was 
detected between children with rAOM and COME.
Discussion
In this study, we investigated whether the clinical signs and symptoms specific for rAOM 
and COME could be differentiated microbiologically by the presence of bacteria and viruses 
in middle ear fluid. The results of our study show that in this region of The Netherlands, the 
predominant bacterial pathogen associated with middle ear fluids obtained from children 
suffering from rAOM and COME is H. influenzae, and that presence of S. pneumoniae (8%), 
H. influenzae (36%) or M. catarrhalis (25%) is not significantly different between rAOM 
or COME children. However, Coates et al. (2008) demonstrated that bacteria can reside 
inter- and even intracellularly within the middle ear mucosa, leading to persistent otitis 
media [18, 33, 36]. Since we analyzed middle ear fluid per se and not the middle ear mu-
cosa in this study, our bacterial findings might represent an underestimation of the actual 
frequency of bacterial pathogens present in the middle ears of rAOM and COME children.
With respect to the nasopharynx, as with middle ear fluids, H. influenzae was the 
most frequent bacterial pathogen detected, though the role of nasopharyngeal carriage 
of the bacterial pathogens S. pneumoniae, H. influenzae and M. catarrhalis on the risk 
for OM disease is not yet fully understood. Some studies have reported that increased 
bacterial carriage rates are associated with an increase in OM [19, 37], while other stud-
ies have failed to demonstrate a correlation [38]. Further, the colonization density [8], 
as well as early colonization of pathogens in the nasopharynx, is considered to increase 
the risk of OM [20, 39], and it is also suggested that carriage of newly acquired bacteria 
is associated with OM [40]. Further studies are required in order to determine whether 
any of these factors play a significant role in the development of disease in rAOM and 
COME children compared with healthy children.
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We provide evidence that co-colonization with 2 or more pathogens in the nasophar-
ynx is significantly associated with the presence of bacteria in the middle ear of patients 
suffering from COME. However, this effect might be partially explained by the subtle yet 
statistically significant age differences observed between the two patient groups in this 
cohort study.
Previous studies described nasopharyngeal colonization in relation to the bacteria 
found in OM, but did not emphasize on nasopharyngeal colonization with multiple 
pathogens [16, 41]. Others showed correlations between nasopharyngeal colonization 
of either S. pneumoniae, H. influenzae or M. catarrhalis [42], or related nasopharyngeal 
colonization to clinical observations of AOM [26, 38]. Krishnamurthy et al. (2009) were 
the first who described a murine colonization model, which showed that increased inci-
dence of pneumococcal OM was affected by polymicrobial colonization, and in particular 
M. catarrhalis [43].
Fifty-five per cent of the children in this study did not possess S. pneumoniae, H. 
influenzae or M. catarrhalis in their middle ear fluids, and 11% of the children did not 
have any of these 3 pathogens in their nasopharynx. Hence, it appears that bacterial 
colonization of the nasopharynx is only a poor indicator of the presence of bacteria in 
the middle ear of children suffering from rAOM and COME. Although we found a positive 
association between H. influenzae in the nasopharynx and H. influenzae in the middle 
ear, as well as S. pneumoniae in the nasopharynx and middle ear, the actual numbers 
of bacteria present in the middle ear fluids were small, and these associations were only 
observed when the rAOM and COME study groups were combined.
Pathogen isolates were characterized using serotyping and/or MLST in order to 
investigate whether the pathogens present in the nasopharynx and middle ear were 
genetically identical within the same child (but genetically distinct between different 
children). Studies investigating the genetic relatedness of bacteria obtained from differ-
ent locations of the upper respiratory tract, and within a single patient, tend to appear 
sporadically in the literature. Among the different studies described, various approaches 
were used to determine this genetic relatedness, i.e. ribotyping, pulsed-field gel electro-
phoresis and amplified fragment length polymorfism [44-47]. The bacterial pathogens 
that were detected in the middle ear fluids of our cohort were genetically identical to 
those isolates cultured from the nasopharynx, as compared by MLST, which is in line 
with previous publications [44-47]. Further, the S. pneumoniae, H. influenzae and M. 
catarrhalis genotypes isolated from the total cohort of children represented a genetically 
heterogeneous population structure, i.e. the isolates were genetically highly diverse, 
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even though they all originated from a relatively restricted geographical region of The 
Netherlands.
The ability of upper respiratory tract viruses to pave the way for secondary bacterial 
infection in AOM has been described extensively in literature [27, 48-49]. Influenza A 
and S. pneumoniae, RSV and H. influenzae, and PIV and M. catarrhalis are just a few 
examples of viral-bacterial interaction investigated in both animal models and human 
studies [50]. Further, rhinoviruses have been implicated in the pathogenesis of COME 
[51]. However, whether the presence of upper respiratory viruses is a causative etiologic 
factor, or merely a remnant of previous infection, in rAOM and COME disease remains 
largely unknown. In the present study, a positive association for the co-occurrence of: 
1) rhinoviruses and S. pneumoniae, 2) rhinoviruses and H. influenzae, and 3) entero-
viruses and M. catarrhalis was observed in the nasopharynx, though no association 
between the co-occurrence of these viruses and bacteria was established in middle ear 
fluids. To our knowledge, we are the first group to analyze the co-occurrence of bacteria 
and viruses in middle ear fluids and its relationship to nasopharyngeal colonization.
In conclusion, a prospective cohort study was performed in Nijmegen, The Nether-
lands, to investigate the frequency of bacterial and viral pathogens in the middle ear 
and nasopharynx of children suffering from rAOM or COME. Results showed that the 
same pathogenic bacterial species and viruses are implicated in the pathogenesis of 
both rAOM and COME disease. Therefore, our findings do not support the assumption 
that COME is merely a consequence of persistent sterile inflammation in the middle ear.
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Abstract
Group A Streptococcus (GAS) and Moraxella catarrhalis are important colonizers and 
opportunistic pathogens of the respiratory tract. However, the majority of knowledge 
gathered to date regarding the colonization and pathogenic potential of these two 
pathogens has been mainly derived from work involving single bacterial species. Im-
portantly, evidence increasingly indicates the significance of polymicrobial infections in 
facilitating respiratory disease pathology.
In this respect, comparative co-culture experiments were set up in order to study 
the effect of M. catarrhalis co-cultivation on the global GAS serotype M3 gene expres-
sion profile. Co-culture generated a distinct GAS gene transcription profile, with a sig-
nificantly increased (≥4-fold) gene expression for the GAS virulence genes hyaluronan 
synthase (hasA), streptococcal mitogenic exotoxin Z (smeZ) and IgG-endopeptidase 
(ideS). In contrast, significant decreased (≥4-fold) gene expression was observed with 
respect to genes involved in energy metabolism.
This study provides the first evidence to indicate that polymicrobial infections involv-
ing GAS and M. catarrhalis may affect the expression of GAS related virulence and 
biofilm genes, possibly leading to an increased pathogenic potential for GAS during 
polymicrobial infections compared to pure GAS infections alone.
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Introduction
Streptococcus pyogenes, group A Streptococcus, is responsible for a wide range of 
infections including the relatively benign GAS-mediated pharyngitis, the life-threatening 
necrotizing fasciitis and streptococcal toxic shock syndrome. GAS is also an important 
cause of post-infectious sequelae such as post-streptococcal glomerulonephritis and 
rheumatic fever [1-4]. In contrast, Moraxella catarrhalis is an exclusive colonizer and 
opportunistic pathogen of the human respiratory tract, the bacterium being associated 
with both upper (e.g. otitis media (OM)) and lower (e.g exacerbations of chronic obstruc-
tive pulmonary disease (COPD)) respiratory tract infections. However, both GAS and M. 
catarrhalis share the same respiratory biological niche, particularly with respect to up-
per respiratory tract infections [5]. For example, although Streptococcus pneumoniae, 
Haemophilus influenzae and M. catarrhalis are considered the predominant organisms 
causing OM, studies have shown that GAS may also be included as one of the most 
frequent causative agents of OM, including in the development of OM complications such 
as acute mastoiditis [6-7]. However, the role of GAS in OM is often underappreciated 
due to the effectiveness of β-lactam antibiotics in eliminating this organism. Further, 
recent communications have indicated an increase in S. pyogenes related OM infections 
in Hungary between 2006 and 2008 (personal communication Dr. Éva Ban, Semmelweis 
University, Budapest, Hungary; manuscript in preparation).
Research has shown that co-colonization of bacterial respiratory pathogens leads 
to increased colonization and infection. For example, Xu et al. (2009) reported that 
H. influenzae could enhance the binding of S. pyogenes to epithelial cells [8]. Further, 
Armbruster et al. (2010) showed that co-colonization of M. catarrhalis and H. influenzae 
could influence biofilm formation and antibiotic resistance, while Verhaegh et al. (2010) 
showed that co-colonization of infants by M. catarrhalis and H. influenzae was signifi-
cantly more likely than single species colonization alone [9-10]. In fact, Armbruster et 
al. (2010) showed that a quorum sensing signaling mechanism positively influences M. 
catarrhalis biofilm formation, a system utilized by many pathogenic bacterial species to 
coordinate their gene expression as a response to the local bacterial population density. 
Until recently, there was little association between GAS and biofilm formation reported 
in the literature. One of the first observations was reported by Akiyama et al. (2003), 
and a limited number of studies since have demonstrated GAS biofilm formation in 
vitro and in vivo [11]. Nowadays, there is a growing understanding of the importance 
of biofilm formation in GAS-related colonization and infection. It has been found that 
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many GAS genes required for biofilm formation are also important virulence factors. 
Finally, polymicrobial infections may also promote the survival of bacterial species via 
the phenomenon of ‘indirect pathogenicity’. For example, S. pneumoniae is protected 
from the action of certain β-lactam antibiotics in the presence of BRO β-lactamase 
positive M. catarrhalis [12-13].
Due to the increasing evidence linking the importance of polymicrobial infections 
to the pathogenesis of respiratory disease, we sought to investigate the changes in 
global gene transcriptome patterns in GAS during GAS and M. catarrhalis co-culture. We 
utilized an established GAS microarray protocol to identify significantly up- and down-
regulated GAS genes, including those that could have an influence on GAS pathogenicity 
during polymicrobial clinical disease.
Methods
Bacterial strains and growth conditions
The isolates used in this study were a serotype M3 GAS strain MGAS16655 (cultured 
from a patient with pharyngitis and closely related to the reference strain MGAS315) 
[14], and M. catarrhalis strain JMF150 (isolated from a child presenting with OM and 
provided by Texas Children’s Hospital, Houston, United States). For co-culture experi-
ments, both organisms were cultured in Todd-Hewitt broth supplemented with 0.2% 
yeast extract (THY) at 37°C with 5% CO2 aeration. Further, each strain was grown 
in triplicate so that triplicate experiments could be performed. In order to quantify 
viable GAS and M. catarrhalis, both as single cultures and in co-culture, bacteria were 
grown in THY broth, and enumerated (colony forming units, CFU/ml) and OD600 readings 
determined at serial time points.
RNA extraction from co-cultures was obtained from isolates in the exponential/early-
stationary phase of growth after an incubation period of 2.5 hours, with control RNA 
being extracted from MGAS16655 grown under identical conditions as described above, 
but in pure culture. One milliliter of co-culture was added to volumes of RNA protect 
(Qiagen) and bacteria were incubated at room temperature for 5 minutes, then pelleted 
by centrifugation at 4000×g at 4°C for 10 minutes, and stored at -80°C until ready for 
RNA extraction.
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RNA extraction
RNA was extracted from exponential/early-stationary phase bacterial cells using the 
QIAGEN RNeasy mini kit according to the manufacturer’s instructions. RNA samples 
were treated with Ambion TURBO DNase to remove any contaminating DNA, and the 
quality of the RNA was analyzed using an Agilent 2100 bioanalyzer.
cDNA synthesis, fragmentation, 3’ end-labeling 
and hybridization
cDNA synthesis, fragmentation, 3’ end-labeling and hybridization was prepared from 
total RNA according to the GeneChip® expression analysis technical manual supplied 
by the manufacturer (Affymetrix Inc.), with slight modifications. Poly-A RNA controls 
were added to each RNA aliquot, and random primers to a final dilution of 25 ng/µl 
(Invitrogen) were annealed (10 minutes at 70°C, followed by 10 minutes at 25°C). 
First-strand cDNA synthesis was performed using 25 U/μl SuperScript III (Invitrogen) 
in the presence of 0.5 mM dNTPs, 0.5 U/μl SUPERase•In RNase inhibitor (Ambion), and 
10 mM dithiothreitol (10 minutes at 25°C, followed by 60 minutes at 37°C, 60 minutes 
at 42°C and 10 minutes at 70°C). RNA was removed by hydrolysis in 1 N NaOH (30 
minutes at 65°C), and neutralized with 1 N HCl before cDNA purification using the 
QIAquick 96 kit (Qiagen) according to the manufacturer’s recommendations. For cDNA 
fragmentation, 6-10 μg of cDNA and 0.2 U/μg of DNase I (Roche) were used (5 minutes 
at 37°C, followed by 10 minutes at 98°C). The fragmented cDNA (averaging 50 to 200 
bases) was 3′ end-labeled using GeneChip® DNA labeling reagent (Affymetrix Inc.) (60 
minutes at 37°C) according to the manufacturer’s instructions. The fragmented and 
end-labeled cDNA was added to the microarray hybridization solution without further 
purification. End-labeled cDNA was added to a custom GAS Affymetrix microarray [15] 
and incubated at 45°C overnight (~16 hours). The slides were then washed using a Flu-
idics Station 450 (Affymetrix Inc.). Microarray slides were scanned using a GeneChip® 
Scanner 3000 (Affymetrix Inc.) and analyzed.
Microarray transcriptome expression analysis
Microarray expression studies were performed in triplicate using a custom-made Affyme-
trix GeneChip that contained 100% of the ORFs of the GAS reference strain MGAS315 as 
previously described [15-17]. Briefly, samples used for microarray analysis were collected 
from cultures in THY at 2.5 hours after co-culturing. Controls comprised RNA extracted 
from GAS grown in pure culture under identical conditions as co-culture experiments. 
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Genes that were statistically significant (two-sample t-test; P<0.05) and had a ≥4-fold 
change in expression were included in the analysis. As a final step, the complete genome 
of M. catarrhalis strain RH4 [18] was compared to the genome of GAS strain MGAS315 
for regions of sequence similarity. If a gene was found to be similar in both species 
using a cut off of >95% similarity, then this gene was removed from the analyses due 
to possible problems with cross-hybridization of GAS and M. catarrhalis RNA transcripts.
Quantitative PCR analysis
Confirmatory quantitative gene transcript analysis was performed on 2 important GAS 
virulence associated genes, and the constitutively expressed control gene pros, using 
TaqMan quantitative real-time PCR (qRT-PCR) and a 7500 Fast Real-Time PCR System 
(Applied Biosystems) as previously described [15, 19-20]. Transcripts were compared 
to the internal reference gene tufA as previously described [21]. Sequence data for the 
respective TaqMan primers and probes are listed in Table 1. All TaqMan experiments 
were performed in quadruplicate.
Table 1. TaqMan quantitative real-time PCR primers and probes utilized in this study
Gene
Spy no.
in strain 
MGAS315
5’ primer 3’ primer TaqMan probe
hasA SpyM3_1851
ACCGTTCCCTTGTCAATA-
AAGG
CGTCAGCGTCA-
GATCTTTCAAA
CGCCATGCTCAAGCGT-
GGGC
proS SpyM3_1688
TGAATTTATCATGAAAGAC-
GGCTATAGTTTC
AATAGCTTCGTAAGCTT-
GACGATAATC
TCGTAGGTCACATCTA-
AATCTTCATAGTTG
speB SpyM3_1742
CGCACTA-
AACCCTTCAGCTCTT
ACAGCACTTTGGTAACC-
GTTGA
GCCTGCGCCGCCACCAGTA
Results
Characterization of serotype M3 GAS strain 
MGAS16655 and M. catarrhalis JMF150 growth as 
single cultures and in co-culture
Prior to characterizing the transcriptome of GAS, we studied the growth of strains 
MGAS16655 and JMF150 in THY medium in co-culture and as pure cultures. Both strains 
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grew rapidly in this medium, and the bacterial density reached ~108 CFUs/ml in the 
exponential/early-stationary phase (Figure 1). Further, the experiments showed that 
we were able to reproducibly correlate OD600 readings to CFU concentrations for both 
MGAS16655 and JMF150.
Changes in the GAS transcriptome induced by co-
culture with M. catarrhalis
Microarray expression analysis was used to test the hypothesis that GAS gene transcript 
levels differed significantly during growth in co-culture with M. catarrhalis compared 
to GAS pure culture alone. Principal component analysis (PCA; Partek Genomics Suite) 
was performed and indicated that the two different growth conditions (co-culture versus 
single culture) generated distinct GAS gene transcription profiles, with multiple virulence 
and energy metabolism genes being differentially expressed upon co-culture compared 
to the constitutively expressed control gene proS (Table 2).
GAS transcription expression levels were affected by a factor of at least 4-fold or 
greater for a total of 207 genes (61 genes with increased expression and 147 genes 
with decreased expression), after growth in co-culture and relative to the growth of 
GAS alone. Further, BLAST searching of whole genome sequences revealed that only a 
small percentage of the M. catarrhalis RNA transcripts were predicted to cross-hybridize 
with the GAS MGAS315 gene chip. When these potentially cross-hybridizing genes were 
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Figure 1. Characterization of growth curves for GAS serotype M3 MGAS16655 [], M. catarrhalis 
isolate JMF150 [l], and co-culture [ or ]. Bacterial growth was measured over time in 3 
independent experiments by determination of A) the OD600 and B) the CFU/ml, at hourly time 
points. The growth curve displayed represents the mean OD600 and CFU/ml values. Error bars 
indicate the standard error of the mean between individual experiments. Sampling time points 
for the start of co-culture [1], and for the harvesting of cells for RNA-isolation [2] are indicated 
by arrows.
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Table 2. List of GAS serotype M3 MGAS16655 genes exhibiting the most significant difference 
in expression during co-culture with M. catarrhalis when compared to GAS serotype M3 culture 
alone
Spy no.
in strain 
MGAS315
Fold 
change
Gene Function
SpyM3_1851 181,321 hasA Hyaluronan synthase
SpyM3_0616 34,675 pyrF Orotidine phosphate decarboxylase
SpyM3_0617 29,003 pyrE Orotate phosphoribosyltransferase
SpyM3_0558 26,203 pyrR
Uracil phosphoribosyltransferase / Pyrimidine operon regulatory protein 
PyrR
SpyM3_0559 24,299 pyrP Uracil permease
SpyM3_1716 22,044 - Streptococcal mitogenic exotoxin Z (SmeZ)
SpyM3_0132 20,776 - hypothetical protein
SpyM3_1853 20,445 hasC UTP-glucose-1-phosphate uridylyltransferase
SpyM3_0777 19,294 radC DNA repair protein RadC
SpyM3_1543 16,992 - Nicotinamidase
SpyM3_0618 15,182 amiC 6-aminohexanoate-cyclic-dimer hydrolase
SpyM3_0561 13,653 carA Carbamoyl-phosphate synthase small chain
SpyM3_0583 12,703 -
Immunoglobulin G-endopeptidase (IdeS) / Secreted immunoglobulin 
binding protein (Sib38)
SpyM3_0560 12,479 pyrB Aspartate carbamoyltransferase
SpyM3_0562 11,733 - -
SpyM3_1652 -49,579 salA Lantibiotic salivaricin A
SpyM3_1655 -51,635 lacF PTS system, lactose-specific IIA component
SpyM3_1678 -53,819 ulaA Transport protein SgaT, putative
SpyM3_1657 -54,741 lacC.2 Tagatose-6-phosphate kinase (EC 2.7.1.144) / 1-phosphofructokinase
SpyM3_1482 -58,292 lacD.1 Tagatose 1,6-diphosphate aldolase
SpyM3_1486 -78,036 - PTS system, galactose-specific IIC component
SpyM3_1742 -79,421 speB
Strepotococcal cysteine protease (Streptopain) / Streptococcal pyrogenic 
exotoxin B (SpeB)
SpyM3_1484 -84,780 lacB.1 Galactose-6-phosphate isomerase, LacB subunit
SpyM3_1679 -93,265 - PTS system IIB component
SpyM3_1656 -106,265 lacD.2 Tagatose 1,6-diphosphate aldolase
SpyM3_1659 -109,750 lacA.2 Galactose-6-phosphate isomerase, LacA subunit
SpyM3_1485 -125,047 lacA.1 Galactose-6-phosphate isomerase, LacA subunit
SpyM3_1751 -162,809 - PTS system, cellobiose-specific IIB component
SpyM3_1680 -371,559 - Transcription antiterminator, BglG family
SpyM3_1677 -431,501 - Transaldolase
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subtracted from the list of statistically significant, ≥4-fold, GAS expression transcripts, 
a total of 192 genes (207 minus 15 genes) remained. The final list comprised 52 genes 
with significantly increased expression and 140 genes with significantly decreased ex-
pression (Figure 2).
Significant down-regulation was observed for many genes of the functional subcat-
egories as shown in Figure 3 (73% of the genes whose expression was modified were 
down-regulated in co-culture relative to single culture), for example genes involved 
in signal transduction were all down-regulated. In contrast, genes encoding proteins 
involved in purine/pyrimidine metabolism were generally up-regulated. A key finding 
was that a ~180-fold increase and ~80-fold decrease in the expression of hasA and 
speB was observed, along with a significant decrease in the expression of many genes 
involved in carbohydrate utilization. Further, gene expression in co-culture resulted in 
significant differences in several GAS two-component systems and response regulatory 
systems (Table 3), compared to the results observed for GAS pure culture alone.
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Figure 2. Genes showing significant changes in expression, using a 4-fold cut-off value, for GAS 
serotype M3 MGAS16655 when grown in co-culture with M. catarrhalis. Results were calculated 
relative to gene expression values obtained for GAS M3 MGAS16655 grown in pure culture alone. 
One hundred and ninety-two genes were either 4-fold increased (52 genes) or 4-fold decreased 
(140 genes) in expression, which corresponds to 10% of the MGAS315 genome. The hasA, ideS, 
smeZ and speB genes have been associated with GAS virulence.
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Validation of DNA microarray data
TaqMan quantitative real-time reverse transcription PCR analysis confirmed the valid-
ity of the DNA microarray results for 2 representative and significantly up- or down-
regulated virulence genes, and the constitutively expressed control gene proS (Table 4).
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Figure 3. Number of genes up- or down-regulated after GAS co-culture with M. catarrhalis. Genes 
were classified into 13 main functional categories. Genes associated with energy metabolism 
comprised the most frequent down-regulated genes.
Table 3. Significant differences observed in GAS response regulatory (RR) systems for GAS 
serotype M3 MGAS16655 and M. catarrhalis JM150 grown in co-culture and relative to GAS 
serotype M3 MGAS16655 grown as a pure culture
Colonization Persistence
Spy no.
in strain 
MGAS315
RR Gene Kreikemeyer 
et al. (2003)
This 
study
(fold 
change)
Spy no.
in strain 
MGAS315
RR Gene Kreikemeyer 
et al. (2003)
This 
study
(fold 
change)
SpyM3_1227 Mga emm + +1.7 SpyM3_0480 RALPs sagA - -2.8
SpyM3_1726 Mga scpA + +7.6 SpyM3_0097 RALPs nra - -3.9
SpyM3_1630 Mga fba + +1.7 SpyM3_1728 RALPs mga - +1.6
SpyM3_0097 Mga nra + -3.9 SpyM3_1301 RALPs speA - +2.5
SpyM3_1728 Mga mga + +1.6 SpyM3_1742 RALPs speB - -79
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Discussion
The primary goal of this study was to investigate the effect of M. catarrhalis co-culture 
on global GAS serotype M3 gene expression, compared to GAS serotype M3 growth in 
pure culture alone. In this comparative co-culture study, the expression of 192 GAS 
genes were found to be significantly affected by at least a 4-fold difference as compared 
to growth of GAS serotype M3 alone. Several of the most significantly up-regulated 
genes during co-culture were known virulence genes (hyaluronan synthase, streptococ-
cal mitogenic exotoxin Z and IgG-endopeptidase), as well as genes involved in purine 
and pyrimidine metabolism. In contrast, in general, the genes most significantly down-
regulated upon co-culture were genes involved in energy metabolism.
The hyaluronic acid capsule (hyaluronan synthase gene hasA) is a virulence fac-
tor of GAS, playing a role in resistance to phagocytosis, bacterial aggregation, biofilm 
maturation, resistance to host defense peptides and neutrophil extracellular killing [2, 
22]. GAS also produces a number of highly potent exotoxins that act as superantigens. 
The streptococcal mitogenic exotoxin Z (SmeZ) is the most potent bacterial superan-
tigen so far discovered and enhances the cascade of pro-inflammatory events that 
follow invasive streptococcal infection [23-24]. GAS also secretes a highly effective 
IgG-endopeptidase (IdeS) that inhibits phagocytic killing by cleavage of specific IgG 
[25-27]. These virulence genes were all up-regulated during co-culture, indicating that 
the presence of M. catarrhalis could lead to an increase in the pathogenic potential of 
GAS (with concomitant clinical implications) compared to GAS infection alone.
Biofilm formation may be considered a developmental process that is characterized 
by the expression and regulation of distinct structural and regulatory genes during 
the steps that are required for cell-surface interactions (binding), maturation (sessile 
Table 4. Fold-change in gene expression observed for 2 virulence-associated genes (and a control 
proS) during co-culture versus pure culture, using a GAS MGAS16655 microarray and gene 
specific TaqMan assays
Gene Spy no. in strain MGAS315
Fold-change co-culture
(MGAS16655 Array)
Fold-change co-culture
(MGAS16655 TaqMan)
hasA SpyM3_1851 181,3212 472,4987
proS SpyM3_1688 -1,9155 -2,2436
speB SpyM3_1742 -79,4210 -75116,0372
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phase) and for a return to the planktonic lifestyle [28]. Recently, biofilms have become a 
topic of interest in the study of GAS, as many GAS genes show a cell density-dependent 
pattern of regulation. Further, GAS genes required for the development of biofilms are 
also important virulence factors, being important for invasion and survival of GAS in 
the human host [29-34]. For example, in a study performed by Cho et al. (2005), the 
hyaluronic acid capsule was found to be essential in biofilm formation, and an increase 
in speB expression was observed in biofilm formation compared to planktonic culture 
[34]. However, these results were in contrast to the study of Roberts et al. (2010), who 
found that an increased activity of SpeB contributed to the loss of the biofilm phenotype 
[30]. From our own results, speB was down-regulated 80-fold, though confusingly, hasA 
showed a 180-fold increase in expression. These often contradictory findings between 
hasA and speB may possibly be explained by the fact that only a subset of GAS strains 
is able to form biofilms, and that the studies performed used different GAS serotypes 
[31-32]. However, the authors could find no information regarding the biofilm forming 
capacity of serotype M3 GAS, or previous research on the effect of M. catarrhalis on GAS 
gene expression and biofilm forming capacity.
With respect to GAS response regulators and regulatory networks, Kreikemeyer 
et al. (2003) indicated distinct patterns of gene regulation associated with particular 
global response regulators during colonization, persistence and spread of GAS [35]. 
Though our results are not conclusive, comparison of our data to the data presented 
by Kreikemeyer et al. (2003), appeared to indicate a transition from GAS colonization 
to persistence during co-culture, which would be consistent with a hypothesis involving 
biofilm formation. Moreover, our results were obtained by comparing co-culture GAS 
with pure culture GAS, this means that our results were corrected for any possible 
effect associated with the time of isolate sampling, i.e. sampling at the transition from 
exponential to early-stationary phase. Co-culture may therefore increase the GAS popu-
lation of cells undergoing the transition from a colonizing to a persistence phase in a 
polymicrobial culture.
Our findings with respect to transcriptome expression are particularly relevant in the 
context of recent research detailing the effect of quorum sensing on the polymicrobial 
interactions of other respiratory bacterial pathogens. In particular, a recent study by 
Armbruster et al. (2010) showed that co-colonization of M. catarrhalis and H. influenzae 
(bacterial pathogens sharing the same respiratory niche as GAS) results in increased 
M. catarrhalis biofilm formation and resistance to antibiotics. This process was achieved 
via an autoinducer-2 (AI-2, luxS) quorum signaling system [9]. At the same time, 
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Verhaegh et al. (2010), showed that co-colonization of M. catarrhalis and H. influenzae 
was significantly more likely than single species colonization with either M. catarrhalis 
or H. influenzae alone, adding clinical epidemiological evidence to the laboratory-based 
findings [10]. In fact, many species of bacteria use quorum sensing systems to coor-
dinate their gene expression and biofilm formation, dependent on the local bacterial 
cell density. A homolog of luxS, the genetic determinant for AI-2 production, has been 
identified in GAS, though a luxS homolog in M. catarrhalis has not been found. However, 
evidence from whole genome sequencing does suggest that M. catarrhalis possesses 
an AI-1 luxR sensing system, but no quorum signaling system [36]. Currently, a role 
for quorum sensing systems in facilitating the observed GAS - M. catarrhalis polymi-
crobial interaction is still open to question, not least due to the fact that less ‘targeted’ 
mechanisms could be responsible for the change in GAS transcriptome profile during 
co-culture, including competition for nutrients.
The 15 genes that showed the most significant decrease in expression during co-
culture were mainly involved in energy metabolism, with an emphasis on galactose 
metabolism. Nutrient availability is a signal by which pathogens sense their external 
environment and to which they respond through regulated production of various viru-
lence factors. Studies have shown that co-cultures compete for nutrients and that in-
teractions between co-cultured strains also involve species-specific pH limits for growth 
and differential utilization of growth substrates [37-38]. The success of GAS, which 
thrives in diverse host niches, depends on the acquisition of nutrients from very differ-
ent sources and GAS virulence gene expression is highly responsive to carbohydrate 
source and availability; however, the pathways linking metabolism and virulence remain 
poorly understood [15, 39]. The authors observed trends in the metabolism-related 
transcriptional response of GAS during co-culture with M. catarrhalis, with the majority 
of the most significant differences occurring in the down-regulation of genes involved 
in carbohydrate utilization. This finding could be associated with a GAS transcriptional 
response to depletion of carbohydrate (and possible other nutrients) within the environ-
ment, thereby helping GAS to conserve its ‘energy reserves’, and ultimately facilitating 
entry into a sessile ‘state of rest’ (associated with biofilm formation) [40]. However, 
it should be noted that M. catarrhalis is biochemically asaccharolytic, meaning that 
it is unable to metabolize glucose or other carbohydrates [41]. Therefore, the true 
relationship between M. catarrhalis and GAS co-culture, carbohydrate depletion, and 
the down-regulation of genes involved in carbohydrate utilization remains to be further 
elucidated.
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Conclusion
The transcriptome profile of GAS is markedly altered in response to co-culture with M. 
catarrhalis, with genes involved in virulence (up-regulated) and carbohydrate utiliza-
tion (down-regulated) being especially affected. There also appeared to be an increase 
in GAS transition from a colonizing to a persistence phase. This study is a first step 
in understanding the mechanisms that help facilitate colonization and disease during 
polymicrobial infections with GAS and M. catarrhalis. The results may be useful in de-
termining the prognosis of infection, with respect to polymicrobial versus pure culture, 
as well as identifying new pathologies in GAS-M. catarrhalis polymicrobial morbidity.
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Abstract
The primary Moraxella catarrhalis-specific humoral immune response, and its associa-
tion with nasopharyngeal colonization, was studied in a cohort of infants from birth to 
2 years of age.
Results indicated that the levels of antigen-specific IgG, IgA and IgM showed exten-
sive inter-individual variability over time, with IgM and IgA levels to all 9 OMPs being 
relatively low throughout the study period. In contrast, the level of antigen-specific 
IgG was significantly higher for Hag385-863, MID764-913, MID902-1200, UspA1557-704 and 
UspA2165-318 OMPs in cord blood compared to 6 months of age (P≤0.001). This was 
a consequence of maternal transmission of antigen-specific IgG to newborn babies, 
possibly indicating a future role for these three surface antigens in the development of 
an effective humoral immune response to M. catarrhalis. Further, genetic variation in 
immunologically relevant regions of vaccine candidate genes was observed, indicating 
that the M. catarrhalis OMPs UspA1, UspA2 and Hag/MID are likely to possess major 
epitopes for immune evasion.
Finally, at 2 years of age, the levels of antigen-specific IgG still remained far below 
that obtained from cord blood samples, indicating that the immune response to M. 
catarrhalis has not matured at 2 years of age. We provide evidence that a humoral 
antibody response to OMPs UspA1, UspA2 and Hag/MID may play a role in the immune 
response to community acquired M. catarrhalis colonization events.
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Introduction
Moraxella catarrhalis is an aerobic, Gram-negative diplococcal commensal of the respi-
ratory tract. Although healthy children are frequently colonized with this bacterium, it is 
also able to cause disease, being especially associated with otitis media (OM), as well as 
exacerbations of chronic obstructive pulmonary disease (COPD) in adults.
Studies have shown that the bacterium colonizes the nasopharynx soon after birth 
and that the carriage rate of M. catarrhalis in healthy children may differ per geographi-
cal region, season and year of isolation [1]. For example, in a German study (November 
1991 to April 1992), 9% of children attending day-care centers ranging in age from 
4 months to 3 years old were colonized with M. catarrhalis [2]. In a Japanese study 
conducted in 1999, children aged 1 month to 5 years attending day-care centers, 35% 
were found to be colonized [3]. In The Netherlands, a comparative study of 1.5 to 14 
month old children born between February 2003 and August 2005 indicated a carriage 
rate for children ranging from 11.8% at the age of 1.5 months to 29.9% at the age of 6 
months and 29.7% at the age of 14 months [4]. In general, despite local geographical 
variation, infants tend to become colonized with M. catarrhalis at a very early age, 
resulting in a nasopharyngeal colonization peak for M. catarrhalis at 2 years of age [5].
Bacterial adherence to the respiratory mucosa is an essential step towards coloniza-
tion of the human respiratory tract epithelium, and research has indicated that the most 
important adhesins responsible for the attachment of M. catarrhalis to host cells include 
the outer membrane proteins (OMPs) UspA1, UspA2 and Hag/MID, though several other 
surface-exposed outer membrane proteins have been described that may also play a role 
in the process. Further, with respect to M. catarrhalis, it has been shown that colonization 
of the human respiratory tract epithelium results in an increased risk of disease, specifi-
cally OM disease (both chronic and acute) in children [6, 7]. Therefore, it is reasonable 
to expect that an effective immune response raised against UspA1, UspA2 and Hag/MID, 
for example via vaccination, will have a significant effect on colonization and disease.
OM is one of the major childhood diseases that necessitate visits to general practitio-
ners [8]. In 2004, the American Academy of Pediatrics (AAP) published new guidelines 
that addressed the diagnosis and treatment of acute otitis media (AOM), largely because 
the treatment of AOM is not always appropriate, and the long-term overuse of antibiot-
ics increases the risk of the development of antimicrobial resistance. The AAP guidelines 
recommended the use of observation as a potential strategy for the treatment of AOM, 
although global rates of antibiotic prescription for AOM still vary greatly [9-11].
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An alternative strategy to the use of antibiotics in the treatment of OM disease is 
vaccination [12]. However, there is currently no licensed vaccine available against M. 
catarrhalis, and none of the antigens so far described (which may serve as potential vac-
cine candidates) have progressed to clinical trials. The challenge in identifying potential 
vaccine candidates for M. catarrhalis lies in identifying antigens that are able to generate 
an appropriate immune response that prevents the process leading from colonization to 
infection. It is known that healthy adults possess naturally acquired serum antibodies 
directed against several M. catarrhalis OMPs, apparently via the acquisition and elimina-
tion of many different M. catarrhalis strains [13]. Further, changes in antibody response 
are observed in adults suffering from M. catarrhalis-mediated COPD disease [14].
Several new M. catarrhalis OMP vaccine candidates have been described in the 
literature, and previous studies have indicated that a multivalent vaccine comprising 
a combination of epitopes of these M. catarrhalis OMP vaccine candidates should form 
the basis of a vaccine to prevent M. catarrhalis-mediated colonization and disease [13, 
15, 16].
However, relatively little is known about the humoral immune response to these vac-
cine candidates, especially within the first few years of life. The present study was per-
formed to determine the humoral immune response to currently available M. catarrhalis 
OMPs in healthy Dutch children from birth to 2 years of age. Further, the relationship 
between M. catarrhalis colonization and immune response was also investigated.
Materials and methods
Study cohort
This study was embedded in the Generation R Study, a population-based prospective 
cohort study, designed to identify early environmental and genetic causes of normal and 
abnormal growth, development and health from fetal life until young adulthood [17]. 
This study was performed in a randomly selected subgroup of Dutch children whose 
parents are ethnically homogeneous (two parents and four grandparents born in The 
Netherlands), in order to exclude possible confounding factors associated with ethnicity.
In total, 57 infants who were born between February 2003 and August 2005 were 
included in this study. Three or 4 serial serum samples were collected from each infant 
for inclusion in the study. The collection totalled 177 samples, comprising 54 (31%) cord 
blood samples, 32 (18%) samples obtained at 6 months, 46 (26%) samples obtained 
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at 14 months, and 45 (25%) samples obtained at 24 months of age. The bacterial colo-
nization status was determined by taking nasopharyngeal swabs at the ages of 1.5, 6, 
14 and 24 months of age, with swabs being taken at the same time as serum samples. 
Swabs were obtained from 40 (70%), 49 (86%), 50 (88%) and 48 (84%) infants at 1.5, 
6, 14 and 24 months of age, respectively. The colonization status was determined using 
standard M. catarrhalis culture and detection techniques [1].
Moraxella catarrhalis antigens
The previously described M. catarrhalis recombinant proteins UspA1557-704 (aa 557–704 
of UspA1), UspA2165-318, MID764-913, MID902-1200, Hag385-863, MhaC, McaP51-333, orf 238 
and orf 296 were used in this study [13, 18-22]. These recombinant proteins represent 
the majority of the M. catarrhalis immunogenic proteins discovered to date.
Antigen coupling
Recombinant proteins were coupled to SeroMAP™ beads, which are carboxylated beads 
that are developed for serological applications. The coupling procedure was performed 
as detailed by Verkaik et al. [23]. Briefly, 5.0×106 microspheres were resuspended 
in 100 mmol/L monobasic sodium phosphate (pH 6.2) buffer. For activation of the 
carboxyl groups on the surface of the beads, 10 µl of 50 mg/ml of N-hydroxysulfosuc-
cinimide (Sulfo-NHS) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide was used 
(Pierce Biotechnology). The coupling buffer consisted of 50 mmol/L 2-(N-morpholino) 
ethanesulfonic acid, pH 5.0 (Sigma-Aldrich) in which 25 μg of protein was added. The 
final concentration of microspheres was adjusted to 4000 beads/µl with blocking-
storage buffer (PBS-BN; PBS, 1% bovine serum albumin, and 0.05% sodium azide [pH 
7.4]). The microspheres were protected from light and stored at 4°C until required. All 
centrifugation steps were performed at 12,000 g for 2 minutes at room temperature 
(RT).
Uncoupled beads were used as a negative control, and to determine non-specific 
binding. If minor non-specific binding was observed, then the median fluorescence 
intensity (MFI) values obtained from this non-specific binding was subtracted from the 
antigen-specific results.
Multiplex M. catarrhalis antibody assay
The multiplex procedure was performed as described elsewhere [23]. Briefly, after 
validation of the assay (where human pooled serum (HPS) MFI multiplex assay val-
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ues were compared to corresponding HPS MFI singleplex assay values), the different 
antigen-coupled microspheres were mixed to a working concentration of 4000 beads 
per color per well. Serum samples were diluted 1:100 in PBS-BN for measurement 
of antigen-specific IgG and IgA and 1:50 for measurement of IgM. Fifty microliters 
per diluted sample was incubated with the microspheres in a 96-well filter microtiter 
plate (Millipore) for 35 minutes at room temperature on a Thermomixer plate shaker 
(Eppendorf). The plate was washed twice with PBS-BN that was aspirated by vacuum 
manifold, and the microspheres were resuspended in 50 μl of PBS-BN. In separate 
wells, 50 μl of a 1:100 dilution of R-phycoerythrin (RPE)-conjugated AffiniPure goat 
anti-human IgG and IgA and 50 μl of a 1:50 dilution of RPE-conjugated donkey anti-
human IgM (Jackson Immuno Research) were added. The plate was incubated for 35 
minutes at room temperature and washed. The microspheres were resuspended in 100 
μl of PBS-BN. Measurements were performed on the Luminex 100 instrument (BMD) 
using Luminex IS software (version 2.2). Tests were performed in duplicate, and the 
fluorescence intensity values, reflecting quantitative antibody levels, were averaged. 
The coefficient of variation of these values was then calculated for each serum sample 
and averaged per protein and antibody isotype.
Vaccine gene carriage
M. catarrhalis isolates were grown from glycerol stocks at 37°C overnight on blood agar 
plates. DNA was extracted using the MagNA Pure LC System (Roche Applied Science). 
PCR was performed to detect the major identified M. catarrhalis vaccine candidates 
uspA1, uspA2 and hag/mid genes. Primer pairs were used to detect the uspA1 (RTF1-
8 5’-cgttatgcactaaaagagcaggtc and RTB1-8 5’-gcatctgaccagcttagaccaatc) and uspA2 
(RTF2-10 5’-gcatctgcggataccaagtttg and RTB2-10 5’-ttgagccatagccaccaagtgc) genes 
according to the protocol of Meier et al. [24]. For the detection of the hag/mid gene, the 
primers McatHag-2 (5’-gtcagcatgtatcattttttaagg) and McatHagR4 (5’-tgagcggtaaatggtt-
taagtg) were used [16].
Further, PCR was performed to detect ompJ types (a surrogate genetic lineage 
marker), and 16S rRNA types as previously described by Hays et al. and Verhaegh et 
al. [16, 25].
To identify the 16S rRNA types of individual M. catarrhalis isolates, 16S rRNA PCR 
products were digested using the enzymes FspBI (10 U) and HhaI (10 U) according to 
Verhaegh et al. [16].
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Isolate genotyping and vaccine-related gene 
diversity
M. catarrhalis genotyping was performed using pulsed-field gel electrophoresis (PFGE) 
as detailed by Verduin et al. [26]. Briefly, M. catarrhalis plug digestions were performed 
using SpeI at 20 U/reaction and an electrophoresis protocol comprising a 1st block with 
a constant voltage of 6 V cm-1, a pulse time from 3.5 to 25 seconds during the first 12 
hours, followed by a 2nd block of 8 hours where the pulse time increased linearly from 1 
to 5 seconds. All PFGE patterns were analyzed using BioNumerics (Applied Maths), with 
gel lanes normalized against a lambda DNA ladder (Bio-Rad) and band tolerance set to 
1.5%. PFGE products between 48.5 and 339.5 kb were included in the band matching 
analysis.
The genetic diversity of the top three vaccine candidate genes (uspA1, uspA2 and 
hag/mid) was assessed by aligning available NCBI gene sequences (http://www.ncbi.
nlm.nih.gov/guide/) of M. catarrhalis uspA1, uspA2 and hag/mid genes (Sci Ed Central 
for Windows 95, v1.2), in order to determine any variation present within M. catarrhalis 
OMP regions of interest [19, 20, 22].
Statistical analysis
Statistical analyses were performed using SPSS PASW version 17. The Wilcoxon signed-
rank test was used to compare the anti-Moraxella antibody levels between different age 
groups. The Mann-Whitney U-test was used to compare differences in antibody levels 
between colonized and non-colonized children. A P-value of ≤0.05 was considered to be 
statistically significant.
Results
Isolate genotyping, vaccine gene carriage and 
vaccine-related gene diversity
A high degree of genotypic heterogeneity in M. catarrhalis isolates colonizing children in 
the focus cohort was maintained over the entire study period, with no association found 
between genotype and any of the antigen-specific MFI values (Figure 1).
Ninety-seven percent (29/30) of the consecutive M. catarrhalis isolates were found 
to be positive for uspA1, with 90% (27/30) positive for uspA2, and 87% (26/30) 
positive for hag/mid gene carriage. In total, 87% (26/30) of the M. catarrhalis isolates 
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were categorized into 16S type lineage 1 (16S type 1; sero-resistant lineage), with the 
remaining 13% belonging to the 16S type lineage 2 (16S type 2 and 3; sero-sensitive 
lineage).
Of the 16 available NCBI complete gene sequences available for UspA1, when 
translated into protein, three submissions showed a deletion in the CEACAM-binding 
region, located in the vaccine region of UspA1557-704. Alignment of the 15 available 
UspA2 protein sequence data revealed a high degree of variability within the vaccine 
region UspA2165-318, including deletions and insertions when compared to the refer-
ence strain M. catarrhalis ATCC25238. In parallel, alignment of the 8 available Hag/MID 
protein sequence data for the vaccine candidate Hag385-863 revealed a high degree of 
variability within the vaccine region, including deletions and insertions when compared 
to the reference strain M. catarrhalis O35E. For the recombinant proteins MID764-913 and 
MID902-1200, alignment of the 8 NCBI Hag/MID protein sequences revealed a high degree 
of gene variability within the MID764-913 protein, including insertions and deletions, while 
for the IgD-binding protein MID902-1200, 97% similarity was observed for the vaccine re-
gion between the two proteins sequences that differed the most in the initial alignment.
Dynamics of the anti-Moraxella antibody response
The changes measured in anti-M. catarrhalis IgG, IgA and IgM during the first 2 years 
of life are shown in Figure 2. The levels of antigen-specific IgG, IgA and IgM showed 
extensive inter-individual variability over time. The level of antigen-specific IgG in cord 
blood (maternal antibody) was significantly higher for Hag385-863, MID764-913, MID902-
1200, UspA1557-704 and UspA2165-318 than at 6 months of age (P≤0.001), presumably due 
to passive immunization by maternally acquired IgG antibodies in utero. Such passive 
immunity typically remains until approximately 6 months after birth [27].
IgG levels against MID764-913, MID902-1200, UspA1557-704 and UspA2165-318 rose signifi-
cantly between 6 months to 2 years of age. IgG levels to M. catarrhalis OMPs Hag385-863, 
McaP51-333, MhaC, orf238 and orf296 remained relatively low and did not significantly 
increase over the 6 month to 2 year time period.
IgM and IgA levels to all 9 OMPs were relatively low throughout the study pe-
riod. However, IgM levels to the OMPs MhaC, MID764-913, MID902-1200, UspA1557-704 and 
UspA2165-318, and IgA levels to Hag385-863, MID764-913, MID902-1200, UspA1557-704 and 
UspA2165-318 increased significantly (P≤0.05) over the 6 month to 2 year time period. 
Finally, not every infant developed an antigen-specific IgG, IgA or IgM response to all of 
the proteins tested in the first 2 years of life.
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Relationship between colonization and anti-M. 
catarrhalis antibody levels
In order to relate colonization status to changes in anti-M. catarrhalis antibody levels 
(which would provide an estimation of the efficacy of the immune response in prevent-
ing M. catarrhalis colonization), results were utilized from sera and nasopharyngeal 
colonization data of children at 6, 14 and 24 months of age where concurrent sera and 
nasopharyngeal swab data were available. Children were divided into colonized or non-
colonized at each time period and their IgG levels to Hag385-863, MID764-913, MID902-1200, 
UspA1557-704 and UspA2165-318 plotted.
In total, 9 (33%), 10 (24%) and 11 (29%) of the children were found to be colo-
nized with M. catarrhalis at the time of sampling at 6, 14 and 24 months, respectively. 
There was no significant difference in IgG levels for all antigens between colonized and 
non-colonized children, except for MID902-1200 at 24 months of age (P=0.04) (Figure 
3). Further, the increase in IgG antibody response did not result in a decrease in the 
percentage of infants nasopharyngeal colonized by M. catarrhalis, although antigen-
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Figure 2. Levels of IgG, IgM and IgA directed against M. catarrhalis immunoglobulin D-binding 
protein (MID) and ubiquitous surface proteins A1 (UspA1) and A2 (UspA2) in 57 children at birth, 
6 months, 14 months and 24 months. Antibody levels are reflected by MFI values. Each dot 
represents a serum sample. Median values are indicated by horizontal line.
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Figure 3. Relationship between M. catarrhalis colonization and anti-Hag/Mid, UspA1 and UspA2 
IgG levels at 6, 14 and 24 months of age, as reflected by MFI values. Median values are indicated 
by horizontal line. A significant difference between non-colonized and colonized children was 
observed for MID902-1200 at 24 months of age (* P=0.04).
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specific IgG levels significantly increased for MID764-913, MID902-1200, UspA1557-704 and 
UspA2165-318 between 6 months and 2 years of age (Figure 4).
Discussion
The research performed in this publication represents the most extensive study of the 
infant immune response to potential vaccine candidates of M. catarrhalis performed to 
date, utilizing 9 different M. catarrhalis OMPs in a cohort of 57 healthy children followed 
from birth until 2 years of age. Further, the study was performed using multiplexed 
Luminex’s xMAP technology that proved to be a rapid method for research into humoral 
immune response changes during M. catarrhalis colonization.
In our study, the level of antigen-specific IgG to M. catarrhalis antigens in cord blood 
was significantly higher compared to the anti-M. catarrhalis IgG level at 6 months, most 
likely due to the presence of maternally derived IgG antibodies that were transferred to 
the fetus through the placenta. The passage of antibodies between mother and baby, 
via the umbilical cord, gives rise to ‘passive immunity’, which generally tends to confer 
humoral protection against infection until approximately 6 months after birth [27]. Dur-
ing this 6 month period, passively acquired antibodies disappear and are replaced by 
antibodies generated by the infants’ own ‘actively acquired’ humoral immune response. 
This actively acquired immune response may be generated by successive rounds of 
colonization and/or infection by pathogens, leading to the development of a host-
specific immune response and eventual pathogen clearance. In this respect, Ejlertsen et 
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Figure 4. Relationship between M. catarrhalis colonization and anti-M. catarrhalis IgG levels at 6, 
14 and 24 months of age, as reflected by MFI values.
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al. (1994) showed a significant fall in antibody concentration during the first 3 months 
of life, and a steady low level was maintained in the age group from 3 to 10 months, 
similar to the results obtained in this study [28]. Further, from the age of 1 year, the 
immune response of the children in the study of Ejlertsen et al. (1994) and Tan et al. 
(2006) increased slowly to reach maternal levels at the age of 10 years and in healthy 
adults, and though only sampling children up to 2 years of age, our study also showed 
increases in IgG antibody response for the antigens MID764-913, MID902-1200, UspA1557-704 
and UspA2165-318 between years 1 and 2. The peak level of M. catarrhalis colonization (2 
years of age) and where children have a high susceptibility to M. catarrhalis infections 
coincides with the age where the levels of M. catarrhalis IgG antibodies are low [5, 28]. 
This suggests an association between the lack of a host-specific protective humoral 
immunity towards M. catarrhalis and colonization.
Although M. catarrhalis is considered to be a major mucosal pathogen of the human 
respiratory tract, the salivary immunoglobulin A (IgA) response towards OMPs of M. 
catarrhalis remained relatively low throughout the study period. Two forms of IgA can be 
distinguished based upon their location (serum IgA and secretory IgA). In its secretory 
form, IgA is the main immunoglobulin found in mucous secretions, including respiratory 
epithelium. Studies have shown that human salivary IgA response is directed consis-
tently against a small number of major OMPs in healthy adults and adults suffering from 
COPD. It is also found in small amounts in blood [29]. This may explain the relatively 
low levels of IgA found in this study, as serum antigen-specific IgA levels were measured 
and not secretory IgA [30, 31].
The IgM levels to all 9 OMPs were also relatively low throughout the study period. 
IgM antibodies appear early in the course of an infection and usually reappear, to a 
lesser extent, after further exposure. In contrast to IgG, IgM (and also IgA) antibodies 
do not pass across the human placenta.
Though an antibody response was generated against our M. catarrhalis OMP vac-
cine candidates in our focus cohort group during the first 2 years of life, the relatively 
constant level of M. catarrhalis nasopharyngeal colonization observed within the cohort 
suggests that the antibody response measured did not provide significant protection 
against M. catarrhalis nasopharyngeal colonization up to 2 years of age, with the ex-
ception of antigen MID902-1200. Non-colonized children showed significantly higher IgG 
levels for MID902-1200 compared to colonized children at 24 months of age. This result 
provides preliminary evidence that antibodies raised against MID902-1200 could offer 
protection against M. catarrhalis colonization. If indeed confirmed, then a MID902-1200 
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vaccine may possibly be used to boost immunity levels at or before 2 years of age, 
in order to provide protection against M. catarrhalis colonization, and hence disease. 
However, further research is required to investigate this hypothesis.
The factors influencing M. catarrhalis colonization and elimination are not yet fully 
understood, though genetic variation and adhesion to mucosal receptors appear to play 
an important role in colonization dynamics [32]. For example, several studies have 
shown that children acquire and eliminate a number of different strains throughout the 
first 2 years of life by the ability of evading the host immune system, caused by phase 
variation and antigenic variation [33]. Under ‘immune pressure’, antigenic variation 
due to sequence changes in virulence genes may provide a selective advantage for 
bacterial isolates expressing novel sequence variants. Alternatively, mutations may 
generate phase variable gene expression, switching off genes that are recognized by 
the immune system. Specifically, M. catarrhalis OMPs UspA1, UspA2 and Hag/MID are 
known to undergo phase variation, with antigenic variation reported in the target region 
of monoclonal antibody (MAb) 17C7 (a conserved UspA1 and UspA2 binding site) [34-
39]. The relatively constant level of M. catarrhalis nasopharyngeal colonization observed 
within the cohort could also be related to host factors, for example relatively low levels 
of antibody at 2 years of age, or lack of effective antibody neutralizing activity [28, 40]. 
In any case, our genotyping results indicated that circulating M. catarrhalis isolates 
cultured during the study period were non-clonal in nature, a factor that may need to 
be taken into consideration upon further investigation of the efficacy of the OMP isolates 
utilized in this study.
Further research is required in order to determine whether increased IgG levels 
against the OMPs UspA1, UspA2, and Hag/MID (induced for example via vaccination) 
would significantly reduce the incidence of M. catarrhalis colonization and infection in 
infants up to 2 years of age (and in later life). In this respect, further studies are being 
planned at 5 years of age.
The introduction of a vaccination strategy against M. catarrhalis (either in children 
and/or in adults) is still a topic for debate, though the continuing high prevalence of 
OM disease in children and the rising prevalence of COPD in adults means that M. 
catarrhalis-associated disease continues to increase in global significance. Further, the 
introduction of successful vaccines against respiratory bacterial pathogens that occupy 
the same niche as M. catarrhalis, e.g. S. pneumoniae and H. influenzae, could facilitate 
a concomitant increase in M. catarrhalis colonization and infection. Though further 
research is required, our results indicate that at 2 years of age, the antibody response 
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to M. catarrhalis is still developing, and is largely based on an IgG isotype of antibodies 
raised against 3 major OMPs (i.e. UspA1, UspA2 and Hag/MID). We also provide prelimi-
nary evidence to suggest that antibodies directed against Hag/MID may be effective in 
preventing M. catarrhalis colonization, though natural variation in amino acid sequences 
of this protein may act to limit the potential of vaccines created to generate an immune 
response against Hag/MID.
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Abstract
A prospective clinical cohort study was established to investigate the humoral immune 
responses against bacterial surface proteins in children suffering from rAOM and COME 
disease. Specifically, the humoral immune responses against putative vaccine candi-
dates of M. catarrhalis and S. pneumoniae were determined in serum and MEF and their 
association with COME and rAOM disease was investigated. The association between 
humoral immune response and nasopharyngeal colonization was also studied.
Results indicated that the levels of antigen-specific IgG, IgA and IgM showed ex-
tensive inter-individual variation, with significantly higher serum IgG levels observed 
for the pneumococcal proteins PLY and PsaA in children suffering from COME compared 
to rAOM (P=0.029 and P=0.039). In MEF, significantly higher IgG and IgA levels were 
observed for children suffering from COME compared to rAOM for the pneumococcal 
proteins sp0376 and PpmA (P=0.044 and P=0.046). Day-care attendance was a risk 
factor for M. catarrhalis colonization in COME, and M. catarrhalis non-colonized children 
suffering from COME showed significantly higher IgG levels against the M. catarrhalis 
antigen MID764-913 when compared to COME colonized children (P=0.027). Further, 
OM S. pneumoniae negative children suffering from COME showed significantly higher 
MEF IgG and IgA levels to the pneumococcal proteins BVH-3 and IgA-1 compared to 
OM S. pneumoniae positive children (P=0.046 and P=0.022). A strong correlation was 
observed between antigen-specific serum and MEF IgG levels.
Based on our preliminary findings, the pneumococcal BVH-3 and IgA-1 proteins 
and M. catarrhalis Hag/MID antigen should be further investigated as possible vaccine 
candidates in COME children.
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Introduction
Otitis media (OM) is an important upper respiratory tract disease of early childhood 
and the primary reason for children to visit a physician. The disease has a considerable 
negative impact on the quality of life during childhood and causes much concern to 
parents. OM encompasses a spectrum of conditions, including acute otitis media (AOM) 
and otitis media with effusion (OME), with approximately 80% of children experienc-
ing an episode of AOM by the age of 3 years. Up to one-third of children will have 
experienced recurrent infections, with many of these episodes being facilitated by a 
bacterial infection [1-2]. In fact, bacteria may be isolated from the middle ear fluid 
(MEF) of approximately 80% of children with AOM, and 30% of chronic middle ear 
effusions obtained from children presenting with OME [3]. In many countries, OM is 
a common reason to prescribe antibiotics, or to undergo surgery for the placement of 
grommets [4-5], resulting in a significant burden on healthcare systems and being a key 
contributor to antibiotic resistance [6]. This means that the direct costs associated with 
OM are substantial [7], and that the prevention of OM disease via alternative methods 
such as vaccination offer a promising approach to reduce the burden of OM disease and 
its economic consequences.
Streptococcus pneumoniae is reported to be the predominant bacterial species 
cultured in AOM disease, followed by Haemophilus influenzae and Moraxella catarrhalis. 
However, H. influenzae tends to predominate in OME disease, followed to a lesser ex-
tent by S. pneumoniae and M. catarrhalis [8-10]. These rankings are subject to some 
debate, as there are still issues relating to which bacterial species actually play the most 
significant role in middle ear infections [9, 11], though all of these common OM-related 
bacterial species may be cultured from the nasopharynx of children during OM episodes, 
either as single pathogens or as co-cultures [12]. Normal healthy children are only 
occasionally colonized with these pathogens, and after they become colonized, they 
rapidly eliminate the pathogens. In contrast, children suffering from OM are colonized 
earlier, more frequently and for longer periods. In fact, the pattern of nasopharyngeal 
colonization is an important determinant for OM disease [13-14]. Research has also 
indicated that, as well as bacterial species, the adaptive and native immune system, 
Eustachian-tube dysfunction, viral load, and genetic and environmental factors are all 
involved in the pathogenesis of OM [15-20].
The recent recognition of M. catarrhalis as an important human pathogen has 
stimulated active investigation into the molecular mechanisms of pathogenesis of M. 
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catarrhalis. An essential step in colonization and infection is bacterial adherence to the 
respiratory tract mucosa of the human respiratory tract epithelium. A growing number 
of adhesins have been identified in M. catarrhalis and most of these proteins are highly 
conserved, immunogenic and express epitopes on the bacterial surface. This means 
that they may be suitable as potential M. catarrhalis vaccine candidates [21]. However, 
relatively little is known regarding the development of the humoral immune response 
to these potential vaccine candidates in children. As yet, no licensed vaccine has been 
marketed against M. catarrhalis, and to date, none of the putative vaccine candidates so 
far described in the literature have actually progressed to clinical trials.
Currently, several pneumococcal surface proteins and combinations have been sug-
gested as putative vaccine candidates [22-24]. These proteins could serve, either alone 
or in combination with the pneumococcal conjugate vaccines, as more effective vaccines 
than these currently available, providing a broad coverage against most pneumococcal 
serotypes. However, similar to the situation faced by vaccine candidates of M. catarrha-
lis, relatively little is known about the development of the humoral immune response to 
S. pneumoniae protein-based vaccine candidates within children.
With this study, we provide insights into the anti-M. catarrhalis and anti-pneumococ-
cal humoral immune response in a cohort comprising Dutch children exhibiting recurrent 
and chronic episodes of OM. Studying their immune response will allow us to distinguish 
the bacterial factors that are expressed in vivo and which may be involved in the patho-
genesis of recurrent acute otitis media (rAOM) and chronic otitis media with effusion 
(COME). This may lead to a better understanding into the pathogenesis of OM disease. 
Furthermore, the relationship between the immune response and the presence of M. 
catarrhalis and S. pneumoniae in the nasopharynx and in MEF was also investigated.
Materials and methods
Study cohort
This study was performed as part of a prospective clinical cohort study (Stol et al., 
manuscript in preparation) set up at Radboud University Nijmegen Medical Centre 
(RUNMC), Nijmegen, The Netherlands, to determine the immune response to putative 
vaccine candidates of M. catarrhalis and S. pneumoniae in children suffering OM disease.
Patients were enrolled in two hospitals in Nijmegen, The Netherlands, from April 1st 
2008 to July 1st 2009, their ages ranging from birth up to 5 years of age and suffering 
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from rAOM or COME for whom tympanostomy tube insertion was indicated. Recurrent 
OM was defined as 3 or more episodes of AOM in the last 6 months or 4 episodes in the 
last 12 months. The COME patient population consisted of children who experienced a 
period of persistent OM lasting longer than 3 months. Signs, symptoms, audiometry 
and tympanometry were documented prior to surgery by an ear, nose and throat (ENT) 
specialist in order to confirm OM diagnosis.
Patient characteristics and risk factors were identified using a questionnaire. Per-
mission was obtained from the Committee on Research Involving Human Subjects in 
January 2008 (CMO 2007/239, international trial register number: NCT00847756).
Cl inical materials and bacterial culture
Middle ear fluid and a nasopharyngeal swab were collected during surgery. Nasopha-
ryngeal swabs were cultured according to standard laboratory procedures in order to 
determine the presence of M. catarrhalis and S. pneumoniae. Quantitative real-time 
PCR (Q-PCR) was performed in order to determine the presence of M. catarrhalis and S. 
pneumoniae in MEF (Stol et al., manuscript in preparation).
Moraxella catarrhalis antigens
The previously described M. catarrhalis recombinant proteins used in this study com-
prised: ubiquitous surface proteins A (UspA1557-704 (aa 557–704 of UspA1) and UspA2165-
318), Moraxella immunoglobulin D-binding proteins (MID764-913 and MID902-120), human 
erythrocyte agglutinin (Hag385-863), M. catarrhalis hemagglutinin-like proteins (MhaB 
and MhaC), M. catarrhalis adherence protein (McaP51-333), and the hypothetical proteins 
orf 238 and orf 296 [25-29].
Streptococcus pneumonia antigens
The previously described S. pneumoniae recombinant proteins used in this study com-
prised: choline binding protein A (PspC/CbpA), α-enolase (Eno), hyaluronidase (Hyl), 
immunoglobulin A1 (IgA-1) protease, neuraminidase (NanA), pneumolysin (PLY), a 
double mutant of pneumolysin (PdbD), putative protease maturation protein A (PpmA), 
pneumococcal surface adhesion A (PsaA), pneumococcal surface protein A (PspA), the 
pneumococcal histidine triad (Pht) proteins (SP1003 (PhtD) and BVH-3 (PhtE)), strep-
tococcal lipoprotein rotamase A (SlrA), S. pneumoniae proteins (SP proteins) SP0189 
(hypothetical protein), SP0376 (response regulator, intracellular location), SP1651 (thiol 
peroxidase, intracellular location), and Pilus A [24, 30].
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Multiplex M. catarrhalis and S. pneumoniae 
antibody assay
Recombinant proteins were coupled to SeroMAP™ beads, carboxylated beads that are 
developed for serological applications, as detailed by Verkaik et al. [31]. Uncoupled 
beads were used as a negative control and to determine non-specific binding. If non-
specific binding was observed, then the median fluorescent intensity (MFI) values 
obtained from this non-specific binding was subtracted from the antigen-specific results.
The Luminex multiplex procedure was performed as described previously [31]. 
Briefly, after validation of the assay (achieved by comparison of human pooled serum 
(HPS) MFI values obtained using the multiplex assay with HPS MFI values obtained 
using the singleplex assay), the different antigen-coupled microspheres were mixed to 
a working concentration of 4000 beads per color per well. Serum samples were diluted 
1:100 in PBS-BN for measurement of antigen-specific IgG. Fifty microliters per diluted 
sample were incubated with the microspheres in a 96-well filter microtiter plate (Milli-
pore) for 35 minutes at room temperature on a Thermomixer plate shaker (Eppendorf). 
The plate was washed twice with assay buffer (PBS-BN) and aspirated using a vacuum 
manifold. The microspheres were resuspended in 50 μl of assay buffer, and 50 μl of 
a 1:200 dilution of R-phycoerythrin (RPE)-conjugated AffiniPure goat anti-human IgG 
(Jackson Immuno Research) was added in separate wells. The plate was incubated for 
35 minutes at room temperature and washed. The microspheres were resuspended in 
100 μl of assay buffer. Measurements were performed on the Luminex 100 instrument 
(BMD) using Luminex IS software (version 2.2). Tests were performed in duplicate, and 
the MFI values, reflecting quantitative antibody levels, were averaged. The coefficient of 
variation was calculated for each serum sample and averaged per protein and antibody 
isotype. The procedure for MEF was identical to that outlined above, except that IgA 
and IgM were also measured. Briefly, MEF samples were diluted 1:100 in PBS-BN for 
measurement of antigen-specific IgG and 1:50 for measurement of IgA and IgM. Fifty 
microliters of a 1:100 dilution of RPE-conjugated AffiniPure goat anti-human IgG and 
IgA and 50 μl of a 1:200 dilution of RPE-conjugated donkey anti-human IgM were then 
added. For assay validation, MFI values obtained from pooled MEF (PMEF) using the 
multiplex assay were compared to MFI values obtained from PMEF obtained using the 
singleplex assay.
Chapter 9  145
Statistical analysis
Statistical analyses were performed using SPSS PASW Statistics version 17. The Mann-
Whitney U-test was used to compare anti-Moraxella and anti-pneumococcal immuno-
globulin (Ig) levels between children diagnosed with rAOM and COME and to compare 
differences in Ig levels between colonized and non-colonized children. We also analyzed 
whether the presence of siblings and day-care attendance influenced M. catarrhalis and 
S. pneumoniae colonization using Fisher’s exact test. Correlations between antigen-
specific IgG in serum and MEF were assessed using Spearman’s correlation coefficient. 
A P-value of ≤0.05 was considered to be statistically significant.
Results
Dynamics of the anti-Moraxella and anti-
pneumococcal antibody response in children with 
recurrent and chronic otit is media disease
A total of 156 children were included in the analysis of the antibody response to M. 
catarrhalis and S. pneumoniae proteins in serum. Forty-two children were diagnosed 
with rAOM, whereas 114 children were diagnosed with COME. No significant difference 
in anti-M. catarrhalis serum MFI values (anti-M. catarrhalis IgG levels) was observed 
between the rAOM or COME groups for all antigens tested, though significantly higher 
IgG levels were observed for the pneumococcal proteins PLY and PsaA in children suf-
fering from COME compared to children with rAOM (P=0.029 and P=0.039) (Figure 1).
A total of 121 children were included in the analysis of the antibody response to 
M. catarrhalis and S. pneumoniae proteins in MEF, with 25 children and 96 children 
diagnosed with rAOM and COME, respectively. No significant difference in M. catarrhalis 
and pneumococcal MEF IgG levels were found for all proteins tested, except for the 
pneumococcal protein sp0376 (P=0.044). Additionally, there was no significant differ-
ence in IgA and IgM levels in MEF, with the exception of anti-PpmA IgA (P=0.046) 
(Figure 1).
Effect of the presence of sibl ings and day-care 
attendance on nasopharyngeal colonization
Fisher’s exact test was used to determine whether the presence of siblings and day-care 
attendance influenced M. catarrhalis and S. pneumoniae nasopharyngeal colonization 
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(Stol et al., manuscript in preparation). With respect to M. catarrhalis, no statistically 
significant difference was found between children with siblings or with no siblings, and 
M. catarrhalis colonization (P=0.35), though significant results were observed for day-
care attendance (P=0.05). With respect to S. pneumoniae, no statistically significant 
difference was observed between children with siblings or with no siblings, (P=0.15), or 
day-care attendance and S. pneumoniae colonization (P=0.20).
Relationship between colonization and anti-
Moraxella and anti-pneumococcal antibody levels 
in children with recurrent and chronic otit is media 
disease
A total of 156 children were included in the analysis of the antibody response to M. 
catarrhalis and S. pneumoniae proteins in serum. Forty-two children were diagnosed 
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Figure 1. Relationship between disease state and antibody response in children suffering from 
chronic otitis media disease, as reflected by MFI values. A. Serum: children suffering from COME 
possessed significantly higher levels of serum IgG against the pneumococcal antigens PLY and 
PsaA. B. MEF: Significantly higher levels of IgG were observed against sp0376 in MEF, as well as 
significantly higher levels of IgA to PpmA.
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with rAOM, whereas 114 children were diagnosed with COME. M. catarrhalis non-
colonized children suffering from COME showed significantly higher IgG levels against 
the M. catarrhalis antigen MID764-913 compared to COME colonized children (P=0.027). 
No significant difference was observed for S. pneumoniae colonization and serum IgG 
levels against the pneumococcal antigens (Figure 2).
A total of 117 children were included in the analysis of the antibody response to 
M. catarrhalis and S. pneumoniae proteins in MEF, including 23 children suffering from 
rAOM and 94 children suffering from COME. Similar to the antibody response in serum, 
no significant difference in IgG, IgA and IgM levels in MEF was observed for all M. 
catarrhalis and S. pneumoniae antigens between OM M. catarrhalis and S. pneumoniae 
positive and OM M. catarrhalis and S. pneumoniae negative children suffering from 
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Figure 2. Relationship between COME colonization and anti-Moraxella and anti-pneumococcal IgG 
levels in serum and MEF, as reflected by MFI values. A. Non-colonized children suffering from 
COME showed significantly higher serum IgG levels against the M. catarrhalis antigen MID764-913. 
B. OM S. pneumoniae negative children suffering from COME showed significantly higher MEF 
IgG and IgA levels against the S. pneumoniae antigens BVH-3 and IgA-1, respectively. OM, otitis 
media; Sp, Streptococcus pneumoniae.
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either rAOM or COME. However, OM S. pneumoniae negative children suffering from 
COME showed significant higher IgG and IgA levels against the pneumococcal pro-
teins BVH-3 and IgA-1 compared to OM S. pneumoniae positive children, respectively 
(P=0.046 and P=0.022) (Figure 2).
Correlation between anti-M. catarrhalis and anti-
pneumococcal IgG levels in serum and MEF
To determine the correlation between the levels of anti-Moraxella and anti-pneumococcal 
IgG in serum compared to MEF, samples from 111 children who donated both blood and 
MEF at tympanostomy surgery were included. The mean IgG levels (reflected by MFI 
values) in these samples were calculated for each protein (Figure 3). IgG levels in serum 
showed a strong correlation to IgG levels in MEF for both M. catarrhalis (R2 = 0.97) as 
well as S. pneumoniae (R2 = 0.89).
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Figure 3. Correlation between IgG levels in serum and MEF. Mean IgG levels in serum and MEF 
were used to calculate the correlation statistics for each respective M. catarrhalis (A) or S. 
pneumoniae (B) protein.
Discussion
This study was performed as part of a prospective cohort study to determine the immune 
response to the major vaccine candidate outer membrane proteins of M. catarrhalis and 
protein vaccine candidates of S. pneumoniae in children suffering from rAOM and COME.
Children are frequently colonized with M. catarrhalis at an early age and frequent 
colonization with M. catarrhalis has been reported to increase the risk of OM [13]. 
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Studies have shown that the presence of siblings and day-care attendance are impor-
tant risk factors for early and frequent colonization by M. catarrhalis and S. pneumoniae 
in the first years of life [16, 18, 32]. In this study, the presence of siblings and attending 
day-care did not result in an increase in M. catarrhalis and S. pneumoniae coloniza-
tion within this cohort of children, with the exception of M. catarrhalis colonization 
and day-care attendance. Previous studies in healthy children have however indicated 
that both the number of siblings and day-care attendance are associated with sig-
nificant nasopharyngeal colonization by both of these respiratory pathogens [16, 18]. 
The apparent difference observed between the current and previous studies could be 
explained by the fact that previous publications published data on healthy children, 
whilst the current study has been performed in a group of children exhibiting recurrent 
and chronic episodes of OM. Children suffering from OM tend to be colonized earlier, 
more frequently, and for longer periods of time compared to healthy children [33], 
meaning that these populations may be unsuitable for comparative association statistics 
involving nasopharyngeal colonization events.
The adaptive and native immune system are also important factors in the patho-
genesis of OM [17]. The high incidence and high rate of ‘spontaneous’ recovery from 
OM suggests that recovery is a natural phenomenon and part of the gradual maturation 
of the child’s immune system. However, a defective or immature antibody response 
to pathogens causing OM may explain the increased susceptibility of some children to 
OM [34]. With respect to the adaptive immune system, significantly higher serum IgG 
levels were observed for the pneumococcal proteins PLY and PsaA in children suffering 
from COME, compared to children with rAOM. This observation may be explained by a 
previous observation indicating significantly higher numbers of S. pneumoniae in the 
nasopharynx of children with COME compared to children with rAOM (Stol et al., manu-
script in preparation). Additionally, significantly higher serum IgG levels to the putative 
M. catarrhalis vaccine candidate antigen MID764-913 was observed in COME M. catarrhalis 
non-colonized versus COME M. catarrhalis colonized children. A recent study of healthy 
children by Verhaegh et al. (manuscript submitted) indicated that the Hag/MID outer 
membrane protein may be involved in protecting healthy children against M. catarrhalis 
nasopharyngeal colonization, as significantly higher IgG levels against MID902-1200 were 
observed in healthy M. catarrhalis non-colonized versus healthy M. catarrhalis colonized 
children. However, though both MID764-913 and MID902-1200 are derived from the same 
outer membrane protein (Hag/MID), there was no significant difference in IgG levels 
against the MID764-913 antigen observed in healthy children. This observation may be 
150  Chapter 9
related to the fact that in the study of Verhaegh et al., healthy children were followed 
up to a maximum of 2 years of age, while the median age of the current rAOM/COME 
group was 4 years of age (range 10 months – 6 years). The immune response to patho-
gens develops rapidly during the first few years of life, as children become exposed to 
an increasing number of microbial species and strains. The difference in Hag/MID IgG 
levels observed between healthy and rAOM/COME children could therefore be related to 
‘maturation’ of the humoral immune response against Hag/MID, as the children become 
exposed to multiple strains of M. catarrhalis between birth and 4 years of age. With 
respect to clinical applications, it has been found that M. catarrhalis DNA is detected in a 
larger proportion of cases of OME than of AOM, and involves bacterial biofilm formation 
on the middle-ear [21, 35]. The significantly higher IgG levels to the M. catarrhalis 
antigen MID764-913 observed in non-colonized children suffering from COME may indicate 
that the Hag/MID protein should be further investigated as a potential vaccine antigen to 
reduce M. catarrhalis biofilm formation and hence M. catarrhalis-mediated COME disease.
Local production of secretory antibodies is another immunological defense mecha-
nism of the upper respiratory tract. Secretory IgA inhibits pathogen adherence and 
reduces nasopharyngeal bacterial colonization, and children with recurrent OM might 
lack secretory IgA [36]. The MFI levels of antigen-specific IgA showed extensive inter-
individual variability over time, with IgA levels to all M. catarrhalis and S. pneumoniae 
OMPs being relatively low throughout the study period. However, OM S. pneumoniae 
negative children suffering from COME showed significant higher MEF IgA levels for the 
pneumococcal IgA-1 protease protein compared to OM S. pneumoniae positive children. 
Many mucosal pathogens, including S. pneumoniae, express an IgA-1 protease that 
may circumvent the protective effects of IgA, facilitating bacterial adhesion and mucosal 
surface persistence [37]. In this study, we provide some preliminary evidence to indicate 
that antibodies against IgA-1 may have a protective effect in COME children. Interest-
ingly, OM S. pneumoniae negative children suffering from COME showed significantly 
higher MEF IgG levels against the S. pneumoniae antigen BVH-3. This finding may also 
suggest that this protein has a protective effect in children suffering from COME, and 
indeed, in previous studies, the BVH-3 protein has been shown to be capable of eliciting 
protective immunity against pneumococcal disease [38-39].
Finally, a strong correlation was observed between IgG antibody levels in serum and 
in MEF, for both M. catarrhalis and pneumococcal proteins. This is an interesting clinical 
finding, as it indicates that serum antibody levels might be predictive of local antibody 
production.
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Conclusion
Both rAOM and COME children generate antibodies (IgG, IgA and IgM) against a variety 
of novel M. catarrhalis outer membrane and S. pneumoniae proteins. Further, significant 
differences in antibody levels (reflected by MFI values) were observed between ‘patho-
gen colonized’ and ‘pathogen non-colonized’ children suffering from COME. Based on 
our preliminary findings, the Moraxella Hag/MID and pneumococcal BVH-3 and IgA-1 
proteins may be further investigated as possible vaccine candidates in COME children.
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Moraxella catarrhalis colonization and infection
Moraxella catarrhalis is part of the normal bacterial flora of the human respiratory tract. 
It was only relatively recently acknowledged as a true bacterial pathogen, rather than 
simply being a ‘colonizing commensal’ (Chapter 2). In general, the organism is mostly 
associated with upper respiratory tract infections in children (including otitis media (OM) 
and sinusitis) and lower respiratory tract infections in adults (e.g. exacerbations of 
chronic obstructive pulmonary disease (COPD)). M. catarrhalis is also associated with 
more serious sporadic cases including meningitis, urinary tract infection and conjuncti-
vitis [1, 2].
Although colonization by itself may not always result in the onset of symptoms, it is 
the first step towards invasive disease, as well as being a source of horizontal spread 
of M. catarrhalis in the community [3]. Frequent (re-)colonization with M. catarrhalis 
has been reported to increase the risk of OM disease. With this in mind, the risk fac-
tors associated with M. catarrhalis colonization have been studied in different countries 
and age groups, in which crowding and contact with children (including siblings) were 
identified (Chapter 3). Interestingly, the same risk factors are also associated with 
colonization by Streptococcus pneumoniae and Haemophilus influenzae [4].
In Chapter 4, we showed a trend towards a regular 6-monthly M. catarrhalis coloni-
zation cycle in a cohort of healthy children living in Rotterdam (the Generation R study), 
with no pronounced seasonal colonization peak. This observation tends to contrast with 
other studies reporting a seasonal influence on M. catarrhalis colonization. We hypoth-
esized that colonization with M. catarrhalis occurs via regular cycles of colonization 
and clearance, with the apparent increase in M. catarrhalis detection during the winter 
months probably being a consequence of increased viral respiratory infections, result-
ing in increased opportunity for secondary bacterial infection by bacterial pathogens 
[5]. Essentially, a respiratory viral infection may cause i) prolonged dysfunction of the 
Eustachian tube, ii) congestion of the respiratory mucosa, and iii) alteration in middle 
ear pressure, all of which tend to lead to the accumulation of fluid within the middle ear. 
This abnormal pathology may then facilitate invasion, persistence and proliferation of 
nasopharyngeal-colonizing microbial pathogens into the middle ear [6].
Polymicrobial infections and biofi lms involving 
M. catarrhalis
There is growing evidence indicating a role for polymicrobial infection and biofilm forma-
tion in the development of disease [7, 8]. In this respect, M. catarrhalis is no exception, 
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although there remains some disagreement regarding the exact role of M. catarrhalis in 
polymicrobial disease [9]. Recently, Armbruster et al. (2010) showed that co-infection 
with M. catarrhalis and H. influenzae promotes increased biofilm formation and thereby 
resistance to antibiotics, while also hindering host clearance of the bacteria. Further, 
it was shown that this phenomenon occurred as a result of quorum sensing signaling 
via an AI-2 messenger [10]. Interestingly, at the same time we published data from 
a healthy cohort of children (the Generation R Study) indicating that co-colonization 
by M. catarrhalis and H. influenzae was significantly more likely than colonization by 
either bacterium alone (Chapter 4). Additionally, in Chapter 6, we showed that co-
colonization in the nasopharynx with two or more pathogens is associated with the 
presence of bacteria in the middle ear of patients suffering from COME. Taken together, 
these publications indicate the importance of the polymicrobial interaction between M. 
catarrhalis and H. influenzae in facilitating M. catarrhalis colonization. Further research 
is necessary in order to determine the direct effects of this increased colonization on 
(the severity of) resultant disease.
Nowadays, there is also a growing understanding of the importance of biofilm forma-
tion in group A Streptococcus (GAS)-related colonization and disease [11-13]. While the 
published literature mainly reports on S. pneumoniae and H. influenzae as being associ-
ated with M. catarrhalis polymicrobial infections, the interactions between M. catarrhalis 
and GAS are poorly understood [14]. This is important with respect to the increasing 
number of GAS-associated OM infections in certain countries of Europe. The incidence 
of S. pyogenes-mediated OM disease reported in the literature is low, and even rare in 
the West. However, recent communications have indicated an increase in S. pyogenes 
related OM infections in Hungary between 2006 and 2008 (personal communication, Dr. 
Éva Ban, Semmelweiss University, Budapest, Hungary).
Therefore, in Chapter 7, initial studies were performed to investigate the effect 
of M. catarrhalis-GAS co-culture on GAS gene expression, with particular emphasis 
on (GAS) virulence gene expression. We provided evidence that M. catarrhalis may 
positively affect the expression of GAS genes related to virulence and biofilm formation. 
Theoretically, this could lead to increased colonization and pathogenicity of GAS during 
M. catarrhalis-GAS polymicrobial infections. Further research is necessary in order to 
confirm this interesting finding.
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Current treatment of M. catarrhalis-associated 
disease
The recognition of its pathogenic status means that the detection of M. catarrhalis in 
clinical specimens is now a relevant topic in the diagnosis and management of disease. 
It is especially relevant with respect to OM-related disease, a disease that is currently 
associated with the highest prevalence of M. catarrhalis infections. Acute, recurrent 
and chronic forms of OM are the most common reasons to prescribe antibiotics or to 
undergo surgery for the placement of grommets in many countries [15, 16]. This results 
in a significant burden on healthcare systems and national economies, as parents take 
time off from work to visit their general practitioner [17, 18]. The American Academy of 
Pediatrics (AAP) published guidelines in 2004 that address the diagnosis and treatment 
of AOM. The diagnosis of AOM is complicated by a lack of understanding of the correla-
tion between clinical signs and symptoms and responsible pathogens. Consequently, 
antibiotic treatment of AOM is not always appropriate, and the long-term overuse of 
antibiotics in AOM reduces the effectiveness of treatment and places children at an 
increased risk of antibiotic-resistant infections [16]. Although the AAP guidelines recom-
mended the use of watchful waiting as a potential strategy for the treatment of AOM, 
actual rates of antibiotic prescription for AOM still vary to a great extent internationally 
[17, 19, 20]. Differences in regional antibiotics prescribing practices may lead to an 
increase in the prevalence of antibiotic resistant organisms. For example, in a recent 
publication, Khan et al. (2010) showed a significant difference in bro gene (β-lactamase 
resistance) prevalence in non-clonal global M. catarrhalis isolates recovered from chil-
dren and adults. Consistently higher β-lactam minimum inhibitory concentrations were 
found for isolates from the Far East [21]. These differences are most likely associated 
with differences in antibiotic prescribing practices between adults and children and 
between the Far East and other areas of the world. Research has also indicated that 
the presence of β-lactamase positive M. catarrhalis may actually protect some other 
bacterial species against β-lactam antibiotics [22].
It has been calculated that COPD will become the 5th most prevalent disease in 
the world by 2020, and M. catarrhalis causes an estimated 2-4 million exacerbations 
of COPD in adults annually in the United States [23, 24]. If treatment solely relies on 
the use of antimicrobial chemotherapy, then the prevalence of antibiotics resistance 
(not only within M. catarrhalis but also in other non-targeted bacterial species) is likely 
to increase. One method to decrease the reliance on antimicrobial treatment in M. 
catarrhalis-mediated disease would be via the development and implementation of a 
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vaccine against M. catarrhalis. This may both help in reducing the burden of antibiot-
ics resistance as well as the medical and economic consequences associated with M. 
catarrhalis colonization and infection.
Vaccine development
In spite of the technical challenges associated with the development of vaccines that 
target respiratory bacterial pathogens, vaccines have been successfully developed for 
both S. pneumoniae and H. influenzae. A 7-valent vaccine against S. pneumoniae (PCV-
7), which targets the 7 serotypes 4, 6B, 9V, 14, 18C, 19F and 23F, became available in 
the United States in April 2000 and is recommended by the AAP for universal use in chil-
dren 23 months of age and younger to prevent pneumococcal infections [25]. In March 
2001, the same vaccine was marketed in The Netherlands for use in infants and young 
children. The aim for the use of this vaccine was to prevent invasive pneumococcal 
disease (e.g. meningitis and pneumonia) at this age. The introduction of PCV-7 initially 
led to a noticeable reduction in the incidence of S. pneumoniae vaccine targeted strains 
in the etiology of AOM [20]. However, subsequent studies have shown an increase in the 
carriage of non-vaccine targeted serotypes and a consequent increase in non-vaccine 
serotype-associated invasive disease. This increase in invasive disease could reduce or 
even negate the benefits initially obtained through vaccination [26, 27], and possibly 
lead to an increase in antibiotic resistant S. pneumoniae serotype 19A infections [28].
With respect to H. influenzae, a vaccine for diphtheria, tetanus, pertussis (a-cellular), 
poliomyelitis and H. influenzae type b (DKTP-Hib) was introduced in The Netherlands in 
2006. Before introduction of the vaccine, ten percent of all AOM-infections were caused 
by H. influenzae type b. Currently, mainly non-typeable (NT) H. influenzae is isolated 
from AOM-infections. DKTP-Hib is not effective against NT H. influenzae and, to date, no 
vaccine against NT H. influenzae has been developed, although H. influenzae protein D 
has been used as an active carrier protein for pneumococcal vaccines [29].
In 1996, a collaborative surveillance network was established in Europe to monitor 
the impact of routine H. influenzae type b (Hib) vaccination on the epidemiology of 
invasive H. influenzae disease. The data collected between 1996 and 2006 showed that 
the incidence of invasive non-type b H. influenzae was higher than the incidence of Hib 
and was also associated with a higher rate of case fatality [30]. Although there is little 
direct information on the effect of Hib vaccination on the prevalence of OM, it seems 
likely that the serotype replacement effect observed for non-type b invasive disease will 
also be observed for OM-related diseases.
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In contrast to S. pneumoniae and H. influenzae, there is currently no licensed vaccine 
available against M. catarrhalis, and, to date, none of the putative vaccine candidates 
described so far have progressed into clinical trials (several outer membrane proteins 
(OMPs) and lipooligosaccharides (LOS) are described in the literature as potential vac-
cine candidates). The lack of i) correlates of protection and ii) a suitable animal model to 
study M. catarrhalis-mediated disease (especially OM disease), are seriously hindering 
the development of an effective vaccine against M. catarrhalis [31]. A mouse pulmonary 
clearance model, which measures clearance of bacteria from the lungs following bacte-
rial challenge directly into the airways, has been useful for assessing putative vaccine 
antigens [32-35]. However, this model system does not simulate human respiratory 
tract infection, as M. catarrhalis is cleared within 24 hours from the middle ear of mice. 
Although mouse, and also chinchilla, models of OM have yielded important observations 
in the case of S. pneumoniae [36] and H. influenzae [37, 38], they have not been useful 
in studying M. catarrhalis [39].
Current advances in M. catarrhalis vaccine 
development
Bacterial adherence to the respiratory mucosa is an essential step towards colonization 
of the human respiratory tract epithelium. Adhesins responsible for the attachment of 
M. catarrhalis to host cells include i) the family of ubiquitous surface proteins A (UspAs), 
ii) M. catarrhalis immunoglobulin D (IgD) binding protein (MID), also referred to as 
the hemagglutinin (Hag), iii) M. catarrhalis adherence protein (McaP), iv) OMPCD, M. 
catarrhalis hemagglutinin-like proteins (Mha), v) surface-exposed structures such as 
pili, and vi) LOS structures [40-49]. Other putative vaccine candidates for M. catarrha-
lis are involved in nutrient acquisition and virulence and include i) the M. catarrhalis 
surface proteins (Msp) Msp22 and Msp75 [50], ii) outer membrane porin M35 [51], iii) 
M. catarrhalis outer membrane protein B (CopB) [52], iv) transferrin binding proteins 
A and B (TbpA and TbpB) [53], v) OMPE [54], vi) lactoferrin binding proteins A and B 
(LbpA and LbpB) [55] and vii) oligopeptide permease protein A (OppA) [32]. Most of 
these proteins and LOS are highly conserved, immunogenic and express epitopes on 
the bacterial surface, which means that they may be suitable as potential M. catarrhalis 
vaccine candidates. The challenge in identifying potential vaccine candidates for an OM 
vaccine lies in identifying antigens that are present on the surface of all strains, antigeni-
cally conserved among strains, and expressed during infection of the human host. In 
Chapter 5, we found that isolates from children and adults are genetically diverse and 
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that differences exist in the incidence and expression of outer membrane-associated 
virulence genes between child and adult-associated isolates within a global context. 
From these results, it would appear that an ideal M. catarrhalis vaccine may have to be 
based on a multivalent vaccine that contains a combination of immunogenic epitopes 
from multiple vaccine candidates. A multivalent vaccine may offer better protection 
against M. catarrhalis-mediated disease in both children and adults.
As a first step in validating putative vaccine candidate antigens, the antigens need 
to be proven to be immunogenic and capable of inducing a protective immune response. 
Unfortunately, relatively little is known about the development of the humoral immune 
response to M. catarrhalis vaccine candidates in either healthy or ill individuals. In this 
respect, the studies presented in Chapters 8 and 9 were established in order to inves-
tigate whether specific antibodies against currently identified outer membrane protein 
vaccine candidates of M. catarrhalis (and additionally S. pneumoniae, Chapter 9 only) 
were detectable in the sera of healthy and sick (chronic otitis media with effusion and 
recurrent acute otitis media) cohorts of children. We were also interested in determining 
whether antibody levels could be related to colonization or non-colonization prevalences. 
Our results indicated that at 2 years of age, the antibody response to M. catarrhalis 
is still developing, and is largely based on IgG isotypes of antibodies raised against 3 
major OMPs: UspA1, UspA2 and Hag/MID. Further, we provided preliminary evidence 
that the Hag/MID antigen may be a good vaccine candidate for further investigation in M. 
catarrhalis-mediated disease. Specifically, this vaccine antigen may be useful in helping 
to reduce M. catarrhalis colonization and disease in children suffering from chronic and 
recurrent OM infections. Natural variation in the amino acid sequence of this protein may 
however limit the potential of a vaccine based solely on this outer membrane component.
Novel M. catarrhalis prevention and treatment 
options
Currently, watchful waiting and/or the prescription of antibiotics are the most favored 
options for the treatment of M. catarrhalis-associated disease. Treatment with antibi-
otics seems effective, but the chances of the development of antibiotic resistance in 
M. catarrhalis (or non-targeted bacteria) remain high. However, a vaccine against M. 
catarrhalis is not currently available, nor likely to be so within the next 5 years.
Targeting bacterial communication could be a novel treatment methodology, as bio-
film formation is facilitated by bacterial communication, being controlled in part through 
cell density-dependent quorum signaling networks [56, 57]. Many bacteria rely on 
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quorum signaling molecules to control the expression of virulence and regulatory genes, 
which ultimately influence the establishment and progress of disease. If a method could 
be found to block quorum signaling systems and molecules, then the processes leading 
to development of biofilm formation and disease may also be blocked.
The study by Armbruster et al. (2010) indicates that a quorum signaling molecule 
can be an ideal target for disrupting polymicrobial signaling and pathogenicity [10]. 
This disruption could occur via the development of i) anti-AI-2 molecule antibodies, ii) 
enzymes that cleave the AI-2 molecule, or iii) an AI-2 molecule mimic that blocks AI-2 
receptor sites without activating quorum sensing systems [58, 59]. Unfortunately, the 
interspecies targeting of autoinducer molecules may result in undesirable implications, 
as disruption of AI-2 signaling may promote virulence or virulence-related phenotypes 
in Staphylococcus aureus and S. pyogenes. Further, targeting of AI-2 has a potential 
impact on the normal microbiota, as AI-2 signaling may be critical for the establishment 
and maintenance of a normal microbiota and in the defense against pathogens [60].
Future perspectives
OM is an important children’s disease that can be caused by M. catarrhalis. This organ-
ism also appears to play a significant role in exacerbations of COPD. A vaccine directed 
against M. catarrhalis should help reduce the prevalence of its major infections, as well 
as less prevalent diseases such as sinusitis and pneumonia. This will impact on patient 
morbidity, and on the negative economic consequences that are associated with these 
diseases. Further, such a vaccine will provide an alternative to excessive antibiotic use, 
which often leads to the generation of antibiotic resistance.
Unfortunately however, the introduction of vaccines targeting S. pneumoniae and 
H. influenzae has tended to lead to the replacement of ‘traditionally’ virulent bacte-
rial strains with ‘non-traditional’, but equally virulent, strains of the same species. The 
development of a multivalent vaccine consisting of several M. catarrhalis antigens 
should help reduce any ‘serotype replacement’ effect if or when it reaches the market. 
The cost-effectiveness of vaccination compared to current treatment methods for M. 
catarrhalis-mediated disease, as well as the ecological effects on healthy flora, also 
need to be considered.
Ultimately, the successful development and introduction of a M. catarrhalis vaccine 
will be largely dependent upon economic factors. A vaccine that is effective against M. 
catarrhalis and also against other respiratory bacterial and viral pathogens will have the 
highest chance of success.
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Kolonisatie en infectie
Moraxella catarrhalis is een commensaal van de luchtwegen bij mensen, en is pas 
recentelijk erkend als pathogeen (Hoofdstuk 2). M. catarrhalis wordt voornamelijk 
geassocieerd met middenoorontsteking (otitis media; OM) bij jonge kinderen. OM is een 
veel voorkomende aandoening van de bovenste luchtwegen, en een belangrijke reden 
voor een bezoek aan de huisarts of het ziekenhuis. Deze aandoening kan ertoe leiden 
dat de kwaliteit van leven in de eerste levensjaren van kinderen aanzienlijk achteruit 
gaat, en baart ouders grote zorgen. Ongeveer 80% van de kinderen heeft rond het 
derde levensjaar een episode van OM doorgemaakt. Bij volwassenen komt M. catarrha-
lis voornamelijk voor in de onderste luchtwegen en wordt bij deze groep geassocieerd 
met het verergeren van de klachten van chronische obstructieve longziekten (chronic 
obstructive pulmonary disease; COPD).
Hoewel kolonisatie niet per direct hoeft te leiden tot ziekte, is het wel een eerste stap 
in deze richting, en bovendien een oorzaak van verspreiding van M. catarrhalis tussen 
personen. Studies hebben aangetoond dat frequente kolonisatie met M. catarrhalis bij 
jonge kinderen kan leiden tot OM. Het is daarom belangrijk te weten wat de risicofacto-
ren zijn die geassocieerd worden met M. catarrhalis kolonisatie. In Hoofdstuk 3 hebben 
we aangetoond dat crèche bezoek en het hebben van broers en/of zussen belangrijke 
risicofactoren zijn voor M. catarrhalis kolonisatie.
Polymicrobiële infecties
De afgelopen jaren is er meer en meer bewijs verzameld voor het feit dat de aanwe-
zigheid van meerdere soorten bacteriën en het vormen van biofilms een belangrijke 
rol spelen in de ontwikkeling van ziekten (Hoofdstuk 6). Een biofilm is een laag van 
bacteriën vastgehecht aan een oppervlak, bijvoorbeeld het middenoor. De bacteriën 
die in een biofilm leven kunnen totaal andere eigenschappen krijgen dan vrijlevende 
micro-organismen van dezelfde soort. Er is recentelijk aangetoond dat co-infectie van 
Haemophilus influenzae met M. catarrhalis er voor zorgt dat deze bacteriën in biofilms 
beter bestand zijn tegen toxische stoffen zoals antibiotica. Celdichtheid-afhankelijke 
genexpressie, ook wel quorum signaling genoemd, is één van de factoren die daarvoor 
verantwoordelijk is. Dit is een interessante ontdekking, aangezien wij met onze studie in 
Hoofdstuk 4 hebben aangetoond dat co-kolonisatie van M. catarrhalis en H. influenzae 
waarschijnlijker is dan kolonisatie van M. catarrhalis of H. Influenzae alleen. Ondanks 
dat er meer onderzoek nodig is, laten de studies zien dat de interactie tussen M. catar-
rhalis en H. influenzae een belangrijke rol speelt in de kolonisatie van M. catarrhalis.
174  Chapter 11
Een ander organisme waarbij biofilms een belangrijke rol spelen in kolonisatie en 
infectie, is Streptococcus pyogenes, een β-hemolytische groep A streptokok (GAS). 
Hoewel Streptococcus pneumoniae, H. influenzae en M. catarrhalis in de literatuur voor-
namelijk worden beschreven als de belangrijkste veroorzakers van OM, kan GAS ook 
worden beschouwd als een ‘echt’ OM-pathogeen. In het Westen zijn GAS-geassocieerde 
OM-infecties zeldzaam. Niettemin is de incidentie van GAS-gerelateerde OM-infecties in 
sommige landen van de Europese Unie aan het stijgen. Een voorbeeld is Hongarije, waar 
tussen 2006 en 2008 een toename in GAS-gerelateerde OM infecties is waargenomen. 
Er is weinig bekend over de interactie tussen M. catarrhalis en GAS. Daarom is de studie 
in Hoofdstuk 7 opgezet om het effect van M. catarrhalis op de genexpressie van GAS te 
bestuderen, en dan met name de genen die betrokken zijn bij virulentie. Hoewel er meer 
onderzoek nodig is om onze resultaten te bevestigen, is deze studie het eerste bewijs 
dat M. catarrhalis van invloed is op de genexpressie van GAS-genen die onder andere 
betrokken zijn bij virulentie en biofilm formatie. Deze invloed kan mogelijk leiden tot een 
verhoogde kans op kolonisatie en pathogeniteit van GAS tijdens polymicrobiële infecties.
Huidige behandelmethoden
Het erkennen van de pathogene status van M. catarrhalis heeft ertoe geleid dat het 
aantonen van M. catarrhalis in klinische specimens een relevant onderwerp is geworden 
bij de diagnose en behandeling van onder andere OM. In veel landen is het gebruikelijk 
om antibiotica voor te schrijven of om buisjes te plaatsen in de oren wanneer een 
kind lijdt aan OM. Deze behandelmethoden hebben echter een enorme impact op de 
gezondheidszorg en de landelijke economie.
De Amerikaanse academie voor kinderartsen (American Academy of Pediatrics; AAP) 
publiceerde in 2004 richtlijnen met betrekking tot de diagnose en behandeling van OM. 
Het vaststellen van de diagnose OM wordt bemoeilijkt door een onduidelijke samenhang 
tussen klinische symptomen en de daadwerkelijke veroorzakers van OM, met als gevolg 
een mogelijk onjuiste behandeling. De verschillende vormen van OM, maar ook COPD 
bij volwassenen, zijn in veel landen belangrijke redenen voor het voorschrijven van 
antibiotica. De hoeveelheid antibiotica die hierbij wordt voorgeschreven varieert sterk 
tussen verschillende landen. Veelvuldig gebruik van antibiotica reduceert de effectiviteit 
van de behandeling, en tevens lopen kinderen een verhoogd risico om geïnfecteerd te 
raken met antibioticumresistente micro-organismen. De richtlijnen van de AAP schrijven 
dan ook de ‘watch and wait’-methode voor. Hierbij luidt het advies bij vermoedens van 
een OM-infectie eerst een paar dagen af te wachten en paracetamol te gebruiken.
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Vaccinontwikkeling
Een veelbelovend alternatief voor het gebruik van antibiotica is vaccinatie. Preventie 
van OM door het introduceren en toepassen van bestaande en toekomstige vaccins 
lijkt een hoopgevende manier om de last van OM en de bijbehorende economische 
consequenties te verminderen, zowel voor het Westen als voor de ontwikkelingslanden.
Een 7-valent S. pneumoniae vaccin (pneumococcal conjugate vaccine 7; PCV-7) 
gericht tegen de serotypen 4, 6B, 9V, 14, 18C, 19F en 23F kwam in april 2000 in de 
Verenigde Staten op de markt. Dit vaccin is aanbevolen door de AAP voor gebruik bij 
kinderen van 23 maanden en jonger ter preventie van pneumokokkeninfecties. In maart 
2001 werd hetzelfde vaccin in Nederland op de markt gebracht voor gebruik bij kleuters 
en jonge kinderen ter voorkoming van onder andere meningitis en longontsteking. De 
introductie van PCV-7 leidde ook tot een aanzienlijke reductie in de prevalentie van S. 
pneumoniae met betrekking tot OM. Hoewel het gebruik van PCV-7 in eerste instantie tot 
een afname van S. pneumoniae in de etiologie van OM heeft geleid, is er een toename in 
dragerschap van non-vaccin serotypen gesignaleerd. De opkomst van deze non-vaccin 
serotypen is zorgelijk, en kan in de toekomst zelfs het effect van vaccineren teniet doen.
In 2006 is in Nederland een vaccin voor difterie, tetanus, kinkhoest, polio en H. 
influenzae type b (DKTP-Hib) geïntroduceerd. Vóór de introductie van het vaccin werd 
10% van de OM-infecties veroorzaakt door H. influenzae type b, terwijl op dit moment 
voornamelijk de niet-typeerbare H. influenzae (NTHi) bij een OM-infectie wordt geïso-
leerd. Het Hib-vaccin is helaas niet effectief tegen de niet-typeerbare variant van H. 
influenzae. Er is tot nu toe geen vaccin ontwikkeld tegen NTHi, hoewel het H. influenzae 
eiwit D als dragereiwit wordt gebruikt voor pneumokokken vaccins.
Tot op heden is er nog geen vaccin op de markt gebracht tegen M. catarrhalis. In 
wetenschappelijke publicaties zijn verschillende membraanoppervlakeiwitten en lipo-
polysacchariden als vaccinkandidaten geïdentificeerd. Geen enkele van de tot dusver 
beschreven vaccinkandidaten is echter in klinische studies getest. De uitdaging in het 
vinden van vaccinkandidaten ligt in het feit dat potentiële antigenen aanwezig dienen te 
zijn op het membraanoppervlak van alle M. catarrhalis stammen, deze geconserveerd 
dienen te zijn tussen M. catarrhalis stammen, en zij bovendien tot expressie moeten 
komen gedurende infectie. In Hoofdstuk 5 hebben we aangetoond dat er genetische 
verschillen bestaan tussen stammen geïsoleerd bij kinderen en volwassenen, waarbij er 
een verschil is in aanwezigheid en expressie van Hag/MID, een potentiële vaccinkandi-
daat. Een ideaal M. catarrhalis vaccin dient daarom opgebouwd te zijn uit immunogene 
epitopen van meerdere M. catarrhalis vaccinkandidaten. Een dergelijk zogenaamd multi-
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valent vaccin biedt daardoor een brede bescherming tegen M. catarrhalis gerelateerde 
ziekten in zowel kinderen als volwassenen.
Een eerste stap in het valideren van vaccinkandidaten is aan te tonen dat ze in staat 
zijn tot het opwekken van een immuunrespons die uiteindelijk beschermend werkt. Er 
is tot op heden weinig bekend over de ontwikkeling van de humorale immuun respons 
tegen M. catarrhalis vaccinkandidaten in gezonde en zieke personen. De studies in 
Hoofdstuk 8 en 9 zijn opgezet om te bepalen of antilichamen tegen M. catarrhalis 
(en S. pneumoniae, Hoofdstuk 9) vaccinkandidaten aanwezig zijn in het bloed van 
gezonde en zieke kinderen. We hebben ook bestudeerd of de aanwezigheid van deze 
antilichamen van invloed was op M. catarrhalis kolonisatie. Uit deze studies blijkt dat op 
tweejarige leeftijd de immuunrespons gericht tegen M. catarrhalis nog in ontwikkeling 
is, en voornamelijk bestaat uit IgG antilichamen opgewekt tegen de oppervlakte mem-
braaneiwitten UspA1, UspA2 en Hag/MID. We hebben ook aangetoond dat Hag/MID een 
mogelijke vaccinkandidaat is, welke een potentiële rol kan spelen in het reduceren van 
M. catarrhalis kolonisatie en infectie.
Nieuwe preventie- en behandelmethoden
Op dit moment zijn de de ‘watch and wait’-methode en het gebruik van antibiotica de 
meest voorkomende vormen van behandeling tegen M. catarrhalis-geassocieerde ziek-
ten. We hebben al eerder kunnen lezen dat het gebruik van antibiotica voor een toename 
zorgt in het vóórkomen van resistente micro-organismen. Daarnaast is het niet waar-
schijnlijk dat binnen nu en 5 jaar een vaccin tegen M. catarrhalis op de markt komt. Een 
alternatieve behandelmethode is daarom gewenst. Het aanpakken van de communicatie 
tussen bacteriën zou een goede optie kunnen zijn ter preventie en behandeling van M. 
catarrhalis infectie. Veel bacteriën vertrouwen op quorum signaling moleculen om de 
expressie van regulatoire en virulentiegenen te reguleren. Met het blokkeren van deze 
communicatie kan de pathogeniciteit van de betrokken micro-organismen afnemen.
Toekomstperspectief
OM is een belangrijke aandoening bij kinderen die in de meeste gevallen wordt veroor-
zaakt door een selecte groep bacteriële pathogenen, waaronder M. catarrhalis. Behalve 
in OM speelt M. catarrhalis ook een belangrijke rol in de klachten van COPD. Vaccinatie 
is mogelijk een goed alternatief voor het excessieve gebruik van antibiotica. Een vaccin 
gericht tegen M. catarrhalis moet in staat zijn tot het terugdringen van het aantal M. 
catarrhalis gerelateerde ziekten, en de last verlichten die deze ziekten veroorzaken.
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Helaas heeft de introductie van de huidige vaccins geleid tot vervanging van 
‘traditioneel virulente’ bacteriële stammen met ‘niet-traditionele, maar wel virulente’ 
stammen van dezelfde, maar soms ook van andere species in relatie tot OM. Er wordt 
gezocht naar een vaccin dat een brede bescherming biedt tegen zowel virulente als 
niet-virulente stammen van dezelfde bacterie (om bijvoorbeeld serotype-’replacement’ 
te voorkomen). Daarnaast is er meer onderzoek gewenst in de ontwikkeling van multi-
valente vaccins, die effectief zijn tegen zowel bacteriële als virale pathogenen.
Andere aspecten die van belang zijn voor een succesvolle introductie van een mo-
gelijk vaccin zijn de leeftijd waarop kinderen gevaccineerd dienen te worden; of de 
verworven immuniteit na vaccinatie beschermend werkt op latere leeftijd; en of de 
kosten van vaccineren lager zijn dan de kosten die nu gemoeid zijn met pijnstilling, 
antibioticumgebruik en het werkverzuim van ouders.
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Dankwoord
En dan het dankwoord. Het laatst geschreven stuk van mijn boekje, maar zeker niet 
het stuk waar het minst over is nagedacht. Met het schrijven van dit dankwoord is het 
laatste puzzelstukje gelegd en valt alles op zijn plek.
Ik heb de afgelopen 4 jaar hulp gehad van veel mensen, en bij deze daarom ook dank 
aan een ieder die op welke manier dan ook heeft bijgedragen aan dit proefschrift!
De volgende personen wil ik graag in het bijzonder bedanken:
Prof.dr.dr. van Belkum, beste Alex. Het sollicitatiegesprek met jou was een verademing. 
Net als het feit dat ik na dat gesprek dacht dat promoveren een kwestie was van wat 
pipetteren, een nietje door de geschreven stukjes, en dan... klaar! Zo makkelijk is het 
allemaal niet gegaan, maar je hebt aardig je best gedaan om mijn promoveren snel 
te laten verlopen door in een record tempo mijn manuscripten na te kijken. De laag-
drempeligheid waarmee ik je kantoor kon binnenlopen heb ik als heel prettig ervaren, 
zowel voor privé als werkgerelateerde zaken. Dat we de afgelopen maanden een ‘lange 
afstand relatie’ hebben gehad, doet daar niets aan af. Veel succes en natuurlijk plezier 
in het Franse!
Dr. Hays, beste John. Waarschijnlijk zijn er geen twee personen die zo van elkaar ver-
schillen als dat wij doen. Ondanks de verschillen in onze karakters heb ik bewondering 
voor je wetenschappelijke kennis, en de passie die je hebt voor je vak. En Alex heeft 
er een concurrent bij op het gebied van manuscripten nakijken, jij bent namelijk nog 
sneller! Ik wil je bij deze bedanken voor de leerzame momenten de afgelopen jaren.
Prof.dr. Verbrugh. Ik wil u bedanken voor het beoordelen van het proefschrift en het 
plaatsnemen als secretaris in de kleine commissie.
Prof.dr. Hermans, beste Peter. Als het mentor systeem voor Erasmus MC promovendi 
een feit wordt, zal ik jou zeker daarvoor aanbevelen! Dank je wel voor al je input de 
afgelopen 4 jaar.
Prof.dr. Moll, beste Henriëtte. Onze samenwerking resulteerde in 3 hoofdstukken van dit 
proefschrift. Bedankt hiervoor.
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Prof.dr. Hiemstra, beste Pieter. Onze samenwerking in het LUMC 5 jaar geleden was 
maar van korte duur, maar wie had toen kunnen vermoeden dat jij plaats zou nemen in 
mijn grote commissie? Het kringetje is weer rond.
Prof.dr. Hooijkaas, dank voor het plaatsnemen in de grote commissie.
Prof.dr. Riesbeck, dear Kristian. I am honored that you are part of the opposition com-
mittee. Thank you for your contribution to some of the chapters of this thesis.
Dear members of the OMVac consortium. I had the pleasure of working with you the last 
4 years. The friendly atmosphere, the city trips and the fruitful discussions contributed 
to a successful collaboration. Please feel welcome to visit The Netherlands any time! I 
will make sure that the glasses with Dutch ‘snaps’ are filled.
Kim, het zijn roerige tijden geweest, maar uiteindelijk komt alles op zijn pootjes terecht. 
Dank je wel voor de plezierige samenwerking, en veel succes met het afronden van jouw 
promotie onderzoek.
Dr. Musser, dear Jim. I would like to sincerely thank you for giving me the opportunity 
to work in your laboratory. Dr. Flores, dear Tony, thank you for teaching me the neces-
sary laboratory skills with respect to microarray analysis and bacterial gene expression 
analysis. To all people in the Musser lab, thank you for the great time I have had!
I would like to thank all the co-authors for their contribution to the chapters of this thesis. 
Aan alle co-auteurs, dank voor de samenwerking en jullie bijdrage aan dit proefschrift.
Beste Frank en Joris, bedankt voor de mogelijkheid om MolMed cursussen te volgen, 
en natuurlijk om deel uit te maken van de MolMed AIO-commissie. Het was plezierig 
samenwerken met jullie.
Beste collega’s van de afdeling Medische Microbiologie en Infectieziekten.
Marian, Gerjo, Sanne, Mehri, WillemvW, Jurriaan en Irma: met zijn allen in een te kleine 
ruimte gepropt om te werken, overleg te plegen, maar vooral plezier te hebben. Sinter-
klaas gedichtjes, cadeautjes, kruidenthee en een Kerst-CD..., ik heb het bij jullie prima 
naar mijn zin (gehad)! Irma, de afgelopen maanden hebben we intensief contact gehad 
over mijn toekomst, onder andere hoe die wetenschappelijk in te vullen. Ik heb het als 
zeer prettig ervaren om dit met jou te bespreken en wil je bedanken voor alle hulp. 
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Sanne, onze eerste kennismaking vond plaats tijdens de 4e OMVac consortium meeting 
in Amsterdam. Jij werkte toentertijd mee aan het project van Kim, maar bleek een paar 
maanden later een OIO-plek te hebben gevonden op onze afdeling. Van deze eerste 
ontmoeting, naar kamergenoten, tot het moment dat je naast mij staat als paranimf! 
Waar een avondje jenever drinken en karaoke al niet tot kan leiden...
PS. Jurriaan, mocht mijn carrière als wetenschapper op niets uitlopen, dan ga ik onze 
e-mails bundelen en uitgeven in boekvorm. Gegarandeerd een bestseller!
Denise, Deborah, Kimberly, Marcel, Mushtaq, Nicole, Susan, Hélène, WendyvdS, Mit-
chell, Jorick, Jaap, Lodewijk, Wil, WillemvL, Diana, Femke, Kees, Jan-Willem en Carla, 
en een ieder waarmee ik de afgelopen jaren heb samengewerkt, bedankt voor al jullie 
hulp en fijne (lab)momenten!
Corné, dank je wel voor het uitvoeren van alle Luminex experimenten.
Jasper, WendyK, René, Saskia, Michiel, Astrid, Rogier, Patricia, Jeannine, Martijn, Silvie 
en Bibi: veel succes met het afronden van jullie promotieonderzoek. Er zijn anekdotes 
en foto’s (‘helaas’ niet van mijn escapades) genoeg om die ‘Oh oh OIO’ serie mee te 
vullen!
Nelianne, het onderzoek liep inderdaad niet altijd even soepel, maar het is goed om te 
weten dat je bij elkaar terecht kunt. Succes met het afronden van je opleiding.
Gerard, bedankt voor de fijne en gezellige babbel momenten tijdens alle forens-uurtjes 
van en naar station Moerwijk.
Aan alle andere collega’s van de afdeling MMIZ, bedankt voor jullie samenwerking en 
hulp, in welke vorm dan ook!
Lieve vrienden, bij deze dank voor jullie interesse in mijn promotieonderzoek, jullie 
opbeurende woorden en het luisterend oor indien nodig, en heel belangrijk, voor de 
nodige ontspanning!
Hanna, Marieke, Marlou en Stefan, bedankt voor de nodige gezelligheid in ós Limburg.
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Ruumetjes, vijf jaar lief en leed delen als huisgenoten was niet niks, en gelukkig kunnen 
we nog steeds bij elkaar terecht. Mieke, wie had ooit kunnen denken dat sporten een 
hobby zou worden: we kick some ass! Lieve Nien, twee zielen, één gedachte, meer hoef 
ik denk ik niet te zeggen. Een dikke kus voor jou! Jeroen, die denkbeeldige navelstreng 
waarmee wij aan elkaar vastzitten is er eentje om nooit meer door te knippen. Stage 
lopen bij Numico, huisgenoten in Wageningen en vervolgens naar Den Haag om daar te 
gaan wonen en in Leiden te werken. Inmiddels werken we beiden bij het Erasmus MC en 
ben jij ook een promotietraject ingegaan. Dank je wel voor de vriendschap de afgelopen 
10 jaar en dat je mijn paranimf wilt zijn!
Anne, Gonny, Letteke, Linda, Fenny en Yvonne, dames, geen betere naam voor ons 
jaar dan Carpe Noctem! Inmiddels liggen onze activiteiten meer in het verlengde van 
Carpe Diem, maar die dagen worden goed gevuld met gezelligheid. Bedankt daarvoor. 
Lenneke, in datzelfde jaar hebben wij ook elkaar leren kennen en ik ben blij met onze 
vriendschap.
Dennis, Lorens, René, Wim en Wouter, heren, het is goed toeven met jullie. De biertjes 
en de bijna therapeutische praatsessies worden gewaardeerd, haha!
Jeroen, onwennig in een pak, maar in je element met taal. Dank je wel voor het nakijken 
van delen van mijn proefschrift (en voor het trouw komen opdrinken van mijn bijna-
over-datum bier)! Katelijne, heel veel succes met het afronden van je boekje, ik heb nu 
al zin in dat (niet-over-datum) biertje.
Maartje, wij hebben elkaar gevonden tijdens de AID studiemiddag Biologie in Wage-
ningen. De Wageningse Uiterwaarden zijn mooi, en een zuigbuis voor het vangen van 
insecten vast nuttig, maar de combinatie bleek niets voor ons. Gelukkig hadden we 
genoeg gespreksstof om ons toch te vermaken. En dat doen we nu nog steeds.
Eline, many thanks voor het ontwerpen van de kaft van mijn boekje, helemaal super! 
Succes met alles wat je doet. Of het nu hier is of in het buitenland, ik blijf je volgen.
Renee, mijn whisky drinkkwaliteiten hollen achteruit, misschien toch eens weer wat 
vaker dat glas heffen?
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Antoine en Rinske, succes met het Postdoccen in het buitenland, ik kom jullie graag 
opzoeken.
Lieve familie en schoonfamilie, bedankt voor jullie interesse de afgelopen jaren in mijn 
werk.
Oma, jouw appeltaart is toch echt de beste, en dat bord rijstepap doet wonderen: op 
naar de 100!
Lieve zussen, wat heerlijk om er twee te hebben zoals jullie! Miene Lon, lief zusje. 
Dank je wel voor je onvoorwaardelijke zusterliefde. Het was even slikken toen jij 6 jaar 
geleden naar London vertrok om daar te gaan werken en wonen, maar elk nadeel heeft 
ook zijn voordeel: shoppen kun je daar als de beste, net als alle andere leuke dingen 
die daar te doen zijn. En of we nu op bezoek zijn in Blerick, aan de telefoon hangen, 
of samen op reis zijn, ik ben een happy Zannie! Lieve Yvonne. Bedankt voor de warme 
thuisbasis in Venlo en je luisterend oor. Het is fijn om zo’n grote zus te hebben! Karlijn, 
Daan en Sophie, dikke knoevels voor jullie! Maurice and Neil, it is great having you as 
brothers-in-law!
Leef pap en mam. Jullie hebben mij de afgelopen 14 jaar in al mijn studies onvoorwaar-
delijk gesteund, met telkens weer die kleine beestjes als rode draad. Als ik voor een 
weekend langskom, kom ik niet bij jullie op bezoek, maar woon ik er weer even. Dank 
jullie wel voor jullie zorgzaamheid, het reisplezier, bedankt voor alles!
Lieve Frank. Leven in twee verschillende werelden, soms letterlijk en figuurlijk, was 
en is niet altijd makkelijk. Jouw nuchtere kijk op zaken (lees: die spreekwoordelijke 
spiegel) werd niet altijd even gewaardeerd, maar was af en toe o zo nodig. Nog even en 
dan pakken we ons gewone leven weer op. Hoewel gewoon... met jou naast me zal het 
nooit saai worden! Babe, ik hou van jou!
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